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            Liver metastases are often observed with primary cancers, including uveal melanoma 
(UM), breast, ovarian, and colon cancer. Chemokine receptor 4 (CXCR4) is one of the major 
chemokine receptors that overexpressed by cancers due to its role in tumor growth, migration, and 
progression. Organs such as the liver, bone, and brain have an intrinsically high concentration of 
CXCR4 ligand, C-X-C motif chemokine ligand 12 (CXCL12). As a result, CXCR4 is also often 
expressed at metastases in these organs. There is an unmet medical need for noninvasively early 
detecting, staging, and monitoring the prognosis of liver cancers and metastases as well as probing 
tumor microenvironment for target therapy and drug. In this dissertation, we first report the 
elevated expression of CXCR4 in the UM patients’ liver metastases and metastatic UM mouse 
models and validate its role as an imaging biomarker for liver metastases. We then report our 
achievement in the development of a CXCR4-targeted MRI contrast agent, ProCA32.CXCR4, for 
sensitive detection of UM liver metastases using MRI. ProCA32.CXCR4 exhibits high relaxivities 
(r1 = 30.9 mM
-1 s-1, r2 = 43.2 mM
-1 s-1, 1.5 T; r1 = 23.5 mM
-1 s-1, r2 = 98.6 mM
-1 s-1, 7.0 T), strong 
CXCR4 binding affinity (Kd = 1.1  0.2 µM), and the capability of CXCR4 molecular imaging in 
both metastatic and intrahepatic xenotransplantation UM mouse models. ProCA32.CXCR4 
enables robust detection of UM metastases as small as 0.1 mm2 in the liver. CXCR4 receptor 
blockage experiment proved the specific binding of ProCA32.CXCR4 to CXCR4. In addition, the 
application of ProCA32.CXCR4 in primary liver cancer detection and treatment effect monitoring 
are tested in hepatocellular carcinoma (HCC) mouse model. Except for gadolinium, we explored 
the possibility of manganese-based protein contrast agent and proved manganese-based ProCA 
exhibits high relaxivity and strong gadolinium binding affinity. We further designed and 
characterized ProCA32.RGD for integrin v3 molecular imaging to reveal the tumor 
microenvironment. ProCA32.RGD targeted imaging was achieved in a 4T1 breast cancer mouse 
model. Further development of the biomarker targeted imaging agents is expected to have strong 
translation potential for early detection, surveillance, and treatment stratification of cancer and 
related diseases. 
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1 INTRODUCTION  
1.1 Cancer as a metastatic disease 
Cancer (Malignant Neoplasm) is a global public health issue and one of the leading causes 
of death in the United States. Caused by uncontrollable cell division and proliferation, cancer cells 
can invade locally (healthy tissues) and regionally (lymph nodes, tissue, and organs). Data from 
2018 shows the estimated new cases of cancers in the United States is 1,735,350, and cancer causes 
about 609,640 patient deaths in the United States (1). Cancer is the second leading cause of death 
in all age groups after heart diseases (2). 
Metastasis describes the invasion and colonization of tumor cells to tissues or organs that 
are not directly connected with the primary cancer sites. Metastasis is the top cause of cancer 
mortality and responsible for over 90 percent of cancer-related deaths. Most tumors metastasize 
through the bloodstream. The vasculature metastasis dissemination involves multiple stepwise 
processes that include local invasion, intravasation, subsistence in the circulation system, 
extravasation, and finally colonization. First, cancer cells locally infiltrate and invade adjacent 
tissue, and some of them break the basement membrane and leave primary tumor sites. Then, 
tumor cells separate from the primary tumor sites and enter into the vasculature system; this 
process called intravasation. After that, tumor cells migrate through vasculatures and find a way 
of extravasation and form metastases in new locations (3). Although metastasis is an inefficient 
process, it is still the primary cause of tumor-related death. Very few tumor cells can eventually 
survive all the steps and develop metastases. A lot of complicated factors contribute to this whole 
process: the initial mutation endows the tumor cells unlimited proliferation ability; the immune 
tolerance of tumor cells and the tumor cell successfully colonize and take over a new organ.  
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Organ-specific metastasis pattern is observed with various cancers, which means specific 
cancer has preferred sites of metastasis. Breast cancer usually metastasizes to the liver, bones, 
lungs, and brain. Colorectal and pancreatic cancer are more likely to metastasize to the liver and 
lungs. A large portion of prostate cancer goes to the bones, and uveal melanoma almost exclusively 
metastasizes to the liver (over 95%) (4). The reason for the organ-specific metastasis remains 
unknown. Potentially, the expression of genes in primary tumors might provide markers that 
facilitate the organ-specific metastasis. 
The cellular mechanisms involved in metastasis are complicated.  The factors of tumor 
cells include expression of the genes that alter cell adhesion in the primary site (5, 6), strategies to 
survival in the circulatory system (7, 8) and eventually colocalize secondary organ and forming 
new blood supply for further proliferation (9, 10). Also, tumor microenvironment significantly 
affects metastases progression. The various types of cells, such as cancer stem cells, immune-
related cells, stroma cells, and fibroblasts consisted of the microenvironment facilitate and promote 
tumor progression (11). Understanding the mechanism of metastasis, monitoring the metastatic 
progression, and revealing the local anatomical and biological information of cancer metastases 
would be vitally crucial for tumor diagnosis, stratification of therapy and intervention. 
As the improvement of the standard of care (SOC) during the past few decades, the cancer-
related death rate has been decreasing, and most cancers with initial diagnoses of the localized 
disease have promising 5-year survival rates. However, for cancer patients with diagnoses of 
metastatic diseases, it is still an indication of the terminal disease stage. In some metastatic cancer, 
immunotherapy is proved to be able to improve the prognosis. For example, ipilimumab prolonged 
the overall survival of metastatic melanoma (12), and enzalutamide (an androgen-receptor-
signaling pathway inhibitor) can significantly extend the survival of men with metastatic prostate 
3 
cancer (13). However, for the other types of cancer with metastases, such as breast cancer, gastric 
cancer, and pancreatic cancer, the survival rates remain unoptimistic (14-16).  
1.1.1 Cancer diagnosis technology and early detection of cancer 
The diagnosis of cancer is essential before, during, and after the cancer treatment. The 
common diagnostic tests include a review of health history, physical examinations, laboratory 
examinations, biopsy, imaging tests (ultrasound, CT, MRI, PET/CT), and endoscopy, etc. The 
major imaging modalities used in clinical settings are positron emission tomography (PET), single-
photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI) (17, 18).  
The modern technology allows genetic tests as well to provide more precise and further genetic 
information of cancer that could further benefit the cancer treatment. 
 Statistic evidence shows that the early detection of cancer can efficiently improve cancer 
prognosis. More than 90 percent of bowel cancer patients can survive the disease for more than 
five years if diagnosed at the earliest stage. The five-year survival rate of breast cancer patients 
diagnosed at the early stage is 90%; but for the women diagnosed at the most advanced stage, the 
five-year survival rate is 15%. For ovarian cancer, the five-year survival rate drastically dropped 
to 5% in patients diagnosed with the most advanced stage of the disease, compared to 90% of the 
five-year survival rate in patients diagnosed at the earliest stage (19).  
 The early detection and staging of cancer are critically important for the diagnosis and 
prognosis of cancer. The management of cancer becomes more precise and personalized, along 
with a better understanding of cancer pathophysiology. Cancer immunotherapy and targeted 
cancer therapy focus more on molecular and cellular levels than systemic levels. There are 
approved agents to target human epidermal growth factor receptor 2 (HER2) for breast cancer, 
epidermal growth factor receptor (EGFR) for non-small cell lung cancer (20, 21). Thus, knowing 
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the molecular information of tumor cells and microenvironment with non-invasive imaging assays 
becomes an unmet medical need which can be fulfilled by biomarker targeted molecular imaging. 
Our knowledge for cancer biomarkers and imaging capability is essential for the success of early 
detection.  
1.2 Molecular imaging  
“Molecular imaging is the in vivo visualization, characterization, and measurement of 
biological processes at the molecular and cellular levels (22).” On top of the present imaging 
assays, which rely on detecting the microscopical alteration of physiological status, molecular 
imaging enables more specific and quantitative assessment of disease status. Molecular imaging 
can non-invasively profiling the pathological characterizations of diseased tissues and enabling 
early detection, personalizing treatment stratifications, and following up the treatment effect. 
Histological analysis is the gold standard for analyzing the morphology and molecular signatures 
of tissues. However, the prominent disadvantage of histological analysis is the reliance on biopsy 
to collect tissue invasively and does not provide spatial information in the whole organ. The 
advances in molecular and cellular technology, the availability of different animal models and 
small animal scanners facilitate the development of molecular imaging. The rapid development of 
the molecular imaging field promises the possibility of assessing the pathological process on a 
molecular level with non-invasively imaging acquisitions.  
The main deciding factors for molecular imaging, including biomarker, imaging sensitive 
instrumentation, and probes. Molecular imaging development is rooted in nuclear medicine, which 
has relatively higher sensitivity through the administration of radiolabeled tracers. Due to the 
limitation of sensitivity, the major imaging modality in molecular imaging is PET, SPET, and 
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Ultrasound. Recently, near IR fluorescence imaging probes have also been developed (23). For 
MRI, there is no targeted probe has been approved.  
The definition of a biomarker is proposed to be “A characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention.” (24) Biomarkers are widely used in 
disease screening and diagnosing, cancer staging, stratification of treatments. Biomarkers, a 
parameter that considers the individual differences across the same disease, is crucial for cancer 
diagnosis, prognosis prediction, and treatment stratification. For instance, HER2 is found to be 
over-expressed and plays a vital role in breast cancer development. The HER2 status of breast 
cancer patients is related to the prognosis and guides the decision- making regarding the choice of 
using monoclonal antibody Trastuzumab (25, 26). Similarly, research of colorectal cancer shows 
that colorectal patients with KRAS wild type tumors can benefit from treatment with a 
combination of cetuximab and FOLFIRI when compared with FOLFIRI alone. Patients treated 
with cetuximab plus FOLFIRI showed a reduced risk of progression and metastasis (27). The 
selection of biomarker for cancer imaging is very challenging and requires careful validation of 
patient samples.  This dissertation will address the validation of CXCR4 as a biomarker for the 
liver metastases. (Chapter 5) 
1.3 Medical imaging modalities 
PET imaging records the high-energy  rays emitted from the subject. A neutron-deficient, 
positron emitted isotope was selected for labeling biomolecules as PET tracers. Positron emitted 
isotopes that were frequently used for developing PET tracers are 15O, 13N, 11C, and 18F (18). The 
PET radiotracers are made using either a cyclotron (28) or a generator. Fluorodeoxyglucose (FDG), 
an analog of glucose, is the most commonly used biologically active tracer for PET imaging. 
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18FDG introduced to the subject, and the decay of 18F generates positron (e+) and an electron 
neutrino (ve). After emission, the positron travels in the tissue and loses the energy until it 
annihilates with an electron and emits two annihilation gamma rays in opposite directions (29) 
(Figure 1.1). PET imaging has high sensitivity in the range of 10−11–10−12 mole/L and with no 
depth limitation. As a result, PET imaging is a very robust imaging modality for clinical usage. 
 
Figure 1.1 The principles of positron emission.  
Positron emitted along with the decay of the neutron-deficient isotope, the detection of 
annihilation photons within the time window. 
 
Single-photon emission computed tomography (SPECT) is less sensitive than PET 
imaging. However, SPECT has the advantage of allowing the usage of various isotopes with 
different energy γ-rays, which enables the simultaneous detection of multiple events at the same 
time.  
Optical imaging as another approach to achieve molecular imaging has the advantage of 
being economical and has the potential of achieving multichannel imaging by using optical probes 
with different imaging spectra. Optical imaging, including bioluminescence imaging, fluorescence 
imaging, has the advantage of being detected at a very low level due to the background-free nature 
of the emitted light. The technical barrier of optical imaging is how to conquer the low light 
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transmission efficiency and detect the light emitted within the living subjects, especially for bigger 
animals. 
Magnetic resonance imaging (MRI) obtains the three-dimensional imaging of the human 
body without radiation involvement and has been widely used in clinic settings.  This technique 
has been rapidly developing, evolving, and deriving the different clinical applications due to its 
high resolution and sensitivity to soft tissues. MRI has the potential for molecular imaging due to 
its advantages of higher spatial resolution and non-radiation exposure. The sensitivity of current 
MRI contrast agents limits its applications in molecular imaging. This dissertation aims to develop 
novel biomarker targeted contrast agents to extent MRI application for molecular imaging.  
1.4 Magnetic Resonance Imaging  
1.4.1 Physics 
The MRI technique builds on the basic principles of nuclear magnetic resonance and 
generates imaging information of the anatomy, function, and metabolism of tissues without 
causing ionizing irradiation.  The nuclear magnetic resonance (NMR) phenomenon was described 
by Bloch and Purcell in 1946 (30, 31). Damadian proposed in 1971 that relaxation time for two 
solid malignant tumors, Walker sarcoma and Novikoff hepatoma are distinct from the healthy 
tissues (32). This discovery ignited the hope of distinguishing benign and malignant tissue using 
MRI. By detecting water relaxation in a strong magnetic field following a temporary pulse 
sequence, MRI provides the internal picture of tissues and organs for diagnosis.  
Atoms with an odd number of protons and/or an odd number of neutrons exhibit the 
phenomenon of nuclear magnetic resonance because of the spin angular momentum they possess. 
Of the atoms exhibiting this phenomenon, such as 1H, 31P, and 23Na, 1H is the most abundant in 
the body and most practical for MRI imaging application. By applying a static magnetic field B0, 
8 
all the 1H spins will align with the direction of B0 (z-direction) and produce a magnetization 
moment M. While the proton spins aligned in the z-direction interact with the radiofrequency field 
in the transverse direction, a torque will be induced, and the magnetization moment M will rotate 
away in a procession motion from its equilibrium position along with z-axis. M will eventually go 
back to the initial equilibrium position along with z after being excited by a radiofrequency field. 
In the process, the transverse component of M, Mxy decays while the longitudinal component Mz 
grows. Two parameters, T1 and T2, are introduced to characterize the return of different 
components of M. Introduced contrast agents alter the relaxation time constant and provide signal 
enhancement on imaging. 
1.4.2 MRI contrast agents 
 Although MRI is a non-radiation, high-resolution imaging modality, the sensitivity of MRI 
is limited by the water background. To resolve this issue, MRI contrast agents have been applied 
to increase the contrast of imaging results by Lauterbur PC (33) for the first time in 1983. Since 
then, the MRI contrast agents have become an indispensable element of the MR imaging 
technique. Based on the bio-distribution preference of different contrast agents, they can be 
grouped to intravenous contrast agents, intravascular contrast agents, and hepatobiliary contrast 
agents such as gadobenate dimeglumine (Gd-BOPTA), gadoxetic acid (Gd-EOB-DTPA) and 
mangafodipir trisodium (Mn-DPDP). The gadolinium-based contrast agents are the most 
commonly used in medical applications since been first described as a potential NMR agent (34). 
Nine of these agents are commercialized for different imaging purposes.  
MRI contrast between tissues in the image differentiates different tissues and local 
environment and reflects as the different intensity on MRI images. The MRI contrast arises from 
and is affected by multiple factors: proton density, innate T1 and T2 of tissue, perfusion, and 
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diffusion of local water molecules. The MRI contrast agents aim to alter the T1 and T2 of the tissue 
at their presence and enhance the contrast of images. All contrast agents shorten both T1 and T2. 
However, based on the predominant influence on T1 or T2, MRI contrast agents can be divided 
into T1 contrast agents and T2 contrast agents. More specifically, when a contrast agent alters 
longitudinal relaxation rate (1/T1) and transverse relaxation rate (1/T2) in a similar level, the 
contrast agents are T1 weighted contrast agent, because the intrinsic faster T2 of tissue contrasts 
enhance dominantly on T1 in a percentage base (35). If a contrast agent alters transverse relaxation 
more predominantly than longitudinal relaxation, the contrast agent is a T2 weighted contrast agent. 
The most commonly used MRI contrast agents, gadolinium-based contrast agents (GBCA), are T1 
contrast agents for the significant influence on T1. There are very few exceptions of the application 
of GBCA that use the T2 effect. The T2 effect of gadolinium-based contrast agents reflects as 
darkening the signal on MRI images, and it only shows up when the contrast agent concentration 
is in mM range.  For imaging purposes, the contrast agent concentration is usually much lower 
than one mM (36, 37). The T2 effect of gadolinium contrast agents is limited by the increased risk 
of toxicity at a higher dosage. 
Superparamagnetic iron oxide is T2 weighted contrast agents because they affect the T2 
relaxation and show a darkening enhancement on T2 weighted images (38). Transitional metal ion 
manganese (II) has five unpaired electrons that possess T1 property and weak T2 property, and 
attempts of using manganese-based contrast agents for enhancement have been made (33, 39, 40). 
The gadolinium-based MRI contrast agents in clinical use are formulated with a chelator 
to protect the dissociation of free Gd3+, which potentially causes toxicity (41). Due to the seven 
unpaired electrons, gadolinium possesses paramagnetic properties. Current GBCAs can be divided 
into linear and macrocyclic based on the structure of chelating ligands (42, 43). According to their 
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charges, they can be further divided into sub-categories of ionic and non-ionic ones. In general, 
macrocyclic contrast agents are more stable than the linear “open chain” ones, for the reason that 
the previous ones form a structure that cages the gadolinium ion. Ionic contrast agents are more 
stable than non-ionic ones for the stronger electrostatic interactions between Gd3+ and the donor 
groups (44, 45).  
There are fundamental features that researchers are trying to look for in the design of 
gadolinium-based contrast agents, including high relaxivity, high stability, low toxicity, tissue 
specificity, or even biomarker specificity. Relaxivity (r1 and r2) is the capability of contrast agents 
shorten T1 and T2 and provides contrast enhancement on images. The higher relaxivity of contrast 
agents enables the same signal intensity by less concentration or increases the signal intensity by 
equivalent dosage. Developing MRI contrast agents with higher relaxivity increases the imaging 
sensitivity and reduces the contrast agent’s toxicity potentially. High stability contrast agents are 
considerably safer. The linear contrast agents are less stable than macrocyclic contrast agents. 
Additionally, the majority of reported nephrogenic systemic fibrosis (NSF) cases were associated 
with the administration of the non-ionic, linear contrast agent Omniscan (46). Tissue specificity 
enables the contrast enhancement in a specific tissue and expands the application of the contrast 
agent. For example, the hepatocytes-specific contrast agents can be specifically uptake by 
hepatocytes and assist in the differentiating diagnosis of hepatocellular carcinoma. Biomarker-
specific contrast agents that target specific biomarkers, especially cancer biomarkers, arise from 
the development of molecular imaging. Biomarker-targeted MRI contrast agents are expected to 
improve the understanding of diseases at a molecular level and help to make decisions regarding 
diagnosis and therapeutic stratification. 
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1.4.3 MRI contrast agents for molecular imaging 
An important factor in achieving molecular imaging with MRI is to improve the relaxivity 
of contrast agents. MR imaging has lower sensitivity compared with nuclear medicine imaging 
approaches such as PET. As a result, MRI contrast agents must reach specific local concentrations 
to achieve imaging enhancement of biomarkers. The relaxation time of tissues is various. Taking 
tissue relaxation time measurement under 3.0 T as an example, the T1 of gray matter is 1460 ± 33 
ms (47), white matter is 840 ± 50 ms (48), the liver is 840 ± 50 ms (49). Assuming relaxation time 
of specific tissue is 1000 ms, in order to achieve an observable robust change (0.5 s-1) on MR 
contrast enhancement with current gadolinium-based MRI contrast agents, a minimum 
concentration of 100 µM is required (calculation based on r1 equal to 5 mM
-1 s-1 and binding with 
biomolecule in a 1:1 stoichiometry) (35). Such a concentration of contrast agent cannot be 
achieved in vivo considering the biomarkers present in 10-6 -10-10 concentration in tissue (50) and 
the fast elimination of small molecule contrast agent. 
Attempts have been made to achieve molecular MR imaging. One of the early approaches 
is to label monoclonal antibodies with Gd-DTPA. Matsumura A et al. use monoclonal antibodies 
against 9L glioma cells to conjugate Gd-DTPA and achieve tissue-specific enhancement of mouse 
brain tumors (51). Melanoma-specific enhancement was reported using monoclonal antibodies 
against melanoma conjugated with Gd-DTPA (52). Another example is the alphaVbeta3-targeted 
MRI contrast agent, which is reported to achieve molecular imaging through alphaVbeta3 and 
show the angiogenic 'hot spots' with magnetic resonance imaging (53). The robust enhancement 
of biomarkers requires higher relaxivity contrast agents with targeting capability. 
Various factors attribute to the relaxivity of contrast agents. The rotational motion of 
contrast agents is decisive for the relaxivity. To achieve catalytical relax of bulky water, the 
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gadolinium should efficiently relax the water and the relaxed water can be exchanged quickly with 
the unrelaxed ones. For small molecules, the rotational rate is majorly decided by the relaxation 
efficiency. However, when the rotational motion becomes slower, the water exchange rate 
becomes a predominant factor. This phenomenon has been described with the relaxivity 
measurement of MS-325 and the analog MS-325-BMA. The relaxivity of both contrast agents in 
PBS buffer is similar. However, the relaxivity of MS-325 is significantly higher than MS-325-
BMA in the human serum albumin solution (35). Once the agents were bound with human serum 
albumin, the rotational motion of both contrast agents slowed down, and the water exchange rate 
of MS-325-BMA is slower than MS-325 (54). One approach to improve the relaxivity of 
gadolinium contrast agents is to link multiple gadolinium in one molecule. This can improve the 
concentration of gadolinium in the target region and increase the contrast of images (55, 56). 
Another approach is to locate gadolinium in the center of the molecule and form more rigid local 
structures. In this case, the local motion of gadolinium is restricted and changes the factors 
governing the relaxivity to achieve significantly higher relaxivity (57, 58). Alternatively, the lipid 
platform for MRI contrast agents’ construction and MRI has been reported to target the fibrin and 
detect thrombus in vivo (59, 60). 
 Hydration number q refers to the water molecule directly bound to the gadolinium in the 
inner coordination sphere. The water molecules in the second and outer coordination spheres 
contribute to the relaxivity as well. With more water molecules coordinating in the inner sphere, 
gadolinium contrast agents generate higher relaxivity (61). However, the tradeoff would be that 
the stability becomes less because the introduction of more coordination sites for the ligands 
decreases the thermodynamic stability of contrast agents. 
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Figure 1.2 Physical parameters affect the relaxation of gadolinium-based MRI contrast 
agents. 
 
1.4.4 Protein-based MRI contrast agents 
Designing the MRI contrast agents with higher relaxivity need to consider multiple factors 
including hydration number q, second sphere and outer coordination sphere, rotational correlation 
time (τR), and water exchange rate. We designed a serious of protein-based Gd
3+ MRI contrast 
agents (ProCAs) (62) which chelating the gadolinium (III) ion using the interaction between side 
chains of residues and gadolinium (III) ion, instead of linking the Gd-chelator with protein through 
covalent and noncovalent interaction. This allows optimizing the relaxivity related factors such as 
water number, rotational correlation time and second correlation sphere. We reported a novel MR 
contrast agent ProCA32 that has unprecedented liver imaging capability (63). ProCA32 is derived 
Outer sphere 
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from a parvalbumin scaffold with two gadolinium binding sites. ProCA32 possesses slower 
rotational correlation time (τR) than small molecules such as Gd-DTPA and exhibits a much higher 
relaxivity (both r1 and r2) when compared with current commercially available contrast agent. 
ProCA32 can image small metastases in millimeter-scale (63) whereas imaging capability of small 
chelator MR contrast agents usually limited to a centimeter scale. In addition, ProCAs allows the 
linkage of targeting moieties specific for biomarkers and achieve related biomarker molecular 
imaging. GRPR, PSMA, and HER2 specific imaging can be achieved by the administration of 
corresponding contrast agents (64-66). 
An ideal protein-based MRI contrast agent should satisfy several criteria: high r1 and r2 
relaxivity, strong Gd3+ binding affinity, low toxicity, high stability and solubility, suitable PK/PD 
properties, no interaction with other proteins, and low cost of production. This dissertation is 
focused on the development of CXCR4 targeted contrast agent, ProCA32.CXCR4. 
ProCA32.CXCR4 based on the ProCA32 structure and targeting CXCR4 with targeting moiety at 
the C terminus.  
1.5 Chemokine receptor 4 (CXCR4) 
The chemokines are a family of small, pro-inflammatory cytokines secreted by immune-
related cells, which mediate chemotaxis of cells through the interaction with chemokine receptors. 
Interleukin 8 is the first chemokine been identified and characterized (67). Since then, more and 
more chemokines have been identified, until today, there are over 50 ligands identified in humans 
and mice (68). Chemokines are first appreciated as a chemoattractant for innate immune cells (69). 
The chemokines achieve their biological roles by interaction with the chemokine receptors 
that expressed on the target cells.  Chemokine receptors belong to the family of G protein-coupled 
15 
receptors (GPCR) that have seven transmembrane domains connected by three extra-membrane 
loops (70). Chemokine receptors can be divided into G-protein coupled chemokine receptors and 
atypical chemokine receptors based on their signaling (68). According to the positioning of the 
first two cysteines, chemokine receptors can be classified into four groups (CXC, CC, C, and 
CX3C) (71). Chemokine receptors were first appreciated as the mediators of leukocyte- trafficking 
in acute inflammation and then found to be involved in other biological processes such as T helper 
cell differentiation, angiogenesis, and co-entry of HIV. (72, 73) 
Chemokine receptor 4 (CXCR4), also known as CD184 or “fusion”, is the chemokine 
receptor for stromal-derived factor 1(SDF-1, renamed as CXCL12). Chemokine receptor 4 is a 
rhodopsin-like receptor encoded on chromosome 2.  CXCR4 is widely expressed on many 
different types of cells such as leukocytes, progenitor, stem cells, endothelial, epithelial, and 
stromal cells. CXCL12 is the established natural ligand of CXCR4 since 1996 (74). In 2005, Burns 
et al. (75)  reported chemokine receptor 7 (CCR7) is another receptor for CXCL12. CXCL12 is 
ubiquitously expressed in human tissue and has high expression levels in the liver, kidney, lungs, 
and bone marrow (76, 77). The CXCR4/CXCL12 axis mediates physiological and pathological 
processes such as cell migration, metastatic malignancy, vascularization, and organ homeostasis 
(78, 79). The biological effect of CXCR4 is achieved by binding the nature ligand CXCL12, to 
activate the downstream protein kinase to trigger the signaling pathway (Figure 1.3). Upon the 
activation of CXCR4 by interacting with CXCL12, the downstream signaling pathway is initiated 
by dissociation of βγ subunit and α subunit. A series of complex signal pathways transduction were 
achieved by activation of IP3 (Inositol triphosphate), ERK1/2 (extracellular signal-regulated 
kinases1/2), PI3K (phosphoinositide 3-kinases), JAK and calcium release to mediate a series of 
biological incidences including cell migration, proliferation, survival and gene transcription. 
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Figure 1.3 Chemokine receptor 4(CXCR4) mediated cellular pathways. 
 
Chemokine receptor 4 has been found as co-receptor for HIV entry in 1996 (74). Since 
then, the focus of the CXCR4 study broadened from mere chemoattractant (80) to cell migration 
and cancer metastasis. CXCR4/CXCL12 axis regulates leukocytes trafficking (80), HIV infection 
(74), cell migration, and cancer metastasis (81). CXCR4 has a universal expression in different 
tissues and organs. Both the HPA and GTEx datasets showed that the RNA tissue category is 
expressed in all tissues that been studied (human protein atlas). It has a high expression level in 
immune-related tissues such as bone marrow, spleen, and lymph nodes (82). Functional CXCR4 
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protein is found on human epithelial cells (83, 84), endothelial cells (85), mast cells (86), and 
dendritic cells (87). CXCL12 chemoattracts cells that express CXCR4 along with the CXCL12 
concentration gradients and play a pivotal role in a variety of physiological and pathological 
processes such as embryonic development, hematopoiesis, vascularization, inflammation, immune 
surveillance and cancer metastasis (79, 88). CXCR4 knockout mice exhibit hematopoietic and 
cardiac defects and fetal cerebellar development (89). 
CXCR4 is the chemokine receptor that involves in the complex network of inflammation, 
wound healing, and cancer development. The network parallel with each other and well connected. 
As a result, CXCR4 participates and mediates various directional cell recruitment and triggers 
downstream signaling. 
1.5.1 The significance of CXCR4 in cancer cells 
Chemokine receptors are extensively expressed in the tumor cells and direct the tumor cells 
migration through the interaction with their ligands (90-92). CXCR4 is the major chemokine 
receptor expressed on tumor cells. CXCR4 was found to be expressed by over 23 types of cancer, 
including melanoma, breast cancer, and ovarian cancer (93). The expression levels are different 
between vary tumor types, primary tumor, and metastases and even different subpopulations of 
cells. The expression level of CXCR4 indicates cancer prognosis. Breast cancer is the most 
prevalent invasive cancer for women and comprises 16% of female cancer. Take breast cancer as 
an example; most breast tumor cells exhibit an elevated CXCR4 expression, whereas CXCR4 
barely expressed in normal breast tissue. Xu et al. reported in 2013 that the overall survival and 
disease-free survival are negatively related to the CXCR4 expression level (94). Over 75% of 
triple-negative breast cancer patients have a high expression level of CXCR4 (95), and over-
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expression of CXCR4 at primary tumor sites positively correlates the lymph mode metastasis and 
lower survival rates (96).  
 
Figure 1.4 The roles of CXCR4 in cancer development. 
Figure adapted from reference (90). 
 
CXCR4 contributes to tumor immune suppression. One study shows that malignant human 
ovarian epithelial tumor cells have the high-level expression of stromal-derived factor-1and 
through the interaction with CXCR4, plasmacytoid DCs precursor chemotaxis, and 
adhesion/transmigration was activated. This protects plasmacytoid DCs precursor from tumor 
macrophage interleukin-10–induced apoptosis. (97) CXCR4 facilitates tumor growth. In human 
ovarian tumor cell line IGROV that has a high expression level of CXCR4, CXCL12 can stimulate 
cell growth in vitro (98). 
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 CXCR4 expression levels vary from low to high in AML patients cells and is an 
independent prognostic marker in acute myelogenous leukemia (99).  In multiple myeloma (MM), 
CXCR4 has been shown to involve in cancer homing and migration. The cancerous B-cells are 
attracted to bone marrow, where the stromal-cell secrets high level of CXCL12 (100). In acute 
myelogenous leukemia, the CXCR4/CXCL12 axis directs AML cells that express CXCR4 in the 
same fashion with directing normal hematopoietic stem cells migrate along with the CXCL12 
gradient (101). Marrow stromal cells constitutively secrete CXCL12. Thus, the marrow niche 
provides a primary residual environment after chemotherapy. Specific aiming at mobilizing HSCs 
into the peripheral circulation, AMD 3100 as a potent, selective CXCR4 antagonist can antagonize 
CXCL12 binds to CXCR4 and interrupt the homing of AML cells to bone marrow stromal. By 
mobilization of AML cells into the peripheral circulation, AMD 3100 effectively sensitizing the 
AML cells to chemotherapy (101).  
CXCR4/CXCL12 axis is found to be crucial for organ-specific metastasis, supported by 
the most common metastatic sites for CXCR4 positive cancer are those organs have high CXCL12 
concentrations such as liver, lungs and bone marrow (102). Functional CXCR4 is expressed on 
breast tumor cells, breast tumor cells only metastasis to the organs and tissues strongly express the 
CXCR4 ligand, CXCL12, and the metastasis can be partially blocked by CXCR4 antibody (103). 
The majority of prostate cancer patients eventually develop metastases in the bone, which has a 
high CXCL12 level. It suggests that CXCR4/CXCL12 interaction plays an important role in 
prostate cancer metastasis (104). Therefore, the CXCR4 expression level is proposed to be a 
prognostic factor and therapeutic target for prostate cancer (105). The CXCL12 signaling study of 
human prostate cancer cell line-PC3 study by Fernandis, A.Z. proved that CXCL12 activates 
MEK/ERK signaling and NF-κB, which play an important role in cancerous cell survival (106). 
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CXCR4 inhibitors, including antibodies, peptides, and small molecules can reduce metastasis 
burden of prostate cancer cells in PCa mouse model studies (105, 107). CXCR4/CXCL12 axis also 
involved in regulating the metastasis in non-small cell lung cancer (108). 
 
Figure 1.5 The role of CXCR4/SDF-1α axis in various diseases. 
Figure adapted from reference (109). 
 
1.5.2 CXCL12 in the cancer microenvironment 
To date, numerous researches proved that tumor microenvironment (TME) provides 
habitat that favoring tumor proliferation, migration, and invasion. Carcinoma-associated 
fibroblasts (CAF) is one of the major cell types discovered in different tumors; CAF promotes 
tumorigenesis instead of suppressing tumor growth as normal fibroblasts do (110). CAF secret 
CXCL12 and stimulate breast cancer growth through the CXCL12 and CXCR4 interaction (111). 
CXCL12 promotes the expression of integrin and cancer cell adhesion in small cell lung cancer 
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(SCLC); 2, 4, 5 and 1 integrin mediates the adhesion of SCLC cells to fibronectin and 
collagen upon CXCL12 activation (112). A similar phenomenon is observed in prostate cancer 
PC3 study; CXCL12 treatment promotes the adhesion of PC3 cells to fibronectin (113).  
Angiogenesis is another critical step for cancer progression; new forming vasculature 
guaranteed the nutrient supply for tumor growth. CXCL12 is proved to promote endothelial cell 
tube formation and angiogenesis (114, 115). In vivo study proved that the presence of CXCL12 is 
essential in blood vessel formation through a heme-oxygenase 1 dependent mechanism (116). Also, 
the CXCL12 level in plasma is related to bone marrow angiogenesis in multiple myeloma patients 
(117). 
CXCL12 presented in the tumor microenvironment can also promote tumor cell 
proliferation and survival. In human glioblastoma cell lines study, CXCL12 treatment showed the 
ability to stimulate tumor cell growth; the CXCL12 dependent proliferation is correlated with 
phosphorylation and activation of pathways ERK (extracellular signal-regulated kinases) 1/2 and 
Ark (118). 
1.5.3  CXCR4 as a therapeutic target 
The critical role of the CXCR4-CXCL12 axis in various diseases and different stages of 
inflammation, cancers, and infectious diseases makes CXCR4 targeted therapy has strong 
translational potential. Intensive study on the structural biology of CXCR4 enriches the 
understanding of the CXCR4 structure and the interaction with ligands, including SDF-1 and other 
small molecules significantly. Wu et al. reported the crystal structure of CXCR4 in complex with 
IT1t, a small, drug-like, isothiourea derivative, and CVX15, a cyclic peptide characterized as 
CXCR4 inhibitor (Figure 1.6) (119).  
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Figure 1.6 The chemical structure representation of CXCR4 antagonist IT1t and CVX15. 
 
Massive attempts have been made on the development and optimization of the CXCR4 
antagonists as anti-cancer and/or anti-HIV drugs. Overall, CXCR4 antagonists can be classified 
into peptide derivatives and small molecules. Cyclic peptide CVX15 and T140 can bind with 
CXCR4 and serve as a CXCR4 antagonist. Downsize of T140 to cyclopentapeptides and 
derivatives has successfully generated potent CXCR4 antagonists in cyclopentapeptide structures 
such as FC131 and FC122. FC131[cyclo(-D-Tyr-Arg-Arg-Nal-Gly-)] has the EC50 of 0.4 µM  
(120) and based on which a much more potent CXCR4 antagonist FC122 is synthesized with an 
EC50 of 88 nM (121). 
 Base on the cyclopentapeptides results, the SAR (structure-activity relationship) studies 
on cyclopentapeptide CXCR4 antagonists located the tripeptide motif L-/D-Arg1-Arg2-2-Nal3 as 
the minimal sequence for the antagonistic activity. A series of tripeptidomimetics of motif L-/D-
Arg1-Arg2-2-Nal3 was synthesized and analyzed. Although no potent tripeptidomimetics were 
identified, the core structure still potentially be the bone structure for bulky CXCR4 antagonist 
development (122). 
Another different approach of CXCR4 antagonist development based on the small 
molecules. Vitale et al. identified the phidianidine A (PHIA) as a new CXCR4 ligand through the 
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screening in a small marine natural product library available at ICB-CNR Institute (123). Truax et 
al. designed a series of tetrahydroisoquinoline analogs as CXCR4 antagonist with 3-650 nm 
potencies (124). AMD3100, brand name plerixafor, is a CXCR4 antagonist approved by the FDA 
in 2008 for the mobilization of hematopoietic stem cells (125). The effort has been made towards 
simplifying the AMD3100 structure to single cyclam connect to the aromatic structure by p-
xylylenediamine linker (125). The computational approach to design the small molecule based on 
the SDF-1α interaction with CXCR4 has yield the small molecule CXCR4 ligands of µM scale 
potency (126).  
1.5.4 CXCR4 molecular imaging 
CXCR4, a chemokine receptor involves in numbers of the physio-pathological processes, 
has gained tremendous attention as a therapeutic target. Other than that, how to evaluate the 
CXCR4 expression non-invasively in vivo is the primary importance of monitoring and evaluate 
the treatment effects. However, current imaging techniques and agents are not able to assess 
CXCR4 expression. Hence, there is a critical unmet need for the development of CXCR4 specific 
imaging agent for molecular imaging purpose. 
The important biological function and the potential role of the CXCR4/CXCL12 axis in 
the cancer development make CXCR4 targeting imaging and CXCR4 targeting therapy draw 
tremendous attention in the past decade. Developing CXCR4 specific imaging agent based on the 
research of CXCR4 antagonist development. By labeling the CXCR4 targeted small molecular or 
peptides with imaging agents is a basic approach for CXCR4 imaging agent development. T140 
derivatives, FC131 derivatives, AMD 3100 derivatives, SDF-1α analogs, and CXCR4 targeting 
antibodies are all being used for CXCR4 contrast agent development (Figure 1.7). Among these, 
three classes of compounds are most extensively evaluated (127).  
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1. Bicyclams AMD3100 and AMD3465 with radiolabeling as PET or SPECT tracer. 
2. Labeling of T140 peptide derivatives as PET, fluorescence tracer or hybrid tracer for 
multimodal imaging. 
3. Labeling FC131 cyclic peptide derivatives for PET imaging. 
64Cu-AMD3100 (Figure 1.8 A) imaging capacity has been evaluated in the xenograft 
mouse model (128) and orthotopic and metastatic breast cancer mouse model (129). In the breast 
cancer mouse model, the tumor shows 64Cu-AMD3100 uptake and the imaging effect can be 
blocked by unlabeled AMD3100 (129). The biodistribution study of 64Cu-AMD3100 
accumulation in liver, kidney, and immune-related organs and tissues such as bone marrow, spleen, 
and lymph nodes (130).  [(99m)Tc] pertechnetate labeled AMD3100 (Figure 1.8 B) was used as a 
SPECT tracer to image the PC-3 bearing mouse model (131). It shows favorable CXCR4 binding 
and specific tumor affinity by CXCR4 targeting.  
64Cu-AMD3465 was investigated with glioblastoma models, the tumor-to-muscle and 
tumor-to-noise ratio are much higher than 64Cu-AMD3100, suggesting the superior imaging 
capacity of 64Cu-AMD3465 (132). However, a considerable amount of uptake in the liver and 
kidney were observed as well, although the liver and kidney have an intrinsic expression of 
CXCR4 that explains part of the uptake mediated by receptor. The non-specific liver and kidney 
of cyclams structure imaging agents still need to be further addressed. 
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Figure 1.7 The targeting moieties for CXCR4 molecular imaging agents.  
Targeting moieties including natural ligand of CXCR4, CXCL12 derivatives, CXCR4 antibodies, 
derivatives of CXCR4 antagonists and agonists were used for the current development of CXCR4 
targeting imaging agent. 
 
T140 peptide has a strong CXCR4 binding affinity; the T140 peptide derivatives have been 
labeled a series of radiometals as PET imaging tracer for CXCR4 molecular imaging. 68Ga is 
suggested as a potential candidate for CXCR4 imaging for the favorable pharmacokinetics 
property and better tumor-to-muscle ratio (133). 4-18F-T140 was proved to have low accumulation 
in the metabolic organs, including the liver and kidney (134). The biodistribution of 4-18F-T140 is 
an advantage as opposed to AMD3100 based imaging for differentiating tumors in the metabolic 
organs with better signal-noise-ratio. Nishizawa K et al. reported the application of 




Figure 1.8 Structure of AMD3100 labeled CXCR4 imaging tracer. 
A. 64Cu labeled AMD3100 for PET imaging. B. [(99m)Tc]pertechnetate labeled 
AMD3100 for SPECT imaging. 
  
 F131 cyclic peptide derivatives show superiority as a PET tracer.  68Ga-CPCR4-2 shows 
high stability and CXCR4 tumor specificity in vivo. In addition, it has very low accumulation in 
liver and kidney despite the renal clearance (136). 
Tremendous effort has been made towards the development of CXCR4 specific imaging 
tracer. The majority of CXCR4 imaging tracers are nuclear medicine tracers. By labeled CXCR4 
antagonist AMD3100 and the analogs, T140 peptide and derivatives, F131 cyclic peptide and 
derivatives, CXCR4 imaging have been achieved using PET, SPECT and fluorescence imaging. 
A good CXCR4 molecular imaging tracer is expected to have high tumor-to-muscle signal, low 
unspecific uptake, optimized pharmacokinetics property, and clearance. CXCR4 molecular 
imaging through MRI has not yet been reported. To develop the CXCR4 specific MRI contrast 
agent will fill the unmet need. 
1.5.5 CXCR4 and uveal melanoma (UM) 
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. 
Uveal melanoma almost exclusively metastasis to the liver (over 95%). Although it has 
progressively more early diagnosed but the prognosis still unrealistic cause the early metastasis.  
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 The CXCR4/CXCL12 axis plays a crucial role in this process. First, the liver contains 
significant quantities of CXCL12, the natural ligand of CXCR4; it can attract CXCR4 positive 
cells. Moreover, cell-line based study of RT-PCT and flow cytometry (137) shows that all the 
primary uveal melanoma cell lines expressed CXCR4. Joseph Kim showed the CXCR4 expression 
in 89% (24 of 27) melanoma liver metastasis (138). A study by Bianca. D et al. on the Seventy 
formalin‐fixed paraffin‐embedded uveal melanoma patients’ specimens shows the strong CXCR4 
expression in the cytoplasm of uveal melanoma cells with an average immune reactive score (IRS) 
of 8.2 (139). Blocking the CXCR4-CXCL12 interaction with anti-CXCL12 antibody resulted in a 
reduction of chemotactic response, blocking CXCR4 expression by transfection of CXCR4 siRNA 
inhibited the invasive property of uveal melanoma (140). Besides, cross-talking between the 
CXCR4-CXCL12 axis and the VEGF (vascular endothelial growth factor) pathway were shown 
to benefit the tumor progression. 
The patient tissue study detected CXCR4 protein of 41.4 percent cases (141). Blocking 
CXCR4 gene expression by transfection with CXCR4 siRNA inhibited invasive properties of 
uveal melanoma cells exposed to soluble factors produced by human livers (140).  
The CXCR4-SDF1 axis plays an essential role in the organ-specific uveal melanoma 
metastasis. The CXCR4 expression level in primary melanoma is elevated, but the CXCR4 
expression level in uveal melanoma is controversial, a cell line study conducted by H, Li 
discovered the primary melanoma cell lines express CXCR4 whereas metastasis cell lines showed 
the decreased expression level of CXCR4 (137).  
1.5.6 CXCR4 and hepatocellular carcinoma (HCC) 
Hepatocellular carcinoma (HCC) is the most common primary liver malignant disease with 
poor prognosis. HCC is associated with liver cirrhosis which caused by chronic inflammatory liver 
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diseases such as hepatitis B (HBV) and hepatitis C (HCV) infection, it also related to non-viral 
liver diseases including alcoholic fatty liver disease and non-alcoholic fatty liver diseases.  
The role of CXCR4/SDF-1α in cancer is well recognized, and the intrinsic role of CXCR4 
in HCC development is widely studied as well. One germen group evaluated the association of 
CXCR4 expression with HCC progression in both HCC cell lines and patient tissue study (142). 
They suggested the association of CXCR4 in HCC dissemination and played an important role in 
the tumor progression. In 2007, one immunohistochemical based patient tissue study located the 
CXCR4 overexpression in HCC sinusoidal endothelial cells when compared with none-HCC 
tissue, suggesting the CXCR4 expression mediated the neo-angiogenesis of HCC and can be a 
potential HCC treatment target (143). The same year, one study of mouse HCC cell lines with high 
and low metastases potential proved the relationship of CXCR4 and HCC metastasis again (144). 
Their main finding is CXCR4 has a significantly higher expression on the mouse 
hepatocarcinomatous cell lines with high potential of lymphatic metastasis (Hca-F) as opposed to 
the mouse HCC cell line with low potential of lymphatic metastasis (Hca-P). In addition, CXCR4 
was found to correlate well with HCC patient bone metastasis, and the bone metastasis-free 
survival, which suggesting the CXCR4 expression as an independent risk factor for HCC (145). 
CXCR4 antagonist AMD3100 is used in combination with a broad kinase inhibitor—Sorafenib to 
prevent fibrosis in HCC (146). 
Overall, CXCR4 expression in HCC consider as an independent risk factor and result in 
poor prognosis. The CXCR4 expression in HCC elevated and involved in neo-angiogenesis and 
metastasis. As a result, mapping and monitoring the CXCR4 level in vivo with non-invasive 
imaging assay has strong translational potential and improves the disease management as well as 
treatment. 
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1.6 Motivation and challenges of this research 
The development of non-invasive imaging techniques and probes is pivotally important in 
improving the standard of care in cancer and cancer-related diseases. As the development in 
molecular cell biology, understanding about tumor etiology reach to an unprecedented level. 
Malignant diseases consist of various spectrum of molecular, cellular and systemic events and 
forming complex networks through chemokines chemokine receptors and cell signal pathways. 
Numerous cancer-related research and anti-tumor drug development have been done, and a lot 
more is undergoing. Assessment of cancer can no longer stay at a macroscopic level and satisfy 
the needs of researchers and clinicians. 
Molecular imaging is a relatively new field; the development of molecular imaging 
techniques is an interdisciplinary subject. It has the potential to fulfill the needs in diagnosis, 
monitoring, and prognosis with a more detailed, microscopic, molecular level. The development 
of molecular imaging tracers and probes has the potential to facilitate the disease follow up in a 
personalized fashion tailored to individual patients. Molecular imaging that provides the local 
microenvironment information can guide the treatment stratification.  Screening and assessing 
immune-related drugs more specific for individual targets of cancer required the assistant of 
molecular imaging as well. 
Molecular imaging tracer is necessary for the achieving of molecular imaging. Molecular 
imaging is rooted in radiotracers owing to the intrinsic sensitivity of nuclear medicinal imaging 
modalities. F-18-FDG is widely used in clinical practice. Magnetic resonance imaging has the 
advantage of being non-radiation involved, with no depth limitation and 3D imaging in high 
resolution. Research has been concentrated in apply magnetic resonance spectroscopy, diffusion 
MRI, CEST MRI for molecular MRI. 
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The significance of the CXCR4/SDF-1α axis in cancer-related events is well recognized. 
CXCR4 plays roles in different types of cancers, different stages of cancers, and the 
overexpression of CXCR4 in tumor tissue sees as an independent risk factor leads to poor 
prognosis and higher metastasis potential. Therefore, the development of CXCR4 specific imaging 
agents is significant for cancer-related researches and pre-clinical, clinical cancer research. We 
devoted to developing new classes of protein-based MRI contrast agent platform for a series of 
cancer-related biomarkers including HER2, PSMA, GRPR, EGFR, CXCR4, and collagen. For 
better understanding of tumor microenvironments and identifying treatment targets. The platform 
technique of protein-based contrast agent is translational to different metals and different targeting 
labeling.  
Challenges regarding this research are to develop specific biomarker targeted MRI contrast 
agent with enough sensitivity for the molecular imaging application. Relaxivity is an important 
factor to consider in the development of novel MR molecular imaging. Resolve the delivery of the 
imaging reagents is another challenge. We aim at delivering the MR imaging agents efficiently to 
the tumor region and optimized penetration for heterogeneity biomarkers detection. The cancer-
related biomarker usually in a µM local range, to develop contrast agent with CXCR4 specific 
targeting capability and dynamic imaging capacity to enable the contrast agent specifically 
accumulates at targeting tissue and lesions and minimize the off-target binding is another challenge 
about this research. 
Pharmacokinetics property of contrast agent is closely related to the imaging capacity and 
translational potential. Small molecules contrast agents possess short half-life and clearance to 
have a short time window for imaging. As blood pool agents, it would not be a big drawback. On 
the contrary, the shorter half-life will relatively reduce the risk of unwanted metal retention. 
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However, the in vivo targeting process is dynamic and influenced by blood flow, temperature, local 
tissue permeability, endocytosis. It is a very complicated process and might not be as time 
efficiency. We want to design contrast agents with suitable pharmacokinetic properties to enable 
the efficient in vivo delivery, binding and imaging, at the same time with proper clearance and less 
risk of metal toxicity caused by metal dissociation. To tune the pharmacokinetic property is a fine 
line and requires a great balance between imaging capacity and safety.  
Simultaneous detection of multiple biomarkers that related to each other and reveal the 
spatial coregistration will take molecular imaging further. Owing to the platform technique of 
protein-based contrast agent is readily translational for different metal labeling. Once labeling with 
different paramagnetic metal ions, such as gadolinium, manganese, and dysprosium, ProCAs are 
expected to have different relaxivities. Once different metal ions labeled ProCAs attach to different 
targeting moieties, we expect to achieve simultaneous MR imaging of multi-biomarkers. To 
achieve so, the time of imaging acquisition, imaging acquisition sequence, higher spatial resolution, 
and the influence of innate tissue relaxivities. will be factors that have to take into consideration.  
1.7 Overview of this dissertation 
This dissertation consists of 10 chapters in total. 
Chapter 1 is the introduction chapter and summarized the basic background information of 
this research. Including the cancer disease-related background, molecular imaging development, 
and approaches have been applied, and attempts have been made. Most of the molecular imaging 
research is done with nuclear medicine imaging, including PET, SPECT, and some multi-models 
imaging platform and tracers. Magnetic resonance imaging has the advantages of being non-
radiation, non-invasive, and excellent spatial resolution. CXCR4 is an important chemokine 
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receptor in various cancer-related incidence. Developing CXCR4 targeted MRI contrast agents is 
expected to benefit cancer diagnosis, treatment monitoring, and prognosis. 
Chapter 2 is the chapter of material and methods; it described the related experimental 
details of the experiments conducted in this research. All the material is used, and the method 
conducted is listed in detail in this chapter. 
Chapter 3 is the chapter of CXCR4 targeted contrast agent design and production. Chapter 
3 includes the rationale of design ProCA32.CXCR4, details of protein production and formulation 
and related results are described in this chapter. 
Chapter 4 is the biophysical property study of ProCA32.CXCR4. Chapter 4 introduce the 
relaxivity, metal-binding capability, and selectivity, serum stability, transmetallation study of 
ProCA32.CXCR4. 
Chapter 5 is the chapter of CXCR4 expression and detailed results of cell lines, animal 
models, patients’ tissue.  
Chapter 6 is the chapter summarizes the application of ProCA32.CXCR4 in cancer 
diagnosis, including uveal melanoma and ovarian cancer. Chapter 6 in detail documented the 
animal models, MRI scans, and histology correlation of pathology results with MRI results of 
mouse models. 
Chapter 7 is the chapter regarding the application of ProCA32.CXCR4 in HCC diagnosis 
and treatment effect monitoring. Chapter 7 records detailed background information and related 
experimental results of ProCA32.CXCR4 in hepatocellular carcinoma.  
Chapter 8 is a chapter regarding manganese-based contrast agent and multicolor MRI 
acquisition development. Including the initial result of Mn-ProCA32.CXCR4 relaxivities. 
Prediction of Mn-ProCA32.CXCR4 and Gd-ProCA32.CXCR4 concentration with relaxometer 
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and the potential application for multicolor MRI. Chapter 8 also includes the development of 
integrin v3 targeted contrast agent ProCA32. RGD. The rationale of design integrin v3 targeted 
contrast agent was documented. The initial characterization of ProCA32.RGD, including metal 
binding affinity, relaxivities, and integrin v3 targeting capability were performed. 
ProCA32.RGD has been applied for breast cancer detection in a 4T1 mouse model. 
Chapter 9 is the conclusion and significance of this dissertation research and summarized 
all the important scientific findings of this work and significance. 
2 MATERIAL AND METHODS 
2.1 CXCR4 expression study 
2.1.1 Flow cytometry analysis 
Flow cytometry was performed to quantify the expression of CXCR4. Cultured human 
uveal melanoma cells were dissociated with non-enzymatic cell dissociation solution (Sigma-
Aldrich, St. Louis, MO). Cells were stained for 20 minutes at 4C with APC mouse anti-human 
CD184 (clone 12G5) (BD Biosciences, San Jose, CA). Data acquisition was performed using a 
Becton Dickson Aria IIu FACS sorter (BD Biosciences, San Jose, CA). FlowJo software (Tree 
Star, Ashland, OR) was used for data analysis. 
2.1.2 Immunohistochemical (IHC) analysis  
UM patients’ liver tissue and UM mouse model tissue were stained with CXCR4 antibody 
for IHC study. Briefly, tissue was fixed in 10% neutral buffered formalin and embedded in 
paraffin. The tissue blocks were then sliced with 5 μM thickness for staining. Paraffin-embedded 
sections were first deparaffinized and rehydrated. After rehydration, 1 part of 30% hydrogen 
peroxide and 9 parts of absolute methanol mixture was used to quench endogenous peroxidase 
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activity for 10 min, followed by washing with TBST for 3 times, each time for 5 min. Antigen 
retrieval was achieved by boiling in target retrieval solution (Agilent) for 20 min. Slides were then 
washed with TBST for 3 times, each time for 5 min, blocked in 5% bovine serum albumin (BSA, 
Thermo Fisher) in TBST for 2 h, and incubated with 1:300 dilution of primary antibody anti-
CXCR4 antibody 12G5 (Abcam, ab189048) in TBST O/N at 4C. The IHC staining was performed 
with a red chromogen kit following the corresponding protocol. Counter staining of the nucleus 
was performed with hematoxylin. A CXCR4 positive control (brain specimen) was processed with 
the same protocol. All cases of uveal melanoma (UM) hepatic metastases exhibited high 
expression levels of CXCR4, indicated by the brilliant red color staining. 
2.2 ProCA32.CXCR4 expression, purification, and PEGylation 
2.2.1  Protein design 
ProCA32.CXCR4 is designed by linking a 21-mer targeting moiety to the C-terminus of 
ProCA32 with a flexible linker. The targeting moiety is derived from the N-terminus region of 
CXCR4 binding virus chemokine vMIP-II. The sequence of targeting moiety consists of 21 amino 
acid (LGASWHRPDKFCLGYQKRPLP) and including the key residues for CXCR4 interaction.   
2.2.2  Expression 
 ProCA32.CXCR4 was expressed by BL21 (DE3) pLysS cell strain. Briefly, 
ProCA32.CXCR4 plasmid was transformed to BL21 (DE3) pLysS competent cells and a single 
colony was inoculated to 250 mL of 2.5% LB medium for small-scale culturing overnight at 37°C. 
The small-scale culture was then transferred to 1 L of 2.5% LB medium for large-scale culturing 
at 37°C and monitoring the optical density at 595 nm (OD595). 0.5 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) was used for induction protein expression when the OD595 reach 
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between 0.6 to 0.8. Protein was expressed at 37°C for 3 h after induction, and the temperature was 
adjusted to 25°C for overnight expression. Cell pellets were collected by centrifuging for 25 min 
at 7000 rpm.  
2.2.3 Purification 
Cell pellets collected from expression were suspended by Phosphate-buffered saline (PBS), 
in 1 g cell pellet to 10 mL PBS ratio and mixed thoroughly.  Sonication is then used for breaking 
up the cell membrane and release cell content, cells were sonicated for 10 times, each time for 2 
min, with 5 min intervals between each to avoid over-heat. The cell lysate was then pelleted down 
by centrifuging, and the supernatant was boiled for 10 min to remove impurities. The supernatant 
was incubated with 3% streptomycin overnight at 4°C to remove further impurities (i.e., DNA). 
After repeat centrifuging and boiling, the supernatant was placed in 10 mM HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid) buffer, pH 8.0 overnight at 4°C for dialysis. After 
dialysis, 40mM EGTA (ethylene glycol tetraacetic acid) was added into ProCA32.CXCR solution 
to chelate Ca2+ and other cations, and HiTrap Q HP anion exchange chromatography column (GE 
Healthcare) was used to finish purification.  
2.2.4 Lysine PEGylation 
Methoxy PEG Succinimidyl Carboxymethyl Ester reagent with the molecular weight of 2 
kDa (JenKem Technology) was used for lysine PEGylation. ProCA32.CXCR4 was mixed with 
PEG reagent with a molar ratio of 1:5 and then shake at room temperature for 2 h or at 4°C for 
overnight. Excess non-reacted NHS-ester was quenched by 100 mM Tris buffer for 30 min at 
ambient temperature. The purification of the PEGylated protein sample was achieved by FPLC. 
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Polyacrylamide gel electrophoresis combined with coomassie-blue and iodine (I2) staining was 
applied to test the PEGylation efficiency. 
2.2.5 Cysteine PEGylation 
Methoxy PEG maleimide (JenKem Technology) with a molecular weight of 2 kDa was 
used for cysteine PEGylation. A good protein concentration for PEGylation is between 1-10 
mg/mL. 100x molar excess of Tris (2-carboxyethyl) phosphine hydrochloride (TCEP, Sigma-
Aldrich) was added and reacted at room temperature for 20 minutes to reduce disulfide bond of 
ProCA32.CXCR4. Amicon concentrator was applied to remove the unreacted free TCEP. 
Maleimide PEG was mixed with reduced ProCA32.CXCR4 with a molar ratio of 1:1. The mixture 
was degassed with nitrogen, closed tightly, and reacted overnight at 4°C. MALDI (matrix-assisted 
laser desorption/ionization) Mass-spectrometry and coomassie-blue and iodine (I2) staining were 
applied to analyze the PEGylation product. 
2.3 Determination of r1 and r2 relaxivity values 
         To determine the relaxivity of ProCA32.CXCR4, different concentrations of 
ProCA32.CXCR4 from 0 μM (buffer only) to 100 μM were prepared in 50 mM HEPES, 100 mM 
NaCl, PH 7.2. The samples were incubated at 37°C for one hour before measurement. The 
relaxation times (T1 and T2) of different concentration of ProCA32.CXCR4 were measured by 
Bruker minispec relaxometer (60MHz) and the phantom was scanned by 7.0 T Bruker MRI 
scanner.  Commercial GBCA such us Dotarem, Magnevist, Eovist etc. were prepared with 
the same buffer and measured with same protocol. However, the concentration range was from 0 











                                                                                                                           Equation 2.1 
Whereas the 𝑇𝑖𝑠𝑎𝑚𝑝𝑙𝑒 is the relaxation time of contrast agent samples and the 𝑇𝑖𝑏𝑢𝑓𝑓𝑒𝑟 is 
the relaxation time of buffer only, [𝐺𝑑3+]𝑇 is the Total concentration of Gd
3+. 
2.4 Metal-binding affinity and selectivity study 
2.4.1 Determination of Tb3+ binding affinity of ProCA32.CXCR4 
 Fluorescence spectra were collected with QM1 fluorescence spectrophotometer (PTI) at 
room temperature. Tb3+-tryptophan luminescence resonance energy transfer (LRET) emission 
spectrum (500 nm to 600 nm) was acquired following a 280 nm excitation. 30 μM of 
ProCA32.CXCR4 was added into DTPA chelator buffer (5 mM DTPA, 50 mM HEPES, 150 mM 
NaCl, pH 7.2) for titration. DTPA has a strong binding affinity to Tb3+ (Kd= 10
-21 M, 25 °C). The 
“free” Tb3+ concentration can be calculated by: 
                                              




                                                                                                                                                                                                                     Equation 2.2 
Whereas we assume the “free” Tb3+ is the portion triggered the LRET and cause 
fluorescence signal change, the Tb3+ binding affinity of ProCA32.CXCR4 can be calculated by the 










                                                                                                                                    Equation 2.3 
 
where f is the fractional LRET signal change followed each of titration points, n is the hill 
number. 
2.4.2 Determination of Gd3+ binding affinity of ProCA32.CXCR4. 
A competition method was applied to evaluate the Gd3+ binding affinity of 
ProCA32.CXCR4. 10 µM of ProCA32.CXRC4 and 20 μM Tb3+ were prepared in 5 mM DTPA 
(diethylenetriamine pentaacetate), 50 mM HEPES, 150 mM NaCl at pH 7.2, and incubated with 
different concentrations of Gd3+, from 0 μM to 200 μM, at room temperature for overnight. By 
fitting the fluorescence signal decrease at 545 nm as the Gd3+ concentration increase, the apparent 
Kd of Gd
3+ compete with terbium can be calculated by the equation:  
𝑓 =
([𝑇𝑏]𝑇 + [𝐺𝑑]𝑇 + 𝐾𝑑𝑎𝑝𝑝) − √([𝑇𝑏]𝑇 + [𝐺𝑑]𝑇 + 𝐾𝑑𝑎𝑝𝑝)
2 − 4 × [𝑇𝑏]𝑇 × [𝐺𝑑]𝑇
2 × [𝑇𝑏]𝑇
 
                                                                                                                           Equation 2.4 
Where f is the fractional LRET signal change, [Tb]T is the total Tb
3+ concentration, [Gd]T 
is the total Gd3+ concentration. Kdapp is the apparent dissociation constant of Gd
3+ compete with 
Tb3+. 
The dissociation constant of Gd3+ binds to ProCA32.CXCR4 can be calculated by equation: 
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𝐾𝑑𝐺𝑑,𝑃𝑟𝑜𝐶𝐴32.𝐶𝑋𝐶𝑅4 = 𝐾𝑑𝑎𝑝𝑝 ×
𝐾𝑑 𝑇𝑏,𝑃𝑟𝑜𝐶𝐴32.𝐶𝑋𝐶𝑅4
𝐾𝑑 𝑇𝑏,𝑃𝑟𝑜𝐶𝐴32.𝐶𝑋𝐶𝑅4 + [𝑇𝑏
3+]𝑇
 
                                                                                                                           Equation 2.5 
Where KdTb,ProCA32.CXCR4 is the dissociation constant of Tb
3+ binds to ProCA32.CXCR4, 
[Tb3+]T is the total Tb
3+ concentration. 
2.4.3 Determination of Ca2+ binding affinity of ProCA32.CXCR4 
 The dissociation constant between ProCA32.CXCR4 and Ca2+ was determined by a 
similar assay that was developed by Tsien (147). 10 µM of ProCA32.CXCR4 was prepared in 5 
mM EGTA (ethylene glycol tetraacetic acid), 50 mM HEPES, 150 mM NaCl at pH 7.2. Different 
concentration of Ca2+ was titrated into the system. Fluorescence change upon each titration was 
monitored by the emission spectrum of 200 nm to 300 nm followed by excitation of 280 nm, the 
concentration of free Ca2+ can be calculated by the equation: 




                                                                                                                           Equation 2.6 
Where the dissociation constant of Ca2+ to EGTA (KdCa,EGTA) is 1.51×10
-7 M, The Kd of 







                                                                                                                          Equation 2.7 
Where f is the fractional change of Tryptophan fluorescence intensity, [Ca2+]free is the free 
Ca2+ concentration of each titration. 
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2.4.4  Determination of Zn2+ binding affinity of ProCA32.CXCR4. 
The dissociation constant between Zn2+ and ProCA32.CXCR4 was determined by a 
modified fluorescence competition assay. In detail,  2 µM of Zn2+ and FluoZinTM-1 (ThermoFisher) 
was prepared in 1:1 ratio, different concentrations of ProCA32.CXCR4 were titrated, fluorescence 
emission spectrum of 500 nm to 600 nm was acquired by 495 nm excitation, the apparent Kd of 
ProCA32.CXCR4 competes with Zn2+ can be calculated by the equation: 
𝑓 =
([𝑍𝑛]𝑇 + [𝑃𝑟𝑜𝐶𝐴32. 𝐶𝑋𝐶𝑅4]𝑇 + 𝐾𝑑𝑎𝑝𝑝) − √([𝑍𝑛]𝑇 + [𝑃𝑟𝑜𝐶𝐴32. 𝐶𝑋𝐶𝑅4]𝑇 + 𝐾𝑑𝑎𝑝𝑝)
2 − 4 × [𝑍𝑛]𝑇 × [𝑃𝑟𝑜𝐶𝐴32. 𝐶𝑋𝐶𝑅4]𝑇
2 × [𝑍𝑛]𝑇
 
                                                                                                                           Equation 2.8 
Where [Zn]T is the total Zn
2+ concentration and [ProCA32.CXCR4]T is the total 
ProCA32.CXCR4 concentration, Kdapp is the apparent dissociation constant. Knowing the 
dissociation constant of Zn2+ to Fluozin-1, the dissociation constant between Zn2+ and 
ProCA32.CXCR4 can be calculated by equation: 




                                                                                                                           Equation 2.9 
Where Kdapp is the apparent dissociation constant of ProCA32.CXCR4 compete with 
Fluozin-1. 
2.4.5 Determination of Mn2+ binding affinity of hProCA32.collagen1 
The Mn2+ binding affinity of hProCA32.collagen1 was determined with a competition 
assay similar to Gd3+-ProCA32.CXCR4 binding affinity determination. 10 µM of 
hProCA32.collagen1 was prepared with 20 µM of Tb3+ in 5 mM DTPA, 50 mM HEPES, 150 mM 
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NaCl at pH 7.2, different concentrations of Mn2+ (from 0 µM to 1000 µM) were then added into 
solution and incubate at ambient temperature for O/N.  Fluorescence spectra of each sample are 
collected, and apparent Kd of Mn
2+-Tb3+ competition was fitted against the fractional fluorescence 
signal change at 545 nm by the equation: 
𝑓 =
([𝑇𝑏]𝑇 + [𝑀𝑛]𝑇 + 𝐾𝑑𝑎𝑝𝑝) − √([𝑇𝑏]𝑇 + [𝑀𝑛]𝑇 + 𝐾𝑑𝑎𝑝𝑝)
2 − 4 × [𝑇𝑏]𝑇 × [𝑀𝑛]𝑇
2 × [𝑇𝑏]𝑇
 
                                                                                                                         Equation 2.10 
Whereas the f is the fractional fluorescence signal change, [Tb]T is the total Tb
3+ 
concentration, [Mn]T is the total Mn
2+ concentration and Kdapp is the apparent Kd of Mn
2+-Tb3+ 
competition. 
By knowing the apparent Kd of Mn
2+-Tb3+ competition and the Tb3+ binding affinity of 
protein contrast agent, the disassociation constant of Mn2+ to contrast agent can be calculated by 
the equation: 
𝐾𝑑𝐺𝑑,𝑃𝑟𝑜𝐶𝐴32 = 𝐾𝑑𝑎𝑝𝑝 ×
𝐾𝑑 𝑇𝑏,𝑃𝑟𝑜𝐶𝐴32
𝐾𝑑 𝑇𝑏,𝑃𝑟𝑜𝐶𝐴32 + [𝑇𝑏
3+]𝑇
 
                                                                                                                         Equation 2.11 
2.5 Determination of the water coordination number of ProCA32.CXCR4 
 The water coordination number of ProCA32.CXCR4 was measured by terbium 
luminescence decay of ProCA32.CXCR4 – Tb3+ complex in H2O and D2O adapted from a reported 
assay (148). ProCA32.CXCR4 – Tb3+ complex was prepared in the H2O and D2O solution in 1:1 
and 1:2 ratio. Tb3+ was excited by the xenon lamp at 265 nm and the terbium luminescence decay 
lifetime was collected at the emission of 545 nm. By fitting the decay curve with exponential decay, 
KH2O and KD2O can be obtained, ΔKobs is the difference between luminescence decay of 
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ProCA32.CXCR4 – Tb3+ complex in H2O and D2O. Standard curve of water number of different 
chelators are used to calculate the water number of ProCA32.CXCR4. 
2.6 Cell culture 
Melanoma cell lines, including B16LS9, Mel290, Mel270, 92.1, M20-09-196 were used in 
this study. The culture medium recipe is 500 mL RPMI 1640 1X with L-Glutamine with 10% fetal 
bovine serum (FBS), 12.5 mL Corning™ HEPES, 1 M solution (fisher scientific), 5 mL Corning™ 
Sodium Pyruvate 100mM Solution (fisher scientific), 5 mL Corning™ cellgro™ MEM 
Nonessential Amino Acid Solution (fisher scientific), 5 mL Corning™ MEM Vitamin Solution 
(fisher scientific) and 5 mL Penicillin-Streptomycin solution. All cells were thawed at 37°C and 
transferred to a 100 mm cell culture dish with 6 mL of medium. After reach over 90% of 
confluence, cells were washed by HBSS and suspended by 1 to 2 mL of 1% trypsin and centrifuged 
for 5 min at 1000 rpm. Then cells were passed to two 100 mm culture dish to keep culturing. Cells 
were frozen with a commercial freezing medium containing 10 % DMSO (dimethyl sulfoxide) for 
cryopreserving. 
2.7  Cancer cell targeting study 
2.7.1 Flow cytometry analysis 
The flow cytometry was performed to quantify the expression of CXCR4. Cultured human 
uveal melanoma cells were dissociated with non-enzymatic cell dissociation solution (Sigma-
Aldrich, St. Louis, MO). The cells were stained for 20 minutes at 4C with APC mouse anti-human 
CD184 (clone 12G5) (BD Biosciences, San Jose, CA). Data acquisition was performed using a 
Becton Dickson Aria IIu FACS sorter (BD Biosciences, San Jose, CA). FlowJo software (Tree 
Star, Ashland, OR) was used for data analysis. 
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2.7.2 Immunofluorescence staining 
2.7.2.1 NHS-fluorescein labeling protein 
Fluorescein-5-EX N-hydroxysuccinimide ester (Sigma-Aldrich) was used to label 
ProCA32.CXCR4 and ProCA32. Protein solution concentrated between 1-10 mg/mL was prepared 
in 10 mM HEPES, pH 8.0 (Other non-amide-containing buffers at pH 7.0-9.0 may also be used). 
NHS-fluorescein was equilibrium to room temperature before reaction. 15 molar excess of NHS-
fluorescein was mixed well with the protein solution and react at room temperature for 1 h. Non-
reacted NHS-fluorescein was quenched by adding 100 mM Tris buffer. Protein was purified by 
gel filtration. 
2.7.2.2 Immunofluorescence staining with melanoma cells to evaluate the CXCR4 
binding affinity of ProCA32.CXCR4 
Melanoma cell lines including B16SL9, Mel290, M20-09-196 were used for 
immunofluorescence staining. Melanoma cells were cultured until reaching 50-70% confluence 
and fixed on cover slides with 3.7% formaldehyde solution at 4C. Fixed melanoma cells were 
incubated with 5μM NHS-fluorescein labeled ProCA32.CXCR4 (the control group was incubated 
with fluorescein-labeled ProCA32) for 1 h at 37 C. The cells were washed thoroughly with TBS-
Tween 20 (TBST) buffer. DAPI (4’,6-diamidino-2-phenylindole, ThermoFisher) was used for 
nucleus staining, and the cells were imaged with Zeiss microscope. For colocalization study, after 
incubation with NHS-fluorescein labeled ProCA32.CXCR4, melanoma cells were then blocked 
with 5% BSA (prepared in TBST buffer) for 20 min at room temperature and incubated with 0.1% 
dilutions of primary antibody for CXCR4 (Abcam, ab189048) at 4 C for overnight. After 
thoroughly washed with TBST buffer, melanoma cells were incubated with 0.1% dilutions of Goat 
anti-Mouse secondary antibody (Invitrogen, Alexa Fluor 555) for 60 min at room temperature. 
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DAPI (ThermoFisher) was applied to stain the nucleus, and slides were covered by coverslip and 
sealed. Colocalization analyses of red fluorescence (555 nm excitation) and green fluorescence 
(488 nm excitation) were done using Fiji’s plugin coloc2. 
2.7.2.3 Immunofluorescence staining of mouse tissue 
The liver tissue of Mel290 mice was collected after injection of ProCA32.CXCR4 and 
ProCA32, and immunofluorescence staining was performed on collected liver tissues. 4 M 
Cryosections of Mel290 mice livers were thawed at room temperature for 20 min and rehydrate 
the tissue sections with TBST. Tissue sections were surrounded with a hydrophobic barrier using 
Dako pen (Agilent) and blocked with 5% BSA for 60 min at room temperature then incubated with 
home-made ProCA32.CXCR4 and ProCA32 primary antibody (1:50 dilution) for 60 min at room 
temperature. After thoroughly washed with TBST, tissue slides were incubated with 0.1% dilution 
of Goat Anti-Rabbit secondary antibody (Invitrogen, Alexa Fluro-555) for 60 min at room 
temperature. DAPI (ThermoFisher) was then applied to stain the nucleus, and slides were covered 
and sealed. 
2.7.3 Enzyme-linked immunosorbent assay (ELISA) 
An indirect ELISA assay (Fig. 2.1) was used to quantify the CXCR4 targeting capability. 
Melanoma cells with CXCR4 expression were used to determine the ProCA32.CXCR4 targeting. 
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Figure 2. 1 Determing the CXCR4 binding affinity with indirect ELISA. 
 
2.7.3.1 Preparation of cell lysate.  
 The cells were cultured in T-75 flasks until reach to about 90-95% confluence, and gently 
washed by HBSS before collected by plastic cell scraper. 1 ml of HBSS buffer was added into the 
flask, and cells were scraped from the flask. The mixture solution was transferred to a pre-cold 
tube and centrifuge at 8000 rpm for 10 min at 4C° to pellet down cells. The supernatant was gently 
decanted and 1 ml of RIPA buffer was added to lyse the cells for 1 h at 4C°.  The mixture was then 
centrifuged at 12,000 rpm for 30 min at 4C° to remove the cell debris. The supernatant was 
collected as cell lysate, and the total protein concentration of cell lysate was measured by Bio-Rad 
assay. 
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2.7.3.2 Indirect ELISA 
        Melanoma 290 cell lysate in NaHCO3 solution (pH 9.6) was incubated in 96-well plates 
overnight at 4 °C. The 96-well plates were washed thoroughly by TBST buffer and blocked by 5% 
BSA solution (prepared in TBST) for 60 min at room temperature. Different concentrations of 
ProCA32.CXCR4 (0 nM to 5000 nM, prepared in TBST) was added in different wells and 
incubated for one hour at room temperature. 0.1% ProCA32.CXCR4 antibody (self-generated 
polyclonal rabbit antibody) was added for 60 min incubation at room temperature. The secondary 
antibody, stabilized goat-anti-rabbit HRP-conjugated antibody (Pierce), was incubated for 45 min 
at room temperature. After washed with TBST, 100 µL of 1-StepTM Ultra TMB-ELISA Substrate 
Solution (ThermoFisher) was added into each well to visualize the color change. When a yellow 
gradient color was observed, 100 µL of 1 M H2SO4 was added into each well to terminate the 
reaction. The absorbance intensity at 450 nm wavelength was measured by FLUOstar OPTIMA 
plate reader, and data were plotted using GraphPad Prism 5. 
2.7.4 MRI phantom scanning of ProCA32.CXCR4 incubated melanoma cells 
CXCR4 expression cell lines are cultured according to the requirement. Cells are washed 
with PBS to remove serum and protein in the culture media. After that, cells were incubated with 
ProCA32.CXCR4 at 37°C for one hour. Wash the cells gently for three times with PBS buffer. 
Cells are collected with non-enzymatic cell dissociation solution and centrifuge with 1000 rpm for 
5 minutes. Supernatant decanted gently to remove the PBS and gently resuspend the cells with 
PBS again. Repeat three times. Cell pellets are collected and transferred to the small tube for the 
phantom experiment to determine the relaxivities.  
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2.7.5 Cell attachment assay 
 The cells were cultured overnight under standard conditions. Next day, different cells 
(with appropriate cell numbers) were transferred to a new plate with wells that were coated with 
different proteins (indicated in the figures) with fresh medium. The cells were further cultured for 
35 min in the CO2 incubator at 37°C, upon incubation cells were washed three times gently. The 
attached cells were directly counted. In all attachment assays, the attachment is presented as a total 
number of cells attached to the plate per microscopic view field (calculated from the average of 
three view fields in each well in four wells). 
2.8  Stability study of ProCA32.CXCR4 
2.8.1 Serum stability  
150 µL of 500 µM ProCA32.CXCR4 was mixed with 150 µL mouse serum and incubated 
at 37ºC for the serum stability study. 15 µL of samples were taken after 3 h, 4 h, 1 d, 2 d, 4 d, 6 d, 
8 d, and 14 d of incubation. The samples were boiled for 10 min after being mixed with 2 µL of 1 
M EGTA solution and SDS buffer and analyzed by western blot and Ponceau S staining flowing 
a standard procedure. Briefly, the mixture of protein sample and mouse serum taken from different 
time points at 37ºC incubation were prepared for the SDS-PAGE. Protein bands were transferred 
from the SDS-PAGE to nitrocellulose membrane. Ponceau S solution (Sigma-Aldrich) was used 
to stain the membrane from 5 min and rinse membrane 3-5 times in TBST buffer to achieve the 
desired staining results. 
2.8.2 Transmetallation study 
In order to characterize the resistance of the Gd3+-ProCA32.CXCR4 complex to 
transmetallation by endogenous ions such as Zn2+, a relaxometric transmetallation assessment was 
performed using a reported assay (149). Briefly, ProCA32.CXCR4 and other GBCA were mixed 
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with the same concentration of ZnCl2 (2.5 mM) in pH 7.0 phosphate buffer. The final mixture 
contained 0.026 M KH2PO4, 0.041 M Na2HPO4, 2.5 mM Gd
3+ complex, and 2.5 mM ZnCl2. When 
transmetallation of Gd3+ by Zn2+ occurred, insoluble GdPO4 formed and a decreased proton 
relaxation rate was observed. The longitudinal relaxation rate change of the mixture reflected the 
transmetallation process of Gd3+ by Zn2+ and the thermodynamic index was calculated by r1 of the 
mixture after incubation at the present of Zn2+ over the initial r1 of GBCA. 
2.9 Animal study  
2.9.1  Intrahepatic heterotopic xenotransplantation tumor model 
  10-wk-old female NU/NU mice (Jackson Laboratory, Bar Harbor, ME) were used to 
establish the intrahepatic heterotopic xenotransplantation tumor model. Mel290 cells were 
cultured and suspended in sterile PBS buffer. The mice were anesthetized with ketamine and 
xylazine mixture and placed to the supine position. A small incision was made along the right flank 
of the mouse. The liver was exposed with a small retractor. A 301/2-gauge needle was inserted 
into the liver until its point reached just below the liver sub capsule under a surgical microscope. 
Two million of Mel290 cells were inoculated in a volume of 20 ul PBS. The needle was then 
carefully removed at the same time that a sterile swab held the injection site. Formation of white 
cell bulla between hepatic parenchyma and the capsule was the criterion for successful injection.  
The incision was sutured with a 5-0 absorbable suture. After two to three weeks of Mel290 cell 
injection, melanoma tumor formed in the liver.  
2.9.2 Intraocular melanoma mouse model with hepatic metastases  
Human uveal melanoma M20-09-196 cells and 10-wk-old female NU/NU mice (Jackson 
Laboratory, Bar Harbor, ME) were used to generate the intraocular melanoma mouse model. 
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Subsequently, the mice with intraocular melanoma developed hepatic metastases. An aliquot of 
106 uveal melanoma cells suspension in 2.5 l PBS buffer was inoculated into the supra choroid 
space of the right eye of the nude mouse using a transcorneal technique. The mice were 
anesthetized with an intraperitoneal injection (IP) of ketamine and xylazine mixture. A tunnel was 
prepared from the limbus within the cornea, sclera and ciliary body to the choroid with a 301/2-
gauge needle under a surgical microscope. The tip of a 10 l glass syringe with a 31-gauge / 45-
degree point metal needle (Hamilton, Reno, NV) was used to introduce cell suspension into the 
supra choroid space through the needle track. The eyes were enucleated after two weeks of 
inoculation. Metastases in liver formed after 8-12 months of tumor cells inoculation.   
2.9.3   SKOV3 Orthotropic Human Ovarian Cancer Xenograft Model 
SKOV3 orthotopic human ovarian cancer xenograft mouse model was developed by Dr. 
Lily Yang with the following procedure (150). SKOV3 ovarian cancer cells were cultured in 
McCoy 5A medium with 10 % fetal bovine serum and 1 % penicillin and streptomycin. SKOV3 
cells were collected when the confluence reaches 80 % and suspended in sterile PBS buffer. Mice 
were anesthetized by injecting a mixture of 95 mg/kg ketamine hydrochloride and 5 mg/kg 
xylazine of body weight in sterile saline intramuscularly.  Right ovary of mice was exposed by 
abdominal incision. At least 5 × 104 cells in 20 μL PBS were injected orthotopically into the 
ovarian bursa of each mouse. Close the abdominal incision after injection and monitor the mice 
until completely awake. 
2.9.4 DEN induced HCC mouse model 
Equal number of male and female mice with C57BL/6 genetic background were used for 
developing DEN induced HCC mouse model. Diethylnitrosamine (DEN, Sigma–Aldrich N0756) 
was dissolved in sterile saline. 14-day-old mice were treated with a single dose of 
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Diethylnitrosamine (DEN, Sigma–Aldrich N0756) at a dose of 25 mg/kg body weight by IP 
injection. Mice in one randomly pre-assigned group were euthanized 11 months after DEN 
administration for histological and biochemical analyses. The livers were removed and weighted 
right after euthanasia, the numbers of visible tumors on the liver surface were counted 
macroscopically. The largest lobes were fixed in formalin and embedded in paraffin. Sections were 
stained with hematoxylin and eosin and examined microscopically. Doxorubicin treatment: 
Doxorubicin hydrochloride salt was dissolved in sterile DD water. Mice received doxorubicin (3 
mg/kg) bi-weekly for 4 weeks. The mice were then analyzed for MRI screening and euthanized 
for pathological analyses. 
2.9.5 4T1 breast tumor mouse model 
Luciferase stable transfected 4T1 breast cancer cells were cultured in RPMI-1640 medium 
supplemented with 10 % FBS and 1 % penicillin and streptomycin until confluence reach 80 %. 
Cells were detached by trypsin and suspended in sterile PBS. 5 × 104 cells were orthotopically 
injected to the mammary pad of mice. The orthotopic breast tumors will form around 2 weeks, and 
lung metastases will form around 3 - 4 weeks. 
2.9.6 Subcutaneous UM murine model 
Ten-week-old female NU/NU mice were used for the subcutaneous UM murine model.  
Aliquots of 2*106 Mel 290 cells were suspended in 50 µL of PBS buffer mixed with 50 µL of 
Matrigel Matrix (Corning Life Science) and injected subcutaneously both on the right and left 
side of the back of NU/NU mice. After six weeks, subcutaneous tumors of 60-120 mm3 in 
volume were formed.   
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2.10 MRI scan 
M20-09-196 mice and HCC mice were all scanned with a 7.0 T Agilent MRI scanner at 
the University of Georgia. Mice were anesthetized by breathing in isoflurane through isoflurane 
vaporizer. The respiration rates of animals were monitored throughout the MRI scanning and 
controlled to be 70-80 times per minute. T1 weighted images, T2 weighted images were collected 
by spin-echo and fast spin-echo sequence before and after one bolus injection of 0.025 mmol/kg 
ProCA32.CXCR4 at 3 h, 24h, 48h. T1 map and T2 map were also collected at the same time points. 
T1 map was collected by the fast spin-echo protocol. The parameters of acquisition:  TR, 5000 ms; 
ESP, 8.17 ms; 8 inversion times cover from 0.01 ms to 1.5 ms with the same interval in between; 
FOV, 3.5 cm × 3.5 cm by a matrix of 512 × 512; thickness, 1 mm with no gap. The parameters of 
T2 map acquisition:  TR, 2000 ms; TE, 8 ms to 96 ms with 8 ms interval in between; FOV, 3.5 cm 
× 3.5 cm by a matrix of 512 × 512; thickness, 1 mm with no gap. Control mice were injected with 
one bolus same dosage of ProCA32 and imaged at the same time points with the same parameters. 
The parameters of spin-echo sequence: TR, 500 ms; TE, 14.89 ms; FOV, 3.5 cm × 3.5 cm by a 
matrix of 512 × 512; thickness, 1 mm with no gap. The parameters of fast spin-echo sequence: 
TR/ESP, 4000 ms/ 10 ms; FOV, 3.5 cm × 3.5 cm by a matrix of 512 × 512; thickness, 1 mm with 
no gap. 
M290 mice MR images were all collected on a 4.7 T small-bore Varian MR scanner at 
Emory University. Mice were anesthetized follow a similar procedure and T1 weighted images 
were collected before and after one bolus injection of 0.025 mmol/kg ProCA32.CXCR4 at 12 min, 
50 min, 3 h, 22 h, 46 h by gradient echo sequence. The parameters of gradient echo sequence: 
TR/TE, 140 ms/11 ms; FOV, 4 cm × 4 cm by a matrix of 512 × 512. MR images are processed 
and analyzed by Fiji and MRIcron. 
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MRI results of blocking experiment were acquired with the 7.0 T Bruker MRI scanner at 
Yerkes National Primate Research Center. Subcutaneous UM mice were anesthetized follow a 
similar procedure as detailed above, and T1 weighted images were collected before and after one 
bolus injection of 0.025 mmol/kg Cys-ProCA32.CXCR4 or Lys-ProCA32 at 3 h, 24 h, and 48 h. 
Blocking group mice received i.v. injections of 0.025 mmol/kg CXCR4 blocking reagent 24 h and 
12 h prior to the injection of Cys-ProCA32.CXCR4. The parameters of the RARE sequence were: 
TR/TE, 560 ms/11 ms; FOV, 3.5 cm × 3.5 cm by a matrix of 256 × 256. MRI data were processed 
and analyzed by Fiji and MRIcron. 
 
2.11  Organ distribution, toxicity, and pharmacokinetics study of ProCA32.CXCR4 
2.11.1 Organ distribution study. 
ICP-OES was used to analyze the Gd3+ distribution in different mouse organs after injection 
of ProCA32.CXCR4. Healthy CD-1 mice were injected with 0.025 mmol/kg bolus dosage of 
ProCA32.CXCR4. Animals were euthanized 46 h and 7 days after receiving an injection of 
ProCA32.CXCR4. Organs including heart, liver, spleen, kidney, brain, muscle, and skin were 
subsequently collected and used for ICP-OES analysis. Tissues (0.1–0.5 g) of each organ were 
dissolved overnight in 1 mL of 67-69% nitric acid, OptimaTM (Fisher Chemical). Undissolved solid 
particles were removed by filtration, and the supernatant was retained for Gd3+ content analysis by 
ICP-OES. 
2.11.2  Toxicity study of ProCA32.CXCR4 
         ProCA32.CXCR4 acute toxicity was tested by a bolus injection of 100 μL, 7 mmol 
ProCA32.CXCR4 to 10-week-old healthy CD-1 mice. ProCA32.CXCR4 with two different 
PEGylation (Cys-ProCA32.CXCR4 and Lys-ProCA32.CXCR4) were tested, respectively. For 
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each experiment group, n = 3, the control group are mice with saline injection. Mice were observed 
every eight hours post-injection, then euthanized after five days. Terminal blood was collected by 
cardiac puncture, and serum was transferred immediately to micro-centrifuge tubes. Plasma was 
separated from blood cells by centrifugation at 14,000 rpm, 4°C for 10 min. Serum samples were 
used for blood biochemistry tests and kidney function tests to measure ALT, AST, and electrolyte 
levels. Tissues including heart, muscle, liver, spleen, kidney, tail, and brain, were collected for 
analysis of gadolinium distribution, using ICP-OES. 
2.11.3  Pharmacokinetic study 
Female CD-1 mice (8–10 weeks old) were used to determine the pharmacokinetic 
parameters of ProCA32.CXCR4. ProCA32.CXCR4 (100 L, 0.025mmol/kg) was administered 
through tail vein IV injection. The blood samples were collected at various time points using 
saphenous vein up to seven days using a sparse sampling design (3–6 animals per time point). 
Immediately following blood sample collection, samples were stored on ice, serum was obtained 
through centrifugation, and Gd3+ concentration was determined using ICP-OES. Pharmacokinetic 
parameters were calculated using the non-compartmental analysis tool of Phoenix WinNonlin 
software. The areas under the concentration-time curve (AUClast and AUCinf) were calculated 
using a linear trapezoidal rule. The clearance and volume of distribution (Vss) were estimated 
following IV dose administration. The elimination rate constant value (k) was obtained by linear 
regression of the log-linear terminal phase of the concentration-time profile using at least three 
declining concentrations in terminal phase with a correlation coefficient of >0.8. The terminal half-
life value (T1/2) was calculated using the equation 0.693/k. 
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3 DESIGN, EXPRESSION, PURIFICATION, AND PEGYLATION OF 
PROCA32.CXCR4  
3.1 Introduction 
CXCR4 is found to be expressed in over 23 different kinds of tumors and closely related 
to cancer progression and development of metastases. Chemokine receptor 4 (CXCR4) plays a 
crucial role in cell migration and cancer metastasis to several organs such as liver, bone marrow, 
and lung that have the intrinsically high concentration of its natural ligand CXCL12 (140, 151, 
152). (Figure 3.1). CXCR4 has gained tremendous attention over the past few decades for its 
widely up-regulation in various types of cancers. It is now gradually becoming a novel molecule 
target for anti-cancer diagnosis and treatment. A CXCR4 antagonist, Plerixafor (Mozobil®, 
AMD3100), is approved by the FDA for stem cell mobilization. Another ongoing study is focused 
on the effect of another CXCR4 antagonist, X4P-001, on T-cell infiltration in human metastatic 
melanoma. The importance of CXCR4 in cancer-related incidence is the motivation of achieving 
CXCR4 targeted imaging for cancer. 
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Figure 3.1  Cancers metastasize through the CXCR4-CXCL12 gradient in an organ-
specific pattern. 
Tumor cells that express CXCR4 metastasize through CXCR4-CXCL12 interaction to specific 
organs that have intrinsically high concentration of CXCL12 such as the lung, liver and bone. 
 
vMIP-II, a viral chemokine encoded by human herpesvirus 8, displays diverse interactions 
with both CC and CXCR4 (153-155). vMIP-II interacts with CXCR4 as an antagonist and inhibits 
the Th1-associated inflammation. Due to these properties of vMIP-II, it is a potential candidate for 
anti-inflammatory and anti-HIV drugs. A crystal structure of CXCR4 and vMIP-II complex reveals 
the interaction of vMIP-II to CXCR4 is through the N-terminus and N-loop of vMIP-II (156). The 
central residues that participate in the interaction are mainly in the N-terminus. It supported by the 
study of synthesis peptides with the N-terminus sequence of vMIP-II, the peptide contains the 
amino acid sequence of residues 1- 21 of vMIP-II (LGASWHRPDKCCLGYQKRPLP), displays 
appreciable CXCR4 binding affinity (IC50 = 190 nM) when compared with the vMIP-II (IC50 = 
14.8 nM) (157).  
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MRI imaging is widely used in clinical practice, and MRI contrast agent development can 
efficiently improve the sensitivity of MRI. As stated in chapter 1, the current contrast agents in 
clinical usage are not sensitive enough to achieve molecular imaging. Based on the platform of 
ProCA32, after careful review of the CXCR4 targeting moieties, we designed the CXCR4 specific 
targeting contrast agent, namely, ProCA32.CXCR4. ProCA32.CXCR4 was designed based on the 
platform of protein-based contrast agent ProCA32. ProCA32 was developed by previous lab 
member Dr. Xue, which contains two Gd3+ binding sites. By linking the CXCR4 targeting moiety 
to the C terminus of ProCA32 with a flexible linker, we designed ProCA32.CXCR4 as the CXCR4 
targeted MRI contrast agent for CXCR4 specific molecular imaging with MRI (Figure 3.2). Based 
on the complex X-ray structure of CXCR4 and vMIP-II, we designed the CXCR4 targeting moiety, 
included key CXCR4 interaction residues from vMIP-II, that reach into the binding pocket and 
interact with key residues D262, D97, S285, and E288 of CXCR4 in both chemokine recognition 
sites 1 and (Figure 3.4) (156).  
ProCA32.CXCR4 was bacterially expressed and purified following a previously reported 
protocol (63). One cysteine is introduced for site-specific PEGylation through thiol group with 
maleimide PEG reagent. The post-expression modification was done through NHS-ester 
PEGylation or maleimide PEGylation verified by coomassie blue staining, and iodine (I2) staining. 
 
 




Figure 3.3 Predicted secondary structure, solvent accessibility, and models of 
ProCA32.CXCR4. 
Prediction of secondary structure, solvent accessibility and final models of ProCA32.CXCR4 
using I-TASSER (158). C-score is the confidence of protein model predicted by I-TASSER, which 
is typically in the range of [-5,2], where the higher value of C-score corresponding higher 




Figure 3.4 Model structure of the ProCA32.CXCR4 interacting with CXCR4.    
ProCA32.CXCR4 contains two Gd3+ binding sites, the C terminus of ProCA32.CXCR4 is the 




3.2.1 Expression, purification of ProCA32.CXCR4 
ProCA32.CXCR4 was expressed by cell strain BL21(DE3) pLysS with 0.5 mM IPTG 
induction followed by a protocol described in chapter 2. The expression of ProCA32.CXCR4 
consists of small-scale culture and large-scale expression. Ampicillin resistant agar plates were 
used for transformation of ProCA32.CXCR4 plasmid. A single colony was inoculated in 250 ml 
LB media with 0.1% ampicillin for small scale culture overnight at 37 °C. The second day, small 
scale culture LB media were transferred to 1-liter LB media with 0.1% ampicillin for large scale 
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expression at 37°C. Measure the OD595 of the LB media to ensure large-scale culturing starts from 
OD595 around 0.1. Observing the OD595 change along with time and add 0.5 mM IPTG when 
culture solution OD595 reach between 0.6-0.8. After adding IPTG for inducing expression, keep 
the culturing temperature at 37 °C for three hours, and reduce the temperature to 25°C for overnight 
expression. Different conditions for expression have been tested: 28°C culturing for 4 hours after 
IPTG induction generated comparable yield with 25°C overnight expression. 
 The expression of ProCA32.CXCR4 is confirmed by Coomassie blue staining of SDS-
PAGE (Figure 3.5 A). Molecular weighted of ProCA32.CXCR4 is 14.3 kDa and after induction 
cell pellet clearly shows thicker band of protein around 14.3 kDa. The yield of ProCA32.CXCR4 
expression is calculated to be in a range of 60 to 100 mg/L LB media, varies by the batch of 
expression. 
Purification of ProCA32.CXCR4 followed by a series of steps including sonication, 
boiling, dialysis, and FPLC (fast protein liquid chromatography). Cell pellet from expression LB 
media was collected by centrifuging at 8000 rpm. The cell pellet was resuspended in PBS buffer 
in a ratio of 1:10, more specific, 1 gram of cell pellet resuspended in 10 ml PBS buffer. Sonication 
was applied to break cell structure and release the expressed protein. Sonication was carried out 
10 times in total, every time for 1 minute and with a 10 minutes interval in-between for cooling 
down the solution. After sonication, the solution should become semitransparent and with good 
consistency. Pellet down the solution with centrifuge and boiled the supernatant to further remove 
the impurities. 3% streptomycin was used to sediment the DNA for overnight. Followed by which 
the solution is pellet down with centrifuge and boiled again and dialysis with 10 mM HEPES 
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buffer for overnight. After dialysis, the solution was centrifuged and pellet down, 40 mM EGTA 
was added for incubation for 48 hours, and the sample is ready for FPLC. 
  Ion exchange column was utilized to purify ProCA32.CXCR4 after sonication and 
boiling. Fractions eluted from different peaks of FPLC spectra were collected separately, SDS-
PAGE was applied to verify the components of each elution from corresponding peaks (Figure 3.5 
B, Figure 3.6 B). As shown in the purification SDS-PAGE (Figure 3.6 B), protein sample eluted 
from peak 2, peak 3, and peak 4 were proved to be ProCA32.CXCR4 (MW = 14.3 kDa) and in the 
presence of both monomer and dimer form. As shown in Figure 3.5, a large percentage of the 
ProCA32.CXCR4 present in the monomer form. 
 
Figure 3.5 Expression and purification SDS-PAGE of ProCA32.CXCR4.  
(A) Coomassie blue staining of BL21(DE3) pLysS cell pellets before and after IPTG induction. 
Cell pellets after IPTG induction show significantly thicker protein band around 14.3 kDa. (B) 
Coomassie blue staining of SDS-PAGE of samples collected before FPLC and after FPLC. After 




Figure 3.6 Purification of ProCA32.CXCR4. 
(A) FPLC absorbance spectrum of ProCA32.CXCR4 purification. Peak 1 fractions are unbounded 
protein; peak 2 fractions represented the Ca2+ bound form of ProCA32.CXCR4, fractions from 
peak 4 are the Ca2+ free form of ProCA32.CXCR4, fractions eluted from peak 3 are the mixture of 
Ca2+ loaded and Ca2+ free form of ProCA32.CXCR4. Peak 5 fractions are the DNA impurity. (B) 
SDS-PAGE coomassie blue staining of fractions eluted from FPLC. Protein bands showed on peak 
2, peak 3, and peak 4 elution fractions. (C) The UV absorbance of protein sample collected from 
FPLC peak 4. The red curve shows the absorbance spectrum of Ca2+ bound ProCA32.CXR4. The 
black curve shows the Ca2+ free ProCA32.CXCR4. The UV spectrum of Ca2+ binding form 
ProCA32.CXCR4 show a hump at 295 nm. 
 
3.2.2 PEGylation of ProCA32.CXCR4 
ProCA32.CXCR4 was PEGylated after expression for post-expression modification to 
further optimize solubility, stability, and pharmacokinetic properties. Site-specific PEGylation 
including cysteine specific PEGylation through thiol group with maleimide group of the 
PEGylation reagent and lysine-specific PEGylation through amide group on the lysine side chain 
with NHS ester from the PEG reagent (Figure 3.7).  
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Figure 3.7 Illustration of PEGylation. 
 (A) Reaction mechanism of site-specific maleimide PEGylation (Cys-PEGylation). The 
maleimide group of polyethylene glycol (PEG) specifically react with the thiol group from 
cysteine. (B) Reaction mechanism of NHS ester-PEGylation (Lys-PEGylation). The NHS ester 
group of PEG agent react with the amine group from lysine side chain. 
 
PEGylation of both lysine-specific and cysteine specific were carried out in an oxygen-free 
system with degassing the solution by flushing nitrogen. Cysteine specific PEGylation requires a 
reduced environment to break the disulfide bond and expose the thiol group. Reducing reagent 
TCEP (tris (2-carboxyethyl) phosphine hydrochloride) was used to reduce the disulfide bond 
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before cysteine PEGylation. During PEGylation, the falcon tube was wrapped with aluminum foil 
to avoid light and generation of radical.  
Lysine PEGylation product contains ProCA32.CXCR4 with different PEGylation sites. 
Coomassie blue staining and iodine staining of SDS-PAGE shows multiples bands for the Lysine 
PEGylation products (Figure 3.8). Cysteine PEGylation generates the homogenous PEGylation 
product with only one site been PEGylated, the Coomassie blue staining and iodine staining of 
cysteine PEGylation product shows only two bands, one for the non-reacted ProCA32.CXCR4 
and the upper one is ProCA32.CXCR4 with one cysteine PEGylated (Figure 3.8). 
 
Figure 3.8 PEGylation SDS-PAGE of ProCA32.CXCR4. 
(A) Coomassie blue staining of ProCA32.CXCR4 before and after PEGylation. ProCA32.CXC4R 
form in monomer and dimer before PEGylation, as indicated by the two bands on SDS-PAGE. 
Cys-PEGylation product of ProCA32.CXCR4 composed non-PEGylated ProCA32.CXCR4 and 
Cys-ProCA32.CXCR4, indicated by two bands on SDS-PAGE. Multiple protein bands of Lys-
ProCA32.CXCR4 product represents Lys-ProCA32.CXCR4 with a various number of PEGylation 
sites. (B) Iodine (I2) staining of ProCA32.CXCR4 before and after PEGylation. Iodine staining 




3.3 Conclusion and discussion 
ProCA32.CXCR4 expression, purification, and PEGylation are critically important for the 
generation of CXCR4 specific contrast agent. We aim at producing ProCA32.CXCR4 in an 
economical and time-efficient fashion and the protocol allows for the translational usage for large 
scale production meet industrial standards. 
ProCA32.CXCR4 is bacterially expressed and purified in a relatively simple steps protocol. 
The yield of expression is good (60-100 mg/L LB) by optimizing expression procedures. The 
protein yield exhibit best if follow three hours after induction expression at 37°C and decrease the 
expression temperature to 25°C for overnight expression. ProCA32.CXCR4 is heat resistant and 
structurally stable at boiling temperature. This property enables the purification of 
ProCA32.CXCR4 from a lot of the impurity proteins efficiently. FPLC can further separate 
ProCA32.CXCR4 from remaining impurities and separate the metal (Ca2+) free form of 
ProCA32.CXCR4 with metal (Ca2+) loaded for gadolinium loading formulation. EGTA incubation 
is a critical step for chelating metal ions, majorly Ca2+. 48 hours incubation with EGTA of the 
ProCA32.CXCR4 before FPLC efficiently remove the preloaded metal ions and yield more Ca2+ 
free ProCA32.CXCR4. Longer incubation time is tested as well, no significant difference of Ca2+ 
free ProCA32.CXCR4 and Ca2+ loaded ProCA32.CXCR4 ratio was observed from longer 
incubation time samples.  
PEGylation of ProCA32.CXCR4 has successfully achieved by both cysteine PEGylation 
and lysine PEGylation. After PEGylation, the solubility and stability of ProCA32.CXCR4 is much 
improved and allow for the storage of ProCA32.CXCR4 at higher concentration and longer shelf 
life. Lysine PEGylation increases the molecular weight of ProCA32.CXCR4 by 4-5 sites 
PEGylation on average, which increase the molecular weight by 10 kDa to 30 kDa varies by the 
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length of PEG reagents being used. Lysine PEGylated ProCA32.CXCR4 potentially has longer in 
vivo circulation half-life because of the larger molecular weight. Cysteine PEGylation is more ideal 
in the sense that it generates homogenous PEGylation product. The efficiency of cysteine 
PEGylation is slightly lower than lysine PEGylation, which means more reagents might be wasted 
during cysteine PEGylation procedure. There are several steps worth noting in the PEGylation: 
protein solution should be properly degassed to remove the oxygen; protein sample tube should be 
properly wrapped by aluminum foil to avoid exposure to light. 
pH is an essential factor for the PEGylation, maintaining a pH neutral environment 
improves the efficiency and percentage of PEGylation. Avoid radical is another factor in 
successfully PEGylation; it is recommended to thoroughly degas the solution and avoid light by 
wrapping with aluminum foil. Different PEGylation approaches, including N terminal amide 
PEGylation and different sizes of PEGylation reagents, can be tested for further optimization of 
PEGylation protocol.  
3.4 Summary 
The expression, purification, and PEGylation of ProCA32.CXCR4 was achieved based on 
a previously reported protocol of ProCA32 with minor modification to improve the yield, quantity 
of metal free form of ProCA32.CXCR4 for later gadolinium loading. Different PEGylation was 
tested to optimize the solubility, stability and pharmacokinetic property of ProCA32.CXCR4. 
Lysine specific PEGylation is more efficient in terms of percentage of PEGylated 
ProCA32.CXCR4 over the total amount when compare with cysteine PEGylation. Cysteine 
specific PEGylation has the advantage of generating homogenous PEGylation for industrial 
production standard. 
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4 BIOPHYSICS STUDY OF PROCA32.CXCR4 
4.1 Introduction 
Since the FDA approval of gadopentetate dimeglumine (Magnevist; Bayer HealthCare 
Pharmaceuticals) in 1988, Gd3+-based contrast agents (GBCAs) have been widely used for clinical 
MR imaging. GBCAs was considered to safe until the first nephrogenic systemic fibrosis (NSF) 
been identified in 1997 (159-161). NSF was thought to be a disease only involve skin symptoms, 
and the original name was Nephrogenic Fibrosing Dermopathy (NFD) (160). More and more in-
depth study of NSF makes researchers realized that it is a systemic disease that involves multiple 
organs and tissues and happened mostly in the patients with a history of dialysis because of chronic 
renal diseases. In some cases, NSF patients progress rapidly and lead to severe physical disability 
and deaths (162). P. Marckmann and colleagues proposed the causative role of gadodiamide 
application in the development of NSF. Since then, NSF has been identified as the side effect of 
gadolinium-based contrast agents, especially in the patients with compromised renal function. 
Moreover, the standard and dosage of gadolinium-based contrast agents’ application have been 
modified, and the patients’ renal function listed as a factor that taken into consideration. No 
standard treatment was established for NSF, and some cases showed kidney transplantation and 
extracorporeal photopheresis could help to treat the disease (163). 
   The confidence of GBCAs was reestablished since more stable gadolinium-based 
contrast agents being used, and the usage of GBCA in patients with renal malfunction was limited. 
More recent data demonstrated that, in patients with the history of GBCA administration, 
gadolinium accumulate in tissues including brain, bone, and kidneys regardless of patients’ renal 
function status. Repeatedly exposure to gadolinium increases the risk of gadolinium accumulation. 
(164, 165). The brain deposition of gadolinium was first identified because the signal increase of 
67 
dentate nuclei (DN) in unenhanced T1 weighted MR images of patients with normal renal function, 
and this enhancement was associated with exposure to gadolinium-based contrast agents (166, 
167). Since then gadolinium-based contrast agent was accepted as the primary etiology of brain 
tissue deposition. 
We have carefully considered these factors in the design of ProCA32.CXCR4 for clinical 
translational purpose. The Gd3+ binding sites of ProCA32.CXCR4 was well designed to balance 
Gd3+ binding for safety, and water accessibility for relaxivities. ProCA32.CXCR4 was shown to 
have unprecedented gadolinium kinetic and thermodynamic stability. The Log (KGd) of 
ProCA32.CXCR4 is 21.89. Metal selectivities of ProCA32.CXCR4 for Gd3+ over Zn2+ and Ca2+ 
are 106-1012 times greater than approved contrast agents, Dotarem and ProHance. The inertness of 
ProCA32.CXCR4 in the presence of Zn2+ verified its strong stability against transmetallation. 
Moreover, the improved relaxivity of ProCA32.CXCR4 enabled excellent contrast enhancement 
in vivo with only one-quarter of gadolinium dosage compared with other GBCAs. No trace of 
gadolinium was detected in mice brain after ProCA32.CXCR4 administration and we have also 
not observed any acute toxicity and tissue/organ toxicity. Collectively, strong Gd3+ binding 
affinity, excellent metal selectivity, inertness against transmetalation and less injection dosage 
makes ProCA32.CXCR4 has an excellent safety profile. 
4.1.1 Gadolinium toxicity and deposition 
All clinical approved GBCAs are considered to be safe when administrating in a lower 
dosage (0.1 to 0.3 mmol/kg) in the patients without renal insufficiency (46). Gadolinium is a rare 
earth element and belongs to the lanthanide family. The free Gd3+ is toxic for humans, and the 
chelated form will be far less toxic since it can eliminate from kidney before dissociating from 
chelator. As a result, the toxicity of gadolinium-based contrast agent is considered to positively 
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related to the stability of gadolinium-chelator complex. The free gadolinium deposited in tissues 
including brain, bone, and kidney as well as other lanthanide family metal ions.  In the insufficient 
renal function patients, the half-life of GBCAs elimination is significantly prolonged than the 
patients with normal renal function, which allows more time for free Gd3+ being dissociated from 
chelator. It is one of the reasons that most of the reported NSF patients was administrated with 
nonionic linear GBCA gadodiamide (Omniscan) (168).  
            The GBCAs can be classified into two categories according to their chemical structure, 
linear and macrocyclic. The linear ones have an open-chain structure that is not fully closed where 
the macrocyclic ones are caged in the chelator by the ligands. The etiology of NSF is considered 
primarily to be free Gd3+ release from the chelator complex, and this process is related to two 
factors: kinetic stability and thermodynamic stability (Table 4.1). Kinetic stability of GBCAs 
defined by the dissociation rate of Gd3+ from the gadolinium complex, thermodynamic stability of 
GBCAs characterized by the energy that requires for the dissociation of Gd3+ from chelator 
complex to happen. As a result, GBCAs with higher kinetic stability and thermodynamic stability 
will less readily to release Gd3+. Notably, the description of kinetic stability and thermodynamic 
stability are under pH 1. 
             According to the stability under physiological condition, Frenzel et al. described the 
GBCAs into three different stability classes: macrocyclic, linear ionic, and linear nonionic (45). 
The macrocyclic GBCAs are most stable under physiological conditions (incubation with human 
serum at 37 °C, pH 7.4), the Gd3+ release rate after 15 days incubation is less than 0.1 %, and the 
initial Gd3+ release rate is less than 0.007 %/d. On the contrary, the release of Gd3+ rate of linear 
GBCAs are way faster than predicted value by the conditional stability constant, and nonionic 
linear GBCAs are about 10 times faster than the ionic linear GBCAs. Also, the elevated phosphate 
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level of human serum facilitates the release of Gd3+. These results suggesting evaluation of GBCAs 
under physiological condition will be more clinically relevant, and the thermodynamic stability 
under physiological condition (pH 7.4) is termed conditional stability constant (45). 
Table 4.1 A summary of chemical structure and stability of clinic contrast agents. 
Table adapted from reference (46). 
 
4.1.2 Metal selectivity and stability of ProCA32.CXCR4 
Two major goals are wanted to achieve in the design of ProCA32.CXCR4. First, optimized 
stability is desired for safety consideration. Secondly, sufficient water access and the exchange 
rate is crucial for maximizing relaxivities of ProCA32.CXCR4. By modifying the calcium-binding 
pocket of parvalbumin, we designed binding pockets for gadolinium with ideal ligand 
coordination. The similar radius of calcium and gadolinium facilitates the gadolinium fit in the 
binding pockets, and the 3-positive charge of gadolinium ion results in the stronger coordination 
of gadolinium in the binding pockets than calcium. The thermodynamic stability of 
ProCA32.CXCR4 is accessed under physiological condition (human serum incubation at 37 °C, 
pH 7.4) and the binding affinity (defined by the dissociation constant) of ProCA32.CXCR4 with 
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different metallic ions including terbium, gadolinium, calcium, and zinc are evaluated under the 
physiological condition as well. 
 
4.1.3 Pharmacokinetics and toxicity study 
Pharmacokinetics, abbreviated as PK, described what the body does to a drug. 
Pharmacokinetic includes the studies the absorption, distribution, metabolism and elimination of 
substances. Four fundamental parameters, including volume of distribution, half-life, 
bioavailability, and excretion, provide the basis of understanding pharmacokinetic properties of a 
drug (169). Pharmacokinetics parameters are closely related to each other. When a substance has 
faster clearance, it will show shorter half-life, higher clearance, and lower exposure, otherwise, it 
shows more prolonged blood circulation, lower clearance, and higher exposure. The study of 
pharmacokinetics property of a drug predicts the in vivo behavior of a drug and helps to decide the 
dosage to improve therapeutic effects and minimize side effects (170) . 
Volume of distribution described by the amount of drug in the body over the concentration 
of drug in the plasma or blood. In fact, lots of drugs exhibit volume of distribution larger than the 
volume of the plasma or blood, because of the volume of distribution is an apparent volume pool 
requires for the drug distributed evenly throughout the body. Drugs with good tissue penetration 
can be distributed to the organs faster and only leave a small amount of drug in the plasma or 
blood. The distribution of a drug depends on the patients’ factors and the chemical properties of 
the drug. The binding of the drug to the blood cells, plasma protein, and tissue are deciding factors 
for the distribution as well. 
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Half-life measures the time requires for the concentration of a drug reduce 50%. Half-life 
defined by both changes of volume of distribution and clearance. It provides a way to estimate the 
distribution of drug reach a steady state. 
The bioavailability defined by the amount of intact drug reaches to the sites of actions, or 
the systemic circulation. By definition, a drug’s bioavailability will be 100% right after 
administration if it administrated intravenously. The bioavailability of drug decreases when 
administrated through other routes. 
To study the pharmacokinetic properties of ProCA32.CXCR4 provide a better 
understanding of dosage, imaging time window, specific organ distribution, and toxicity. As for 
the translational application for human patients. We study the distribution of ProCA32.CXCR4 in 
different organs, including the liver, kidney, spleen, heart, muscle by analyzing the gadolinium 
content with ICP-OES and pharmacokinetics profile of ProCA32.CXCR4 was analyzed by the 
change gadolinium concentration in whole blood followed the administration of ProCA32.CXCR4 
along with time. Toxicity evaluated by the clinical pathology profile of mice followed by 
ProCA32.CXCR4 injection and organ toxicity were evaluated by the H & E staining of mouse 
tissue including  
4.2 Results 
4.2.1 Relaxivity study of ProCA32.CXCR4 
 Relaxivity is a crucial property of MRI contrast agent; the major goal of this study is to 
design a novel contrast agent with improved relaxivities to enable molecular imaging using MRI. 
The relaxivities of ProCA32.CXCR4 is evaluated at 1.4 T and 7.0 T respectively because higher 
field application will allow higher resolution imaging and is the future direction of MRI. Also, we 
have noticed that the relaxivities vary with different PEGylation. The relaxivities (both r1 and r2) 
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of non-PEGylated ProCA32.CXCR4, lysine PEGylated ProCA32.CXCR4 (Lys-
ProCA32.CXCR4) and cysteine PEGylated ProCA32.CXCR4 (Cys-ProCA32.CXCR4) were 
evaluated, respectively. 
ProCA32.CXCR4 has two gadolinium binding sites. It raises the question of what the best 
loading ratio of ProA32.CXCR4 and gadolinium are to achieve the optimized relaxivities per 
particle and relaxivities per gadolinium. One experiment was carried out for this study by setting 
the concentration of gadolinium as 50 µM in buffer solution, different concentration of 
ProCA32.CXCR4 (range from 0 µM to 100 µM) were titrated in, and both r1 and r2 values were 
measured at different loading ratio. The result shows that the best relaxivities per gadolinium are 
achieved when loading with ProCA32.CXCR4 in 2:1 ratio (Figure 4.1 A, B). When the 
ProCA32.CXCR4 concentration increase form 0 µM to 25 µM, the relaxivities increase as the 
ProCA32.CXCR4 concentration increase. When the ProCA32.CXCR4 concentration increase 
from 25 µM to 100 µM, the relaxivities (both r1 and r2) decrease as the ProCA32.CXCR4 
concentration increase (Figure 4.1 A, B). The relaxivities of per gadolinium are only half the value 
when loading gadolinium with ProCA32.CXCR4 in 1:1 ratio when compared with load 
gadolinium with ProCA32.CXCR4 in 2:1 ratio (Figure 4.1 C, D). The relaxivities of non-
PEGylated ProCA32.CXCR4, cysteine PEGylated ProCA32.CXCR4 and lysine PEGylated 
ProCA32.CXCR4 exhibited no difference with each other (Figure 4.1 C, D). Further relaxivities 




Figure 4.1 Relaxivities comparison of different PEGylation of ProCA32.CXCR4.  
(A) The r2 relaxivity of 50 µM Gd
3+ loaded with different concentration of non-PEGylated 
ProCA32.CXCR4, cysteine PEGylated ProCA32.CXCR4 and lysine PEGylated 
ProCA32.CXCR4. (B) The r1 relaxivity of 50 µM Gd
3+ loaded with different concentration of 
ProCA32.CXCR4, ProCA32.CXCR4-Cys and ProCA32.CXCR4-Lys (C) Comparison of r2 of 
different PEGylation of ProCA32.CXCR4 loaded with gadolinium in 1:1 and 1:2 ratio. (D) r1 
Comparison of different PEGylation of ProCA32.CXCR4 loaded with gadolinium in 1:1 and 1:2 





Figure 4.2 Relaxivities study of ProCA32.CXCR4 and comparison with clinic GBCAs. 
Comparison of ProCA32.CXCR4 relaxivities with commercial GBCAs. Measurements are done 
under 1.4 T magnetic field. 
 
The per gadolinium r1 and r2 values of ProCA32.CXCR4 were 30.9 mM
-1 s-1 and 40.2 mM-
1 s-1, respectively, at 1.4 T (Figure 4.3 A).  Both r1 and r2 relaxivity values were 8 to 10 times 
greater than the clinically-approved Gd3+-based contrast agents (GBCA) (Figure 4.2 and Table 
4.2). Also, ProCA32.CXCR4 exhibited good relaxivities at higher magnetic field 7.0 T as well 
(Figure 4.3 B), the r1 and r2 relaxivity values of non-PEGylated ProCA32.CXCR4 were 17.4 mM
-
1S-1 and 88.7 mM-1S-1, respectively. Interestingly, the relaxivities of the non-PEGylated form of 
ProCA32.CXCR4, lysine-PEGylated ProCA32.CXCR4 (Lys-ProCA32.CXCR4), and cysteine-
PEGylated ProCA32.CXCR4 (Cys-ProCA32.CXCR4) did not exhibit significant differences  
(Figure 4.1 C, D and Table 4.2). The r1 and r2 relaxivities of ProCA32.CXCR4 are largely retained 
after PEGylation. Overall, ProCA32.CXCR4 exhibited significantly improved r1 and r2 
relaxivities when compared with clinical gadolinium-based contrast agents at both 1.4 T and 7.0 
T. The unique dual relaxation properties are essential for achieving early detection of small size 




Figure 4.3 Determine Relaxivities of ProCA32.CXCR4 at different magnetic fields. 
(A) Relaxivity assessment of ProCA32.CXCR4 with 60 MHz relaxometer. At 1.4 T, r1 of 
ProCA32.CXCR4 is 28.3 mM-1 s-1, r2 of ProCA32.CXCR4 is 40.2 mM
-1 s-1. (B) Relaxivity 
assessment of ProCA32.CXCR4 with 7.0 T MR scanner. r1 of ProCA32.CXCR4 is 17.4 mM
-1 s-1, 
r2 of ProCA32.CXCR4 is 88.7 mM
-1 s-1.  
 
Table 4.2 Relaxivities of investigated contrast agents at the different magnetic fields. 
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4.2.2 Metal-binding and metal selectivity study of ProCA32.CXCR4 
4.2.2.1 Determine the Tb3+ binding affinity of ProCA32.CXCR4 
 In the process of designing new generation MRI contrast agent, improving the sensitivity 
(relaxivity) is primarily essential. Water proton relaxation by gadolinium (III) occurs via a dipolar 
mechanism and has a 1/r6 dependence on the distance between the ion and the nucleus. Because 
of this, it is critical to have one or more exchangeable waters in the inner- coordination sphere. 
Water exchange in and out of the first coordination sphere should be fast. Two major factors 
contribute to increasing the relaxation rate of bulk solvent: the paramagnetic ion should efficiently 
relax the water that accesses it, and the relaxed water should exchange rapidly with the bulk water.  
 ProCA32.CXCR4 has a wide metal binding pocket which allows more accessibility for 
the water molecules and faster bulk water exchange rate. In comparison with commercial MRI 
contrast agent such as Gd (DTPA), ProCA32.CXCR4 has more rigidity in molecular structure and 
slower in rotational speed, which leads to a higher relaxivity. For gadolinium (III) based contrast 
agents, high gadolinium (III) binding affinity is required for safety concern. To determine the 
gadolinium binding affinity can address this issue.  
Gadolinium (III) has no fluorescent property. Therefore, an indirect method first was 
developed for gadolinium binding affinity measurement. Terbium has the similar element radius 
and carries the same charge with gadolinium. In addition, terbium has fluorescence property and 
can be excited with 330 nm wavelength light. One tryptophan was introduced close to the metal-
binding sites to enable the luminescence resonance energy transfer (LRET). Fluorescence 
spectrum of terbium bond ProCA32.CXCR4 was collected (Figure 4.5 A). The terbium-
ProCA32.CXCR4 complex fluorescence spectrum shows a peak at 545nm when excited with 280 
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nm wavelength light. The intensity is increasing in 545 nm indicating Tb3+ bound 
ProCA32.CXCR4 concentration increase. By fitting the intensity increase at 545 nm,  dissociation 
constant of Tb3+ bound with CXCR4 can be calculated from the fractional signal intensity change 
corresponding to the “free terbium” concentration.  
Calibration of Tb3+ can be achieved by either ICP-OES or complexometric titration. ICP-
OES determined the ion concentration by intensity- concentration correlation defined by standard 
curve. Complexometric titration is the titration of the metal ion with the ligand that readily to form 
a complex with the metal ion. Xylenol orange was used as a metal indicator for complexometric 
titration of Tb3+ solution with DTPA buffer with known DTPA concentration. Once the titration 
reaches the endpoint, xylenol orange turns from violet to yellow color; this colorimetric change 
can also be detected more precisely by UV spectroscopy (Figure 4.4). Tb3+ solution concentration 
can be calculated with the equation  
                                    𝐶𝑇𝑏 × 𝑉𝑇𝑏 = 𝐶𝐷𝑇𝑃𝐴 × 𝑉𝐷𝑇𝑃𝐴                                         Equation 4.1 
 

















The Tb3+ binding-affinity of ProCA32.CXCR4 is expected to be strong, and a DTPA buffer 
system was applied to control the free terbium concentration. DTPA chelator buffer contains 5 
mM DTPA, 50 mM HEPES, 150 mM NaCl, and in pH 7.2. The dissociation constant of DTPA 
with Tb3+ is 10-21 M at 25 °C. The “free” Tb3+ concentration can be calculated by Equation 2.2. 
Free Tb3+ has weaker 545nm emission peak when excited with 280 nm UV, a control group 
without ProCA32.CXCR4 was paralleled measured for signal subtraction. The intensity difference 
between the control sample and ProCA32.CXCR4 titration sample represents the signal intensity 
triggered by Tb3+ binding to the ProCA32.CXCR4. By fitting the free Tb3+ concentration and the 
corresponding fractional fluorescence intensity change with Equation 2.3, the Kd value of Tb
3+ 
bound with ProCA32.CXCR4 is 3.38e-22 (Figure 4.5). 
 
 
Figure 4.5 Determination of Kd value of Tb3+ binding affinity with ProCA32.CXCR4.   
Dissociation constant of Tb3+ with ProCA32.CXCR4 determined with DTPA-Tb3+ buffer system 




4.2.2.2 Determine the Gd3+ binding affinity of ProCA32.CXCR4 
The binding affinity of Gd3+ bound with ProCA32.CXCR4 determines the stability of 
gadolinium association with ProCA32.CXCR4 and the safety profile of ProCA32.CXCR4 for in 
vivo application. The Gd3+ binding affinity of ProCA32.CXCR4 is determined with DTPA buffer 
system and competitional titration with Tb3+. Gd3+ and Tb3+ have the same charge and expected to 
possess a similar binding affinity to ProCA32.CXCR4.  
In order to determine the Gd3+ binding affinity of ProCA32.CXCR4. 10 µM of 
ProCA32.CXRC4 and 20 μM Tb3+ were prepared in 5 mM DTPA, 50 mM HEPES, 150 mM NaCl 
at pH 7.2. Different concentrations of Gd3+, from 0 μM to 200 μM, were incubated with Tb3+ 
loaded ProCA32.CXCR4 at room temperature for overnight. Fluorescence signal intensity of 
LRET between Tb3+ and ProCA32.CXCR4 decreases along with the Gd3+ concentration increases 
(Figure 4.6 A). By fitting the signal decrease with Equation 2.4, the apparent Kd of Gd
3+- 
Tb3+competition was calculated (Figure 4.6 B). 
Tb3+-ProCA32.CXCR4 binding affinity and apparent Kd of Tb
3+- Tb3+ competition was 
obtained by fluorescence titration, Gd3+- ProCA32.CXCR4 binding affinity is 1.2e10-22, calculated 
by Equation 2.5.  
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Figure 4.6 Determination of Gd3+ binding affinity of ProCA32.CXCR4. 
The Gd3+ binding affinity of ProCA32.CXCR4 is determined in DTPA buffer system (5 mM 
DTPA, 50 mM HEPES, 150 mM NaCl, pH 7.2) by competing Tb3+ loaded ProCA32.CXCR4 with 
different concentration of Gd3+ and fit the fluorescence signal decrease at 545 nm with one to one 
binding. The Kd of Gd
3+ -ProCA32.CXCR4 binding is 3.38e-22 M. 
 
4.2.2.3  Determine Ca2+ binding affinity of ProCA32.CXCR4  
Assessment of Ca2+ binding affinity of ProCA32.CXCR4 is important. ProCA32 is based 
on the scaffold protein parvalbumin, which is a calcium-binding protein. The gadolinium binding 
pockets of ProCA32.CXCR4 are modified calcium-binding sites. For in vivo application, one 
challenge is to improve the metal selectivity of ProCA32.CXCR4. The physiologically present 
metal ions such as Ca2+ and Zn2+ are competitors for Gd3+ and result in Gd3+ dissociation. The Ca2+ 
binding affinity of ProCA32.CXCR4 was determined by a fluorescence spectroscopy titration. A 
chelator buffer system contains 50 mM HEPES, 150 mM NaCl, and 5 mM EGTA at pH=7.2 was 
applied. 10 μM final concentration of ProCA32.CXCR4 was used for calcium titration. Different 
concentrations of calcium chloride (CaCl2) were added into the buffer system, and the free calcium 
that dissociated from the EGTA buffer system is assumed binds to ProCA32.CXCR4 metal 
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binding pockets. The “free” calcium concentration was calculated using Equation 2.6 (Roger 
Tsien):   
The fluorescence emission spectra record the wavelength from 300 nm to 400 nm followed 
by excitation of 280 nm. The fluorescence intensity changes at 310 nm corresponding to each 
titration point were used to calculate the dissociation constant of Ca2+ bind to ProCA32.CXCR4 
using Equation 2.7, Ca2+ binding affinity of ProCA32.CXCR4 is 1.3 ± 0.1 e-8 M by hill equation 
fitting (Figure 4.7 B). 
 
Figure 4.7 Determine the Ca2+ binding affinity of ProCA32.CXCR4.  
The Ca2+ binding affinity of ProCA32.CXCR4 is determined in EGTA chelator buffer (50 mM 
HEPES, 150 mM NaCl, and 5 mM EGTA at pH=7.2). (A) Fluorescence spectra blue shift, and the 
intensity increases as the CaCl2 titrated to the solution. (B) Fitting of the fluorescence intensity 
change in 520 nm along with an increase in Ca2+ concentration. The Ca2+ binding affinity of 
ProCA32.CXCR4 is 1.3±0.1 e-8 M. Data fitted by Hill equation. 
 
ProCA32.CXCR4 has two metal-binding sites and cooperative bindings between the 
binding sites. Hill equation describes the cooperative binding assuming fixed cooperativity and 
denoted by Hill number n. When n  1, means the whole system exhibits positive cooperativity, 
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when n  1, the whole system exhibits negative cooperativity. Hill equation assumes the multiple 
binding sites possess same binding affinity. 
In order to address the Ca2+ binding affinity of two binding sites, Adair equation 
hypothesized binding affinity depend on the ligand saturation instead of being a fixed parameter. 
It describes the binding affinity of each site more individually by an apparent macroscopic 
association constant Ki. By fitting the “free” Ca2+ concentration versus the fluorescence intensity 
change with Adair equation, Kd of Ca
2+ binding affinity of two binding sites is 1.0 × e108 M and 
6.7e × 107 M respectively (Figure 4.8). 
 
Figure 4.8 The Ca2+ binding affinity of ProCA32.CXCR4 Fitted with Adair equation. 
The Ca2+ binding affinity of ProCA32.CXCR4 is determined in EGTA chelator buffer (50 mM 
HEPES, 150 mM NaCl, and 5 mM EGTA at pH=7.2) and fitted with Adair equation to 
determine the Ca2+ binding affinity of each metal-binding sites. The Kd of Ca
2+-
ProCA32.CXCR4 bindings are 1.0 e108 M and 6.7 e107 M, respectively. 
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4.2.2.4 Determine the Zn2+ binding affinity of ProCA32.CXCR4  
The Zn2+ binding affinity of ProCA32.CXCR4 was determined by a competitional binding 
assay.1 μM of ZnCl2 and 4 μM of Fluozin-1 were added in 50 mM HEPES, 150 mM NaCl, at pH 
7.2 for titration. Different concentrations of ProCA32.CXCR4 from 0 μM to 80 μM were added to 
compete with Fluozin-1 for Zn2+ binding. Fluorescence spectra cover wavelength 500 nm to 600 
nm were recorded following each titration. Fluorescence signal intensity changes at 510 nm were 
fitted with one to one binding and apparent Kd of ProCA32.CXCR4 competition with Fluozin-1 is 
acquired (Figure 4.9).  
Dissociation constant of Fluozin-1 bound to Zn2+ is known to be 8 µM. The Kd between 
ProCA32.CXCR4 and Zn2+ were calculated with Equation 2.9 to be 1.6 ± 0.3 e-8. 
 
Figure 4.9 Determine the Zn2+ binding affinity of ProCA32.CXCR4. 
The Zn2+ binding affinity of ProCA32.CXCR4 is determined by competition assay. (A) By 
competing binding of Fluozin-1 to Zn2+ with ProCA32.CXCR4, fluorescence intensity decreases. 
(B) Fitting the fluorescence intensity decrease at 510 nm along with ProCA32.CXCR4 
concentration increase, apparent Kd of ProCA32.CXCR4-Fluozin-1 competition is 2.01 M. 
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4.2.3 Determine water number (q) of ProCA32.CXCR4 
Water number q of ProCA32.CXCR4 is a key factor affecting the relaxivities of contrast 
agents. The water number of ProCA32.CXCR4 is measured by a lifetime of terbium luminescence 
decay with ProCA32.CXCR4: Tb3+ loading ratio of 1:1 and 1:2 respectively (Figure 4.12). There 
are two components of terbium luminescence decay: radiative decay (Г) and non-radiative decay 
(K). Many factors contribute to non-radiative decay, such as quenching, energy transfer, and 
molecular collation. Water number is an important factor influent non-radiative decay. By 
replacement of H2O molecule with D2O, the water number contribution to the terbium 
luminescence decay is eliminated because D2O does not cause luminescence decay. By this way, 
the difference between terbium lifetime (Δkobs) of ProCA32.CXCR4 prepared in H2O and D2O 
respectively reflect the water number of ProCA32.CXCR4. 
The correlation of water number and Δkobs is established by the water number of other 
chelators and their Δkobs, respectively (Figure 4.11). Water number standard curve was determined 
by fluorescence lifetime of other chelators: DTPA, EDTA, and NTA. The water number of DTPA, 
EDTA, NTA, and aqua is determined by X-ray powder diffraction by reported literature (171). 
The water number of ProCA32.CXCR4 are 0.5 and 0.64 respectively with 1:2 and 1:1 





Figure 4.10 Fluorescence lifetime of different chelators and the corresponding Δkobs. 
The fluorescence lifetime of different chelators including EDTA, NTA, DTPA and aqua. The 
corresponding lifetime difference of EDTA, NTA, DTPA, and aqua are 0.67 ms-1, 1.07 ms-1, 
0.23 ms-1 and 1.97 ms-1. 
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Figure 4.11 Standard curve of water number of different chelators versus Δkobs. 
 
Figure 4.12 Determine water number of ProCA32.CXCR4 with different loading ratio with 
Tb3+.  
Δkobs of ProCA32.CXCR4 is determined by ProCA32.CXCR4 load with Tb
3+ in 1:1 and 1:2 ratio. 
(A) Δkobs of ProCA32.CXCR4 when loaded with Tb
3+ in 1:1 ratio is 0.11 ms-1. (B) Δkobs of 
ProCA32.CXCR4 when loaded with Tb3+ in 1:2 ratio is 0.14 ms-1 
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4.2.4 Serum stability study of ProCA32.CXCR4 
Serum stability of ProCA32.CXCR4 describes the capability of ProCA32.CXCR4 to stay 
structurally intact under physiological conditions. Serum stability study of ProCA32.CXCR4 
carried out by incubating 150 µL of 500 µM ProCA32.CXCR4 with 150 µL of mouse serum at 
37C for up to 14 days. 15 µL of the mixed sample was taken at 0 hours, 3 hours, 4 hours, 1 day, 
2 days, 4 days, 6 days, 8 days, and 14 days after incubation. 300 µL of mouse serum without adding 
ProCA32.CXCR4 was served as control. Samples collected from different time points were 
analyzed by gel electrophoresis and ponceau red staining of the nitrocellulose membrane. 
ProCA32.CXCR4 is stable up to 14 days when incubated with mouse serum under 37C (Figure 
4.13), whereas the mouse serum protein started to degrade at 4 hours after incubation at 37C 
(Figure 4.14). ProCA32.CXCR4 can stay structurally stable under physiological conditions, and 
the serum stability guaranteed the in vivo application of ProCA32.CXCR4. 
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Figure 4.13 Serum stability study of ProCA32.CXCR4 
ProCA32.CXCR4 is stable in mouse serum at 37°C for up to 14 days. Ponceau red staining of 
nitrocellulose membrane with gel transfer shows the ProCA32.CXCR protein bands (highlighted 




Figure 4.14 Ponceau red staining of mouse serum incubates at 37°C for up to 14 days. 
 
4.2.5 Transmetallation study of ProCA32.CXCR4 
The kinetic inertness of gadolinium complex regarding the transmetallation process from 
physiological ions is an important factor to evaluate the suitability of such gadolinium complex as 
an MRI contrast agent. A relaxometric transmetallation assessment was performed to characterize 
the kinetic inertness of the Gd3+-ProCA32.CXCR4 complex to transmetallation process in the 
presence of Zn2+. ProCA32.CXCR4 is mixed with the same concentration of ZnCl2 (2.5 mM) in 
pH 7.0 phosphate buffer. The final mixture contained 0.026 M KH2PO4, 0.041 M Na2HPO4, 2.5 
mM Gd3+ complex, and 2.5 mM ZnCl2. When transmetallation of Gd
3+ by Zn2+ occurred, insoluble 
GdPO4 formed, and a decrease in longitudinal relaxation rate was observed. The longitudinal 
relaxation rate change of the mixture along with time reflected the transmetallation process of Gd3+ 
by Zn2+. The thermodynamic index was calculated by r1 of the mixture after incubation at the 
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present of Zn2+ over the initial r1. Transmetallation of other GBCAs is measured following the 
same protocol as a comparison. 
The transmetallation study (Figure 4.15) indicated that ProCA32.CXCR4 complex with 
Gd3+ has the highest stability in the presence of Zn2+, with a higher thermodynamic index (R1(t) = 
4320 min/ R0(t)= 0 min) of 0.958, over Gadovist (0.952), ProHance (0.926), and Dotarem (0.932) 
(Table 4.3). Other linear reagents such as Magnevist® (gadopentetate) and Eovist® (gadoxetate) 
cannot protect Gd3+ well against transmetallation by Zn2+, and relaxivity measurements of those 
contrast agents were significantly reduced when incubated in the presence of Zn2+ (Table 4.3). 
 
 
Figure 4.15 Transmetallation study of ProCA32.CXCR4 and other GBCAs. 
Transmetallation study of ProCA32.CXCR4 and other GBCAs are carried out with a relaxometric 
assay. Thermodynamic index (R1(t) = 4320 min/ R0(t)= 0 min) represents the preserve of 
longitudinal relaxivity at the presence of Zn2+. ProCA32.CXCR4, ProHance, and Dotarem show 







Table 4.3 Thermodynamic index of ProCA32.CXCR4 and other GBCAs at 72 hours 
incubation with a Zn2+-containing phosphate buffer. 
 
4.2.6 Biodistribution study of ProCA32.CXCR4 
Biodistribution study of ProCA32.CXCR4 aims to assess the amount of ProCA32.CXCR4 
distributed to different organs after a specific time of ProCA32.CXCR4 injection. ICP-OES was 
used to analyze the gadolinium content of different organs, and tissues follow different dosages of 
ProCA32.CXCR4.  
The distribution of Cys-ProCA32.CXCR4 to organs including liver, spleen, heart, and 
kidney were analyzed following the injection of imaging dosage (100 µL of 5 mM Cys-
ProCA32.CXCR4). Gadolinium concentration (µM/g), percentage injection dosage per gram 
tissue (%ID/g), and percentage injection dosage per organ (%ID/organ is calculated). Mice 
injected with Cys-ProCA32.CXRC4 were euthanized 50 minutes, 3 hours, 25 hours, and 30 hours 
after above described dosage of Cys-ProCA32.CXCR4. 
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A standard curve is made of ICP-OES measurement of different known concentration of 
gadolinium solution versus intensity (Figure 4.16). Different tissues, including liver, spleen, heart, 
and kidney, were weighted and dissolved in concentrated nitric acid and filtered before ICP-OES 
analysis. The concentration of gadolinium in tissue solutions was calculated by the standard curve 
and intensity.  
 
Figure 4.16 Standard curve of gadolinium intensity. 
 
The analysis of gadolinium concentration in different organs at different time points ( 50 
minutes, 3 hours, 25 hours, and 30 hours) followed Cys-ProCA32.CXCR4 are listed below ( 
 
Table 4.4 to  
 
Table 4.7, Figure 4.17 to Figure 4.20). Results show that Cys-ProCA32.CXCR4 has high 
liver affinity, the percentage injection dosage in liver account for 17.65 % of total injection after 
50 minutes of injection. The gadolinium concentration in the liver keeps increase up to 25 hours 
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after injection. At 25 hours after injection, the amount of gadolinium in the liver account for 66.64 
% of total injection dosage. 
 
 
Table 4.4 The concentration of gadolinium in the liver at different time points follow the 
injection of Cys-ProCA32.CXCR4. 
 
 
Figure 4.17 Percentage injection dosage of gadolinium in the liver. 
Biodistribution of gadolinium (characterized by percentage injection dosage in the liver) after 50 
minutes, 3 hours, 25 hours, and 30 hours injection of ProCA32.CXCR4. 
 
The gadolinium has the second-highest gadolinium distribution is spleen. However, it is 
significantly lower than the liver. At the peak time point (25 hours), 8.32 % of the total injection 
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dosage of Cys-ProCA32.CXCR4 goes to the spleen. Cys-ProCA32.CXCR4 barely distributed to 
the kidney and heart. 
 
Table 4.5 Gadolinium concentration in the kidney at different time points followed the 
injection of Cys-ProCA32.CXCR4. 
 
 
Figure 4.18  Gadolinium distribution in the kidney. 
Biodistribution of gadolinium (characterized by percentage injection dosage) in kidney after 50 
minutes, 3 hours, 25 hours, and 30 hours injection of ProCA32.CXCR4. 
 
 
Table 4.6 Gadolinium concentration in the spleen at different time points followed the 





Figure 4.19 Gadolinium distribution in the spleen. 
Gadolinium concentration (characterized by percentage injection dosage) in spleen after 50 
minutes, 3 hours, 25 hours, and 30 hours injection of ProCA32.CXCR4. 
 
 
Table 4.7 Gadolinium concentration in the heart at different time points followed by the 




Figure 4.20 Gadolinium concentration in the heart. 
Gadolinium concentration (characterized by percentage injection dosage) in the heart after 50 
minutes, 3 hours, 25 hours, and 30 hours injection of ProCA32.CXCR4. 
 
Biodistribution of gadolinium in different organs after 5 days injection of different 
PEGylation of ProCA32.CXCR4 was analyzed to compare the influence of PEGylation on 
biodistribution and the gadolinium retention after a more extended time. The gadolinium 
concentration in the liver of the mouse with Cys-ProCA32.CXCR4 injection at 5 days further 
decreases than 30 hours, the other organs including heart, spleen, and kidney as well. Interestingly, 
compared with Cys-ProCA32.CXCR4, Lys-ProCA32.CXCR4 exhibited higher gadolinium 
retention; it might be a result of Lys-ProCA32.CXCR4 has multiple PEGylation sites and a longer 
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half-life. The result suggests Lys-ProCA32.CXCR4 has longer time window for imaging than Cys-
ProCA32.CXCR4 and could require less dosage when compared with Cys-ProCA32.CXCR4. 
 
 
Figure 4.21 Gadolinium bio-distribution after 5 days injection of ProCA32.CXCR4 with 
different PEGylation. 
 The liver and spleen are the organs most retain gadolinium, followed by lung, kidney, muscle, 
and brain has almost no distribution. 
 
4.2.7 Pharmacokinetics study of ProCA32.CXCR4. 
Detailed pharmacokinetics study showed ProCA32.CXCR4 has good exposure and 
bioavailability, AUC0-72h of ProCA32.CXCR4 was 113.20 µg·h/mL (Table 4.8), larger than 
ProCA32-P40 (33.77 µg·h/mL). Because of ProCA32.CXCR4 is CXCR4 targeted contrast agent 
and expected to have higher tissue affinity caused by CXCR4 targeting. The clearance of 
ProCA32.CXCR4 was 0.31 mL/min/kg, slightly less than Eovist (0.4 mL/min/kg). 
ProCA32.CXCR4 had a half-time of 9.19 h, with a mean residence time (MRT) of 19.58 h.  
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Figure 4.22 Pharmacokinetics curve of ProCA32.CXCR4. 
 




4.2.8 Toxicity study of ProCA32.CXCR4 
In the toxicity study, ProCA32.CXCR4 with cysteine PEGylation and lysine PEGylation 
were tested respectively. The acute toxicity was tested by a bolus injection of 100 μL, 5 mM 
ProCA32.CXCR4 to 10-week-old healthy CD1 strain mice. Each group contains 3 animals, control 
group with saline injection. Mouse blood collected through a terminal collection by cardiac 
puncture. Serum was collected as previously described in the material and methods section. 
Alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), 
albumin, and bilirubin levels in blood serum were tested to evaluate ProCA32.CXCR4 acute 
toxicity. Alanine transaminase (ALT) is used to metabolize protein in the body. If the liver is 
damaged or not functioning properly, ALT is released into the blood. This causes the ALT level 
to increase. An elevated level of ALT indicates liver damage. Aspartate aminotransferase (AST) 
is an enzyme found in several different tissues and organs, including the heart, liver, and muscles. 
Since AST are not exclusively located in the liver, it usually assists the diagnosis of liver damage 
together with ALT. An elevated AST level indicates liver or muscle damage. Alkaline phosphatase 
(ALP) is an enzyme found in bones, bile ducts, and liver. High level of ALP is an indication for 
liver damage, blockage of the bile ducts, or bone diseases. Children and adolescents may have 
elevated levels of ALP because of bone development. Albumin is the main protein generated by 
the liver. It has many important biological functions. Albumin test measures the ability of the liver 
to produce albumin. A decrease in albumin level is an indication of abnormal liver function. 
Bilirubin is generated in the breakdown process of red blood cells. Bilirubin passes through the 
liver before excreted through bile ducts. Damaged livers cannot efficiently process bilirubin, which 
leads to the abnormally elevated level of bilirubin in the blood.  
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Pathology profile of mice with the injection of ProCA32.CXCR4 is listed in Table 4.9. 
ALP, ALT levels of mice with the injection of the cysteine PEGylated ProCA32.CXCR4 and 
lysine PEGylated ProCA32.CXCR4 are comparable with the results from control mice. AST levels 
show slightly increase when compared with control mice. It could be caused by the in vitro 
hemolysis during the serum sample preparation, which needs to be further verified by repeat the 
toxicity result: Albumin, total bilirubin, bilirubin-conjugated, and bilirubin-unconjugated levels in 
ProCA32.CXCR4 injected mice has no significant difference when compared with control mice.  
Mice tissues, including brain, muscle, kidney, lung, heart, liver, and spleen, were collected 
and fixed by formalin and embedded by paraffin. Tissues are sliced to 5 µM thickness sections 
and stained with H&E staining (Figure 4.23). H&E staining of tissues from mice after seven days 
and fourteen days after injection of ProCA32.CXCR4 shows no difference with healthy tissues. 
Pathology profile analysis of ProCA32.CXCR4 combined with H&E staining of mice tissues 
suggesting the ProCA32.CXCR4 exhibit no acute toxicity in the mouse study. 
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Table 4.9 Clinical pathology profile of mice with the injection of ProCA32.CXCR4.  
Mouse serum samples collected 2 days after injection of saline (control, n = 3) or 0.025 mmol/kg 
of Lys-ProCA32.CXCR4/Cys-ProCA32.CXCR4 (n = 3) were used for pathology profiling. Data 
are expressed as mean  SD. 
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Figure 4.23 H&E staining of mice tissues collected 7 and 14 days after injection of 
ProCA32.CXCR4.  
Mice (n=3) organs, including brain, kidney, heart, spleen, muscle, lung, and liver, were collected 
7 and 14 days after injection of 0.025 mmol/kg ProCA32.CXCR4. No obvious tissue damage 
occurred in the mouse organs. 
 
4.3 Conclusion and discussion 
The biophysics properties including relaxivities, metal binding affinities, water number, 
inertness to transmetallation process were well defined and characterized. ProCA32.CXCR4 
shows both high longitudinal and transverse relaxivities, at the lower and higher magnetic field. 
The r1 and r2 values per gadolinium for ProCA32.CXCR4 are 30.9 mM
-1 s-1 and 40.2 mM-1 s-1, 
respectively, at 1.4 T. At 7.0 T magnetic field, the r1 and r2 of ProCA32.CXCR are 17.4 mM
-1 s-1, 
88.7 mM-1 s-1, respectively. The relaxivities will be doubled if calculated as per ProCA32.CXCR4 
particle relaxivities since ProCA32.CXCR4 has two gadolinium binding sites. PEGylation has no 
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significant influence on relaxivities. ProCA32.CXCR4 with different PEGylation and non-
PEGylation exhibit no significant difference in relaxivities. The relaxivities of ProCA32.CXCR4 
are significantly improved in comparison with other GBCAs and enable more sensitive MR 
imaging.  
The best loading ratio of ProCA32.CXCR4 with gadolinium to achieve the optimized 
relaxivities is 1:2 when setting the concentration of gadolinium and increase the concertation of 
ProCA32.CXCR4, the relaxivities of ProCA32.CXCR4 – Gd3+ complex first increase and then 
decrease. Relaxivity values reach to the highest when the concentration of ProCA32.CXCR4 : 
Gd3+ equals to 1:2. It can be explained by the two Gd3+ binding sites of ProCA32.CXCR4 have 
different gadolinium binding affinity which caused by a difference in metal coordination. Fitting 
Ca2+ binding curve of ProCA32.CXCR4 with Adair equation also validated that two metal-binding 
sites of ProCA32.CXCR4 possess different metal binding affinities. Water number measurement 
of ProCA32.CXCR4 by terbium fluorescence lifetime shows that ProCA32.CXCR4-Tb3+ complex 
(ProCA32.CXCR4: Tb3+ =1:2) has water number of 0.5. The water number measurement validated 
the inequivalence of two metal-binding sites in coordination. The two binding sites of 
ProCA32.CXCR4 only possess one water, one metal-binding site coordinates metal through water 
molecule while the other binding site does not. When the concentration of gadolinium is fixed, 
ProCA32.CXCR4 concentration increases, the Gd3+ initially saturated two binding sites, so an 
increase in relaxivities are observed. When the concentration of ProCA32.CXCR4 reaches the half 
concentration of gadolinium, highest relaxivities are observed because theoretically, all Gd3+ can 
bind to ProCA32.CXCR4. When keep increasing the ProCA32.CXCR4 concentration after that 
point, more Gd3+ starts to go to the binding site with higher affinity. As a result, a decrease in 
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relaxivities is observed because the binding site with higher affinity does not coordinate Gd3+ 
through a water molecule. 
The relaxivities of Mn2+ based ProCA32.CXCR4 have been assessed under both lower and 
higher magnetic field. Mn-ProCA32.CXCR4 has superb relaxivities at both 1.4 T and 7.0 T.  
ProCA32.CXCR4 has a comparable binding affinity with Gd3+ when compared with small 
chelator based GBCAs. However, ProCA32.CXCR4 metal selectivity over physiologically present 
metal ions such as Zn2+ and Ca2+ are much better than other GBCAs. ProCA32.CXCR4 inert to 
metal transmetallation at the presence of Zn2+ and possess high kinetic stability. Serum stability 
shows ProCA32.CXCR4 is stable in serum at 37 °C incubation up to 14 days. No degradation was 
observed.  
Pharmacokinetics study shows ProCA32.CXCR4 has good exposure and relatively fast 
clearance. The volume of distribution of ProCA32.CXCR4 is three times higher than non-targeted 
ProCA32, which is the evidence that ProCA32.CXCR4 has better tissue distribution result from 
CXCR4 targeting.  
ProCA32.CXCR4 majorly distributed to the liver after intravenous administration. The 
percentage injection dosage of each organ shows that liver retains the majority amount of 
ProCA32.CXCR4, followed by the spleen. Kidney and heart have a very small amount of 
ProCA32.CXCR4 distributed.  
The toxicity of ProCA32.CXCR4 is described by pathology profile analysis of mouse 
serum and H&E staining of mouse tissues, including brain, muscle, kidney, lung, heart, liver, and 
spleen. No abnormality of mouse serum pathology profile was identified and H&E staining of 
tissues of the mouse with ProCA32.CXCR4 injection have no significant difference in comparison 
with normal mouse tissues. ProCA32.CXCR4 exhibited no acute toxicity according to the results.  
105 
4.4 Summary 
CXCR4 targeted contrast agent ProCA32.CXCR4 is expressed and purified with high yield 
as described in chapter 3. In chapter 4, biophysics properties and pharmacokinetic properties and 
toxicity of ProCA32.CXCR4 are well characterized. 
ProCA32.CXCR4 has both high longitudinal relaxivity and transverse relaxivity in the 
lower and higher magnetic field. r1 value of ProCA32.CXCR4 is lower at 7.0 T as opposed to the 
value in 1.4 T. r2 value of ProCA32.CXCR4 is higher at 7.0 T as opposed to the value in 1.4 T. 
Both cysteine PEGylation and lysine PEGylation largely retains the relaxivities of 
ProCA32.CXCR4. ProCA32.CXCR4 has much-improved relaxivities than other GBCAs and 
enable the application in molecular imaging. ProCA32.CXCR4 has comparable Gd3+ binding 
affinity with small chelator based GBCAs but better metal selectivity over physiologically present 
metal ions like Ca2+ and Zn2+. The binding affinity to different metal ions is summarized in Table 
4.10. Mn-ProCA32.CXCR4 has better relaxivities than Gd-ProCA32.CXCR4; especially the r2 
value of Mn-ProCA32.CXCR4 (Table 4.11). 
Table 4.10 Summary of the metal-binding affinity of ProCA32.CXCR4. 
 
Table 4.11 Summary of relaxivities of Gd-ProCA32.CXCR4 and Mn-ProCA32.CXCR4. 
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ProCA32.CXCR4 has superior metal selectivity for Gd3+ over Zn2+ (log(KGd/KZn) =16.1) 
(Table 4.12) that is 1011 to 1012 order of magnitude higher than small chelator contrast agents. For 
other physiological metal ions such as Ca2+, ProCA32.CXCR4 also exhibited better metal 
selectivity than small chelator GBCA, such as Dotarem® (gadoterate meglumine) and ProHance® 
(Gadoteridol) (Table 4.12).  
Table 4.12 Metal (Zn2+, Ca2+, Gd3+, and Tb3+) binding affinity and metal selectivity of 
ProCA32.CXCR4 and comparison with clinical contrast agents. 
 
ProCA32.CXCR4 has good serum stability and stay intact in serum up to 14 days. 
ProCA32.CXCR4 inert to the transmetallation process and exhibit good kinetic stability. 
Pharmacokinetics profile shows ProCA32.CXCR4 has good exposure when compared with non-
targeted contrast agent ProCA32. ProCA32.CXCR4 demonstrates no acute toxicity. 
              Since the FDA approval of gadopentetate dimeglumine (Magnevist; Bayer HealthCare 
Pharmaceuticals) in 1988, Gd3+-based contrast agents (GBCAs) have been widely used for clinical 
MR imaging. However, nephrogenic systemic fibrosis (NSF) and gadolinium brain deposition in 
patients and animals associated with GBCAs administration raised the concern of gadolinium 
toxicity (164, 165, 172). We have carefully considered these factors in the design of 
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ProCA32.CXCR4 for clinical translational purpose. The Gd3+ binding sites of ProCA32.CXCR4 
were well designed to balance Gd3+ binding for safety, and water accessibility for relaxivities. 
ProCA32.CXCR4 was shown to have unprecedented gadolinium kinetic and thermodynamic 
stability. The Log (KGd) of ProCA32.CXCR4 is 21.89. Metal selectivities of ProCA32.CXCR4 for 
Gd3+ over Zn2+ and Ca2+ are 106-1012 times greater than approved contrast agents, Dotarem and 
ProHance. The inertness of ProCA32.CXCR4 in the presence of Zn2+ verified its strong stability 
against transmetallation. Moreover, the improved relaxivity of ProCA32.CXCR4 enabled 
excellent contrast enhancement in vivo with only one-quarter of gadolinium dosage compared with 
other GBCAs. No trace of gadolinium was detected in mice brain after ProCA32.CXCR4 
administration and we have also not observed any acute toxicity and tissue/organ toxicity. 
Collectively, strong Gd3+ binding affinity, excellent metal selectivity, inertness against 
transmetalation and less injection dosage makes ProCA32.CXCR4 has an excellent safety profile. 
In summary, ProCA32.CXCR4 has high relaxivity, good stability, good pharmacokinetic 
profile, and low toxicity and makes an ideal candidate for CXCR4 specific MR imaging with 
translational potential for clinical applications. 
5 VALIDATION OF CXCR4 AS A BIOMARKER FOR LIVER METASTASIS AND 
TARGETING ANALYSIS OF PROCA32.CXCR4    
5.1 Introduction 
            Chemokine receptor 4 is by far the most widely expressed chemokine receptor in various 
cancers, over 23 different types of cancer cells showed elevated CXCR4 expression levels (93). 
CXCR4/SDF-1α axis mediates the organ-specific metastasis (173). CXCR4 ligand SDF-1α has 
high expression in the organs, including lung, liver, and bone marrow that represented common 
metastasis destinations in breast cancer and pancreatic cancer (103, 174).  
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            Uveal melanoma (UM) has the specific liver metastases tendency; approximately 50 % of 
uveal melanoma patients will eventually develop liver metastases (175). In the patients that 
develop metastases, 93 %  metastasizing to the liver (176). The involvement of liver metastases is 
a sign of poor prognosis and leading to deaths because of the lack of effective treatment. The liver-
specific metastases of uveal melanoma raise the interest of studying the CXCR4 expression level 
in uveal melanoma cells. CXCR4 expression levels on primary eye uveal melanoma, and uveal 
melanoma metastases were reported. H, Li et al. reported the differentiation CXCR4 expression 
level on primary uveal melanoma cell lines and metastatic uveal melanoma cell lines (137), the 
primary uveal melanoma cell lines express CXCR4 whereas the metastatic uveal melanoma cell 
lines express little or no CXCR4. An immunohistochemistry study on UM patient tissues shows 
the positive IHC staining of CXCR4 in both primary UM tissues and metastatic UM tissues (177). 
Another study based on UM patient tissues reported the CCR7 expression in uveal melanoma is a 
risk factor for poor prognosis, whereas the CXCR4 expression has no clinical relevance (178). H. 
Grossniklaus et al. reported CXCR4 generally expressed by uveal melanoma cell lines and CXCR4 
antagonist downregulated the formation of hepatic micrometastases in mouse model study (179). 
            The CXCR4 expression in UM is controversial and not conclusive. However, the uveal 
melanoma liver metastasis pattern indicating the relevancy of CXCR4 expression and liver 
metastases formation in uveal melanoma patients. Blocking CXCR4 expression by siRNA 
transfection in UM cells resulted in inhibition of chemotactic responses as well as invasiveness of 
UM cells (180). Therefore, the CXCR4 can be a potential biomarker and predicting factor for uveal 
melanoma. We aim to evaluate the CXCR4 expression level with uveal melanoma cell lines, UM 
patient tissues, and UM mouse models and establish the understanding of CXCR4 expression in 
UM development.  
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           Ovarian carcinoma is a common gynecologic malignancy and one of the leading causes of 
cancer deaths in women, in which epithelial ovarian cancer is the most common pathology subtype. 
Region-based studies showed that ovarian cancer has the trend of decreasing age of diagnosis and 
increasing in incidence rate (181, 182). Survival of ovarian cancers has improved owing to surgery 
management and chemotherapy, but the overall prognosis remains dismal. Therefore, new 
therapeutic targets and approaches require ovarian cancers. 
            CXCR4 and CXCL12 are found to be highly expressed in ovarian cancers whereas there is 
no or minimum expression of CXCR4 in healthy ovarian tissue (98, 183), and anti CXCR4 therapy 
has proved to be effective in ovarian cancer (184). It makes CXCR4 a promising therapeutic and 
diagnostic target for ovarian cancer. The overexpression of CXCR4 is recommended as an 
independent risk factor of bad prognosis and resistance for chemotherapy (183, 185).  Imaging of 
ovarian cancer and metastases is critically important for cancer management. CXCR4 targeted 
imaging agent will be beneficial for the detection of ovarian cancer and metastases and 
differentiate the chemo sensitive type to stratify therapy. 
5.2 Results 
5.2.1 Cell lines selection 
Human uveal melanoma Mel290, Mel270, 02-1486, OMM1, OMM2.3, OMM2.5, 92.1, 
OCM1 cells, and mouse uveal melanoma Queens, B10BR11.1 cell is selected for CXCR4 
expression analysis using flow cytometry. 
5.2.2 Evaluate the CXCR4 expression level of melanoma cells 
Flow cytometry was used for screening and evaluating the CXCR4 expression level across 
different melanoma cell lines. In the melanoma cell lines been studied, all of them has CXCR4 
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expression. In Mel290 and M20-09-196), over 90% of cell populations from exhibited CXCR4 
over-expression (Figure 5.1, Figure 5.2). 
            CXCR4 expression in uveal melanoma also evaluated with immunofluorescence staining 
of CXCR4. Human uveal melanoma cell OMM2.3 and mouse melanoma cell B16LS9 showed 
CXCR4 expression, indicated by green fluorescence in Figure 5.3. CXCR4 expression was 
observed in the cytoplasm and cell membrane. 
 
 
Figure 5.1 CXCR4 is expressed by uveal melanoma cell lines. 
Metastatic UM cell lines have elevated CXCR4 expression. FACS result shows generally elevated 
CXCR4 expression across the different UM cell lines. 
 
Figure 5.2 CXCR4 expression in uveal melanoma cell lines. 
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Metastatic UM cell lines have elevated CXCR4 expression. FACS results show generally elevated 
CXCR4 expression across the different UM cell lines, especially in Mel 290, Mel 270, and M20-
09-196, in which over 80% of cell counts were CXCR4 positive, measurements of each cell line 
are triplicate. 
 
Figure 5.3 CXCR4 expression in human and mice melanoma cell.  
             Data from Dr. Hua Yang. 
 
5.2.3 In vivo CXCR4 expression study 
Flow cytometry analysis and immunofluorescence staining of CXCR4 with uveal 
melanoma show CXCR4 overly expressed across different uveal melanoma cell lines. Owing to 
the possibility of discrepancy in cell lines and the in vivo expression of CXCR4, metastatic uveal 
melanoma mouse models and uveal melanoma patient tissues are analyzed by 
immunohistochemical staining of CXCR4 to further investigated the CXCR4 expression in vivo. 
UM patients’ liver tissue with metastases were stained with CXCR4 antibody for IHC 
study. A CXCR4 positive control (brain specimen) was processed with the same protocol. 73% of 
uveal melanoma (UM) hepatic metastases (8 out of 11 cases) exhibited high expression levels of 
CXCR4, indicated by the brilliant red color staining (Figure 5.4). Patient information see table  
 
 
XCR4 expre io  in human and mice 
m lanoma cells
 
















Table 5.1 Patient information of melanoma liver metastasis cases. 
Patient # Age Primary Melanoma 
1 58 Leg, left 
2 32 Chest 
3 66 Scalp 
4 59 "Side" (Neck), left 
5 49 Back 
6 61 Ocular, left-sided 
7 37 Back 
8 66 Ocular (Choroidal), left 
9 59 Back 
10 47 Shoulder, Right 




Figure 5.4 CXCR4 immunohistochemical staining of uveal melanoma liver metastases and 
brain tissue as the positive control. 
(A), (B) CXCR4 immunohistochemical staining of brain tissue. (C), (D) metastatic UM patient 
liver tissue. The metastatic UM in the liver shows strong red staining that indicates CXCR4 
expression throughout melanoma cells. 
 
CXCR4 expression in metastatic uveal melanoma mouse models was validated by 
immunohistochemical staining as well. Metastatic uveal melanoma mouse models derived from 
M20-09-196, M20-07-070, and 92.1 cells were established by protocol introduced in chapter 2.9.2. 
FACS results show that the CXCR4 expression level in M20-09-196, M20-07-070, and 92.1 are 
high, medium, and low. Metastatic mouse models establish with these three UM cell lines. Both 
the primary tumor tissue and the metastases in the liver were stained with CXCR4 antibody, and 
immune reactive score (IRS) was analyzed. 
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CXCR4 IHC staining of mouse tissue shows that, in the primary uveal melanoma tumor, 
the CXCR4 expression level is consistent with the seeding cell lines. M20-09-196, M20-07-070, 
and 92.1 mouse primary uveal melanoma tissue staining exhibited high, medium, and low CXCR4 
expression level, respectively. However, the CXCR4 IHC staining of liver metastases exclusively 
shows high CXCR4 expression level (Figure 5.5 and Figure 5.6).  
 
Figure 5.5 Immunohistochemical staining of CXCR4 in metastatic mouse models. 
Immunohistochemical staining of CXCR4 in metastatic mouse models M20-09-196, M20-07-070 
and 92.1. Primary ocular uveal melanoma tissue and uveal melanoma metastases in the liver were 
stained with CXCR4. CXCR4 expression level is low, medium, and high for 92.1, M20-07-070 
and M20-09-196 respectively in the primary tumor. CXCR4 expression level in metastases in the 
liver is high in three mouse models. (Data from Dr. Hua Yang). 
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Figure 5.6 The immune reactive score (IRS) of CXCR4 in mouse models. 
Immune reactive score of CXCR4 in mouse models M20-09-196, M20-07-070, and 92.1 were 
analyzed. In primary ocular UM, the IRS for M20-09-196, M20-07-070 and 92.1 are 5.4, 2.2 and 
1.4 respectively. When UM metastasis to liver, the liver metastases exhibited elevated IRS 
regardless of the IRS of primary UM. (Data from Dr. Hua Yang) 
 
Figure 5.7 CXCR4 IHC staining of M20-09-196 mouse liver. 
Metastatic uveal melanoma mouse model M20-09-196 has high CXCR4 expression level in the 




Figure 5.8 CXCR4 IHC staining of metastatic uveal melanoma mouse model 92.1. 
Uveal melanoma mouse model developed by 92.1 melanoma cells has liver uveal melanoma 
metastases and high CXCR4 expression of liver metastases, indicated by red color and arrow. 
 
 
5.2.4 ProCA32.CXCR4 targeting study 
5.2.4.1 Immunofluorescence staining to study the CXCR4 targeting of 
ProCA32.CXCR4 
           CXCR4 expression cell line M290 was selected to study CXCR4 targeting capability of 
ProCA32.CXCR4 by immunofluorescence staining (Figure 5.9). 5 µM of fluorescein labeled 
ProCA32.CXCR4 was used to incubate the fixed Mel290 UM cells for one hour at 37 °C. Then 
washed gently by TBST buffer for three times. DAPI was used to stain the cell nucleus. The same 
concentration of fluorescein labeled ProCA32 was incubated with Mel290 with the same protocol 
as a control. After wash, ProCA32.CXCR4 incubated Mel290 cells shows green fluorescence, 
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whereas the control cells do not. The targeting capability of ProCA32.CXCR4 is proved by the 
immunofluorescent staining of Mel290. 
 
Figure 5.9 Immunofluorescence staining of Mel 290 cells. 
CXCR4 targeting property of ProCA32.CXCR4 was studied with immunofluorescence staining of 
Mel290. (A) Mel 290 cells incubated with fluorescein-labeled non-targeted ProCA32 only shows 
blue color nucleus staining (DAPI). (B) Mel 290 cells incubated with fluorescein labeled 
ProCA32.CXCR4 shows green color staining on the cell surface. 
 
             Double staining of ProCA32.CXCR4 and chemokine receptor 4 are expected to reveal the 
spatial colocalization of ProCA32.CXCR4-CXCR4 interaction. Mel290 cells are fixed and 
incubated with 5 µM of fluorescein labeled ProCA32.CXCR4 at 37°C for one hour, then 
chemokine receptor 4 was stained by primary antibody and secondary fluorescence antibody 
following a standard protocol described in chapter 2. Double staining of ProCA32.CXCR4 and 
CXCR4 confirmed that ProCA32.CXCR4 bound to CXCR4 with a high spatial correlation 





Figure 5.10 Immunofluorescence staining of Mel 290 cells and spatial colocalization with 
CXCR4 receptors. 
Fluorescence staining with Mel290 to study the CXCR4 binding effect of ProCA32.CXCR4. (A) 
Blue fluorescence is nucleus staining with DAPI. (B) Green fluorescence shows fluorescein 
labeled ProCA32.CXCR4. (C) Red fluorescence staining indicates CXCR4 receptors on the cell 
membrane. (D) Overlay of blue, red, and green fluorescence of nucleus, CXCR4, and 
ProCA32.CXCR4. ProCA32.CXCR4 has good spatial colocalization with CXCR4; Pearson’s r is 
0.82. 
5.2.4.2 Quantification of CXCR4 binding affinity with indirect ELISA 
A modified enzyme-linked immunosorbent assay (ELISA) was carried out to quantify the 
CXCR4 binding affinity of ProCA32.CXCR4. It followed the steps shown in Figure 5.11. 
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Different concentration of ProCA32.CXCR4 (from 0 nM to 10000 Nm, 16 points in total) was 
added to the wells in 96-well plates that coated with Mel290 cell lysate for incubation. The 
absorbance of each well increases as ProCA32.CXCR4 concentration increase. By plotting the 
data with Prism with one to one binding model, the Kd value of ProCA32.CXCR4 bind to CXCR4 
receptor is calculated. 
The enzyme-linked immunosorbent assay relies on the interaction between epitope and 
antibody to measure the concentration of an analyte in solution. The absorbance of each well 
reflects the quantity of ProCA32.CXCR4. The ELISA distinguishes the specific binding and non-
specific binding of all elements in the solution through a serial of binding processes to a solid 
surface, normally a 96-well microplate material in polystyrene. There are many variants of ELISA 
designed for different application, but all of them depend on the basic components of coating, 
blocking, probing, and signal measurement.  
 
 
Figure 5.11 Illustration of ELISA protocols. 
Indirect ELISA follows the steps of coating of CXCR4, incubate ProCA32.CXCR4 with coated 
plates, wash, primary antibody incubation, and secondary antibody incubation. 
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The coating of ELISA usually depends on the passive absorption of analytes, including 
proteins, peptides, hormones, and antigens to a polystyrene microplate surface. Most proteins can 
be attached to the polystyrene in carbonate/bicarbonate buffer (pH 9.6), and the transparent 
polystyrene facilitates the following colorimetric signal measurement. In typical procedure 
designed to detect an antigen in a protein mixture solution, the antigen immobilization is achieved 
either by direct coating the protein mixture to the 96-well microplate or through antibody absorbed 
to a microplate that can capture the specific antigen. The antibody coated on the microplate to 
capture the antigen called “capture antibody,” it helps more specific capture antigen and 
immobilizes on the plate instead of coating all protein elements form mixture solution by direct 
coating. 
Plate blocking is another important step in the ELISA experiment. Blocking buffer, such 
as BSA, nonfat dry milk, is usually rich in protein and occupy the unsaturated surface of the plate 
with irrelevant protein. The blocking step of ELISA helps prevent non-specific binding, reduce 
ELISA background signal and stable proteins absorbed to the microplates with better interaction. 
ProCA32.CXCR4 shows µM range binding affinity to the CXCR4 receptor. PEGylation 
slightly affected the binding affinity. The CXCR4 binding affinity for ProCA32.CXCR4 is 0.39 ± 
0.02 μM and 1.69 ± 0.28 μM for cysteine PEGylated ProCA32.CXCR4. The binding curve 
indicated a 1:1 binding stoichiometry, and the CXCR4 receptor number per Mel290 cell is 1.2  
0.1  106. 
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Figure 5.12 CXCR4 targeting study of ProCA32.CXCR4.  
CXCR4 targeting capability of ProCA32.CXCR4 is determined by indirect ELISA. The 
dissociation constant of ProCA32.CXCR4 binds to CXCR4 is 0.39  0.02 µM. 
 
Figure 5.13 CXCR4 targeting study of Cys-ProCA32.CXCR4.  
CXCR4 targeting capability of Cys-ProCA32.CXCR4 is determined by indirect ELISA. The 
dissociation constant of ProCA32.CXCR4 binds to CXCR4 is 1.69  0.28 µM. 
5.3 Conclusion and summary 
CXCR4 is widely expressed in cancer cells and plays an important role in mediating 
organ-specific metastasis. Cancers metastasis to lung, liver, and bone marrow, express an 
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elevated level of CXCR4, such as breast cancer and pancreatic cancer. Uveal melanoma exhibits 
the liver-specific metastasis pattern and the intrinsic SDF-1α expression in liver is thought to be 
the reason for liver-specific metastasis of uveal melanoma. 
The expression of CXCR4 in uveal melanoma is controversial. Scientists reported different 
results regarding the CXCR4 expression in uveal melanoma, both primary tumor and metastases. 
Most of the researchers conclude CXCR4 is expressed in both primary and metastases of uveal 
melanoma and is a risk factor for poor prognosis. CXCR4 blockage treatment inhibits tumor 
growth and metastasis.  
We studied the CXCR4 expression using uveal melanoma cell lines, patient tissues and 
metastatic mouse models, and evaluated the CXCR4 expression level in vitro and in vivo. The cell 
lines study with FACS assay demonstrated that CXCR4 expressed across different uveal 
melanoma cell lines, the expression level varies. CXCR4 immunohistochemical staining with 
uveal melanoma patient tissues displays high positive staining rate in uveal melanoma tissues. 
Metastatic mouse models tissue analysis exhibits that CXCR4 expression elevated in the uveal 
melanoma metastases in the liver.  
The targeting study of ProCA32.CXCR4 is carried out by immunofluorescent staining and 
ELISA. ProCA32.CXCR4 is verified to bind to CXCR4 with an excellent spatial colocalization 
(Pearson’s r is 0.82), and the binding affinity is quantified to be 0.39 ± 0.02 μM and 1.69 ± 0.28 
μM for non-PEGylated ProCA32.CXCR4 and ProCA32.CXCR4 with cysteine PEGylation. The 
PEGylation affects the binding affinity but not to a significant extent.  
In summary, CXCR4 overexpressed in uveal melanoma, especially uveal melanoma 
metastases in the liver and is a useful imaging biomarker candidate for detecting liver metastases. 
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ProCA32.CXCR4 is validated to have CXCR4 targeting capability with both 
immunofluorescences staining assay and enzyme-linked immune absorbent assay. 
6 APPLICATION OF PROCA32.CXCR4 FOR EARLY DETECTION AND 
CHARACTERIZATION OF UVEAL MELANOMA AND OVARIAN CANCER 
6.1 Introduction  
6.1.1 CXCR4 in uveal melanoma 
           Uveal melanoma (UM) is the most common primary intraocular malignancy. 
Approximately 50% of UM patients will develop metastases (175). Uveal melanoma metastasizes 
to the liver in ~93% of patients who have metastases and results in death in almost all cases due to 
lack of effective treatments (176). Through histological analysis of postmortem patient samples, 
UM liver metastases can be classified into three stages based on size (i.e., diameter): stage 1 (≤50 
µm in diameter), stage 2 (51–500 µm in diameter), or stage 3 (>500 µm in diameter) (186). 
Pathologically, UM hepatic metastases primarily have two growth patterns: infiltrative or nodular. 
The infiltrative pattern occurs when circulating metastatic UM cells lodge in the sinusoidal space 
and eventually replace the hepatic lobule. The nodular pattern metastases, however, originate in 
the periportal area. UM cells co-opt the portal vein, and when the tumor grows, it exhibits 
angiogenesis and effaces the adjacent hepatocytes (187). 
There are major barriers facing clinicians in UM management, such as the lack of non-
invasive and sensitive imaging methods for metastases, and the resistance of UM to traditional 
systemic chemotherapies (188, 189). Contrast-enhanced CT is a widely used modality for 
screening for hepatic metastases (190); however, it has limited capacity regarding liver lesion 
characterization (191). 2-18F-fluoro-2-deoxy-D-glucose (18FDG) positron emission 
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tomography/computed tomography (PET/CT) can locate the “hot-spot” for characterization of 
liver metastases, but the radiation-dosimetry and the comparatively low specificity are things for 
concern (192). 
            MRI is a preferred clinical imaging modality for the assessment and characterization of 
liver malignancy since it does not use ionizing radiation, and has high soft tissue penetration 
providing morphological, anatomical, and functional information. Dynamic-enhanced MRI, with 
liver-specific contrast agents, is widely used for liver lesion characterization.  However, the 
sensitivity and specificity of clinical MRI are low for lesions less than 1 cm (193). Also, MRI with 
the administration of clinically-approved contrast agents cannot differentiate the different growth 
patterns of UM metastases in the liver (194). Previous studies have demonstrated that molecular 
imaging of corresponding biomarker expression, such as HER2, improves detection sensitivity for 
cancers (195). However, diagnostic biomarkers for imaging UM liver metastases have not yet been 
established until today. Therefore, there is a pressing unmet medical need to develop MRI contrast 
agents for early detection and follow-up of liver metastases, especially for high-risk patients. 
            CXCR4 plays a crucial role in cell migration and cancer metastasis to several organs such 
as liver, bone marrow, and lung that have the intrinsically high concentration of its natural ligand 
CXCL12 (140, 151, 152). A CXCR4 antagonist, Plerixafor (Mozobil®, AMD3100), is approved 
by the FDA for stem cell mobilization. Another ongoing study is focused on the effect of another 
CXCR4 antagonist, X4P-001, on T-cell infiltration in human metastatic melanoma (196). CXCR4 
expression has been proposed as a prognostic factor and a potential therapeutic target. Elevated 
expression of CXCR4 has been reported in several uveal melanoma cell line studies (197, 198). In 
addition, blocking CXCR4 gene expression by transfection with CXCR4 siRNA has been found 
to inhibit invasive properties of uveal melanoma cells exposed to soluble factors produced by 
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human livers (140). Taken together, we hypothesize that CXCR4 will be a potential biomarker 
with treatment implications for imaging UM metastases in the liver.   
6.2 Results 
6.2.1 Detection of uveal melanoma using molecular dynamic contrast imaging 
6.2.1.1 Molecular dynamic contrast imaging of ProCA32.CXCR4 
A liver implanted uveal melanoma mouse model, generated with CXCR4 expression 
melanoma cell line, Mel290, was used to evaluate and validate the in vivo molecular imaging 
capability of ProCA32.CXCR4 at 4.7 T. Molecular dynamic contrast imaging (MDCI) was 
performed to display implanted uveal melanoma in mouse liver by the administration of Cys-
ProCA32.CXCR4 via intravenous tail injection, followed by the acquisition of T1-weighted 
gradient echo MRI as a function of time. The non-targeted contrast agent, ProCA32, was used as 
a control. The melanoma tumor regions exhibited different enhancement patterns between mice 
with ProCA32 and Cys-ProCA32.CXCR4 injection. In Mel290 mice with ProCA32 injection, the 
tumor MRI signal intensity increased at 12 min and 50 min post-injection and decreased after 3 
hours of injection (Figure 6.1, Figure 6.2). However, the tumor MRI signal intensity in the Mel290 
mice with Cys-ProCA32.CXCR4 injection gradually increased to a maximum at 22 h post-
injection, and then began to decrease due to excretion (Figure 6.1, Figure 6.2). The time plot of 
melanoma tumor signal-noise-ratio (SNR) change followed by Cys-ProCA32.CXCR4 injection 
showed that melanoma tumors SNR increased over 40% at 22 hours post-injection when compared 
with pre-injection, whereas SNR of tumor region in the Mel290 mice with ProCA32 injection 
showed a mild increase (10%) right after injection (12 min) then washed out at 3 hours post-
injection (Figure 6.2 B). On the other hand, MR images of Mel290 mice with Cys-
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ProCA32.CXCR4 and ProCA32 injection exhibited similar patterns of SNR changes in the liver 
regions over time (Figure 6.2 C). The liver SNR of both mice with Cys-ProCA32.CXCR4 and 
ProCA32 injection increased drastically right after injection and up to 3 hours, the percentage 
increase of SNR is around 45% at 3 hours post-injection when compared with pre-injection. Such 
enhancement at the liver region gradually decreased due to elimination. Cys-ProCA32.CXCR4 
can target and well distribute to the Mel290 mice tumor tissue. The MR images of the tumor region 
in Mel290 mice with ProCA32.CXCR4 injection showed that the tumor rim enhanced at early time 
points after injection and penetrated the center along with the time (Figure 6.2 A, D).  
The MRI images follow the ProCA32.CXCR4 dynamically change along with time depend 
on the expression level of CXCR4. Tumor tissues with high expression of CXCR4 exhibited 
delayed enhancement than the normal liver tissue since the kinetic targeting to CXCR4 and showed 
the peak of intensity enhancement around 24 hours after injection. The normal liver tissue, 
however, shows the peak of signal noise ratio enhancement at 3 hours after injection for the 
biodistribution of ProCA32.CXCR4 to the liver along with time. This dynamic enhancement of 
ProCA32.CXCR4 is a combined result of blood circulation and CXCR4 targeting and allowing 




Figure 6.1 T1 weighted MR images of Mel290 with ProCA32 and ProCA32.CXCR4 
injection and the signal-noise ratio of liver and tumor regions. 
(A) T1 weighted MR images of Mel 290 uveal melanoma mice with ProCA32.CXCR4 injection 
(upper row) and ProCA32 injection (lower row) at different time points. Yellow circle regions are 
tumor region in the liver. (B) Quantification analysis of liver SNR change before and after 
ProCA32.CXCR4 and ProCA32 injection at different time points. (C) Quantification analysis of 
the SNR changes of Mel 290 mice tumor region before and after injection of ProCA32.CXCR4 
and ProCA32 at different time points. For the Mel 290 mice with ProCA32.CXCR4 and ProCA32 
injection, liver intensity change has the similar pattern after administration of ProCA32 and 
ProCA32.CXCR4. With both contrast agent intravenous bolus administration, liver SNR increases 
right after (10 min) and keep increasing up to 3 hours, after 3 hours, the SNR decrease. The tumor 
SNR of mice with ProCA32.CXCR4 administration keeps increase after injection up to 22 hours 
and the tumor SNR of ProCA32 mice and ProCA32.CXCR4 mice have significant differences 




Figure 6.2 Progressive MR imaging of liver implanted melanoma mice M290 with an 
injection of ProCA32.CXCR4.  
(A) T1 weighted gradient echo MR images of control mice (with the injection of non-targeted 
agent ProCA32) and mice with ProCA32.CXCR4 injection. MRI was scanned before, and after 
injection at different time points until 48 hours, the tumor is represented by the color region in MR 
images. (B) The percentage increase of SNR of melanoma tumor at different time points shows 
the dynamic binding process of ProCA32.CXCR4. Mice with ProCA32.CXCR4 injection showed 
gradual increase intensity in melanoma tumor region up to 24 hours, showing the CXCR4 targeting 
effect and intensity washed out at 48 hours (further time points not acquired). (C) Time plot of 
Liver SNR percentage increase following ProCA32 and ProCA32.CXCR4 injection. The liver 
SNR of both ProCA32 injected mice and ProAC32.CXCR4 injected mice shows a similar pattern 
of the SNR time plot, liver intensity drastically increases up to 3 hours after injection of both 
contrast agents and going down after 3 hours. (D) Time plot of tumor rim and tumor center SNR 
change of mice with ProCA32.CXCR4 injection. ProCA32.CXCR4 exhibits good tumor 
penetration, at early time points (12 min) following injection of ProCA32.CXCR4, tumor rim SNR 
increased, the intensity in the center of the tumor going up until 24 hours after injection, from (A) 
can see the tumor region with ProCA32.CXCR4 injection shows well distributed and heterogeneity 
enhancement. 
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6.2.1.2 Histology analysis and in vivo targeting of ProCA32.CXCR4 
The immunofluorescence staining of Cys-ProCA32.CXCR4 administrated, Mel290 mouse 
tumor tissue showed strong and broadly distributed red immunofluorescence (Figure 6.3). In 
contrast, red fluorescence staining was not observed at the tumor tissues of the Mel290 mice with 
ProCA32 injection. Gd3+ content analysis using ICP-OES indicated that the tumor tissue of Mel290 
mice with ProCA32.CXCR4 injection exhibited significantly higher Gd3+ content than tumor 
tissue of Mel290 mice with the ProCA32 injection (Figure 6.4). These results further validated the 
CXCR4 targeting capability of ProCA32.CXCR4 in vivo with excellent tumor permeability. 
 
Figure 6.3 Immunofluorescence staining of ProCAs on Mel 290 mouse tissues. 
Mouse liver and tumor tissue stained with immunofluorescence for ProCA32 antibody. Mel290 
mouse livers with ProCA32.CXCR4 and ProCA32 injection are stained with primary rabbit 
antibody against ProCA32 and fluorescence secondary antibody. The nucleus is stained with 
DAPI. Melanoma in the liver shows melanin (black color) in the bright field and red fluorescence 
staining recognize the presence of ProCA32/ProCA32.CXCR4. For the Mel290 mouse with 
ProCA32.CXCR4 injection (upper row), the tumor region shows well spread red fluorescence 
color, which indicates the presence of ProCA32.CXCR4 at the tumor tissue. For the Mel290 mouse 
with ProCA32 injection (lower row), tumor regions exhibit no red fluorescence signal, only the 
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DAPI staining shows. Heart tissue is negative control; heart from both mice showed no presence 
of red fluorescence. 
 
Figure 6.4 Biodistribution study of Mel290 mice with contrast agents injection. 
Mel290 mouse tissues were collected and analyzed by ICP-OES after 2 days injection of contrast 
agent ProCA32.CXCR4 and ProCA32. Mel290 mouse tissues, including heart, kidney, tumor, 
liver, spleen, and muscle, were analyzed. The gadolinium content in heart, kidney, liver, spleen, 
and muscle showed no significant difference between mouse with ProCA32.CXCR4 injection and 
mouse with ProCA32 injection. The tumor of Mel290 mouse with ProCA32.CXCR4 injection has 
a significantly high amount of gadolinium when compared with the tumor of Mel290 mouse with 
ProCA32 injection, which demonstrated the in vivo affinity of ProCA32.CXCR4 to the CXCR4 
high expression of tumor tissue. 
 
6.2.2 Detection of uveal melanoma metastases in the liver with ProCA32.CXCR4 
We demonstrated the unique imaging capability of ProCA32.CXCR4 for detection of liver 
metastases, improving the current detection limit, and enabling nodular pattern detection in 
metastatic M20-09-196 mice at 7.0 T. The early detection of UM metastases in the liver of M20-
09-196 mice can be achieved using either Cys-ProCA32.CXCR4 or Lys-ProCA32.CXCR4. Liver 
micrometastases ranging from 0.01 mm2 to 0.08 mm2, which are “invisible” using Eovist or non-
targeted ProCA32 (Figure 6.6, Figure 6.7), were detected with spin echo acquisition and fast spin 
echo acquisition following tail vein injection of 0.025mmol/kg Cys-ProCA32.CXCR4 (Figure 
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6.5). Following the same imaging protocol,  a mouse model with Lys-ProCA32.CXCR4 injection, 
in place of Cys-ProCA32.CXCR4, exhibited metastases enhancement on post-injection as well 
(Figure 6.9). Both the Cys-ProCA32.CXCR4 and Lys-ProCA32.CXCR4 can enhance the small 
metastatic lesions in the liver. Targeting effect shows at 48 hours after administration.  
 
Figure 6.5 T1 weighted, and T2 weighted MRI scanning imaging at different time points 
after Cys-ProCA32.CXCR4 injection.  
The first row shows the T1 weighted MR images after Cys-ProCA32.CXCR4 injection. The red 
arrows pointed to the metastases brighten up after injection of contrast agent. The second row 
shows the T2 weighted images; the green arrows pointed to the enhanced metastases after contrast 
agent injection. 
 
Figure 6.6 MRI imaging of Lysine-PEGylated ProCA32 injected mouse. 
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T1 weighted MR images and T2 weighted MR images were collected before and after the injection 
of lysine PEGylated ProCA32. T1 weighted MR images and T2 weighted MR images are collected 
by spin echo pulse sequence and fast spin echo pulse sequence, respectively. No metastasis lesion 
was observed after the administration of ProCA32 on both T1 and T2 weighted images. 
 
 
Figure 6.7 MR images of metastatic UM mice M20-09-196 before and after injection of 
ProCA32 and Eovist. 
T1 weighted spin echo and T2 weighted fast spin echo MR images of M20-09-196 mice before 
and after injection of ProCA32 (left) and Eovist (right). After 48 hours of ProCA32 injection, no 





Figure 6.8 MR images of metastatic UM mice M20-09-196 and histological correlation.  
(A) T1 weighted spin echo and T2 weighted fast spin echo MR images of M20-09-196 before and 
48 hours after Cys-ProCA32.CXCR4 injection. At 48 hours after injection, both T1 weighted and 
T2 weighted MR images showed four lesions light up when compared with before injection, the 
colormap is the zoom-in view of the yellow rectangular region.  (B) H&E and IHC staining of 
M20-09-196 liver with UM metastases. H&E staining shows four metastasis lesions, highlighted 
by different color circles, that exhibit a similar location as the metastases in MR images. Higher 
magnification images show the growth pattern of metastases to be the nodular pattern. S100 
immunohistochemical staining confirms the lesions are metastatic UM. CXCR4 





Figure 6.9 T1 weighted and T2 weighted MR images at different time points after Lys-
ProCA32.CXCR4 injection.  
The first row shows the T1 weighted MRI images after Lys-ProCA32.CXCR4 injection. The red 
arrows pointed to the metastases brighten up after injection of contrast agent. The second row 




Figure 6.10 MR images of metastatic UM mice M20-09-196 before and after injection of 
Lys-ProCA32.CXCR4.  
T1 weighted spin echo and T2 weighted fast spin echo MR images of M20-09-196 mice before 
and after injection of Lys-ProCA32.CXCR4. 48 hours post-injection of Lys-ProCA32.CXCR4, 
there are three lesions lighten up on both T1 and T2 weighted MR images. Color map shows the 
zoom-in view of the metastases. 
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These small liver lesions, detected by MRI with Cys-ProCA32.CXCR4, were further 
verified by detailed H&E staining analysis, and were found to be exclusively nodular growth 
pattern (labeled by the yellow, blue, red, and green circle) (Figure 6.8 B). The inter-lesion distances 
and diameters of lesions on MR images correlated well with the corresponding measurements in 
H&E staining of tissue sections (y=1.09x + 0.08) (Figure 6.12). The statistical analysis showed 
that MR images could readily differentiate the tumor from the healthy liver, with an AUC of 0.84 
(Figure 6.12). IHC staining of S100 further confirmed the lesions to be metastatic melanoma, and 
IHC staining of CXCR4 verified the CXCR4 expression on metastatic melanoma (Figure 6.8). 
 
Figure 6.11 Immunohistological study of M20 mouse liver tissue using Mouse anti-human 
CXCR4 (ab189048).  
The brown color staining region on liver indicates the CXCR4 expression. CXCR4 has a high 





Figure 6.12 Statistics analysis of M20-09-196 mouse with Cys-ProCA32.CXCR4 injection. 
(A) The measurement of distances between the metastases and diameters of the metastases in the 
MR images correlates well with the H&E histological staining ( y=1.09x + 0.08). (B) The 
stastistical analysis shows ProCA32.CXCR4 provides diagnosis validation for melanoma 




6.2.3 Validation of the in vivo CXCR4 targeting capability of ProCA32.CXCR4 by receptor 
blocking experiment 
We validated the in vivo CXCR4 targeting capability of Cys-ProCA32.CXCR4 by receptor 
blocking experiment. A subcutaneous uveal melanoma (UM) murine model was developed to 
demonstrate that UM tumor signal intensity enhancement following Cys-ProCA32.CXCR4 
administration could be blocked by first administering the CXCR4 blocking reagent. (Figure 6.14. 
A). The blocking reagent was administrated to subcutaneous uveal melanoma model prior to 
imaging, following the protocol illustrated in Figure 6.13. 
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Figure 6.13 The protocol of blocking reagent administration. 
 
 We specifically constructed a CXCR4 blocking reagent by fusing the CXCR4-targeting 
moiety (LGASWHRPDKFCLGYQKRPLP) of ProCA32.CXCR4 to the C-terminal of the GST 
tag to ensure proper blocking. Injection of the non-targeted Lys-ProCA32 only resulted in initial 
SNR enhancement at 3 h post-administration due to blood pool distribution. This enhancement 
returned to baseline at 24 h. In contrast, injection of Cys-ProCA32.CXCR4 resulted in maximum 
SNR enhancement at 24 h post-injection and returned to the baseline at 48 h. Prior injection of 
CXCR4 receptor blocking reagent specifically eliminated the enhancement at 24 h by Cys-
ProCA32.CXCR4 but retained the 3 h initial enhancement due to blood pool effect. (Figure 6.14 
B, C, Figure 6.15) These results indicated that ProCA32.CXCR4 can specifically bind to the 




Figure 6.14 Validating CXCR4 binding specificity by receptor blocking study.  
(A) Comparison of subcutaneous UM tumor intensity change on T1-weighted MR images 
following administration of Cys-ProCA32.CXCR4 with and without prior administration of 
blocking reagent; subcutaneous UM tumors are represented by color region. Tumor from UM mice 
that received Cys-ProCA32.CXCR4 injection showed a significant increase in MRI signal 
intensity after Cys-ProCA32.CXCR4 administration. This enhancement could be blocked by first 
administrating the CXCR4 receptor blocking reagent. (B) Comparison of UM tumor SNR change 
following administration of Cys-ProCA32.CXCR4 and blocking reagent + Cys-ProCA32.CXCR4. 
For the mice that received Cys-ProCA32.CXCR4 injection, the SNR of UM tumor significantly 
increased at 24 h after Cys-ProCA32.CXCR4 administration. This enhancement was blocked by 
first administrating a blocking reagent. As seen with the mice that received the blocking reagent 
and then the Cys-ProCA32.CXCR4 injection, the SNR of UM tumor was significantly lower in 
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comparison with the UM tumor SNR of the mice with Cys-ProCA32.CXCR4 administration. (C). 
UM tumor SNR change following administration of Cys-ProCA32.CXCR4, blocking reagent + 
Cys-ProCA32.CXCR4 and Lys-ProCA32. At 3 h after administration, mice from all three groups 
showed SNR increase. At 24 h, mice with blocking reagent + Cys-ProCA32.CXCR4 
administration and mice with Lys-ProCA32 administration showed an SNR wash out; while mice 
that received Cys-ProCA32.CXCR4 exhibited further SNR increases compared with 3 h. At 48 
hours, mice that received blocking reagent + Lys-ProCA32.CXCR4 and mice that received Lys-
ProCA32 administration exhibited further SNR further decrease. Mice that received Cys-
ProCA32.CXCR4 administration showed SNR wash out in comparison with 24 h. 
 
 
Figure 6.15 MR images of subcutaneous UM mice before and after administration of Cys-
ProCA32.CXCR4, blocking reagent + Lys-ProCA32.CXCR4 and Lys-ProCA32.  
T1-weighted MR images of xenografted mice with subcutaneous UM tumors before and after 
administration of Cys-ProCA32.CXCR4, blocking reagent + Cys-ProCA32.CXCR4 and Lys-
ProCA32; imaging time points include pre-injection, 3 h, 24 h, and 48 h post-injection. Tumors 
are identified by red arrows. Three groups of mice exhibited tumor signal intensity increases at 3 
h after injection of contrast agents. Mice that received the injection of Cys-ProCA32.CXCR4 
presented further tumor signal enhancement at 24 h after injection, and signal intensity then 
washed out at 48 h. CXCR4 blocking reagent pre-treated mice and Lys-ProCA32 administration 
showed signal washout at 24 h and further decreases at 48 h. 
 
6.2.4 Detection of liver metastases in SKOV3 orthotopic ovarian cancer mouse model 
Orthotropic human ovarian cancer xenograft model was established by Dr. Lily Yang in a 
protocol detailed described in chapter 2.9.3. SKOV3 cells are stably transfected with firefly 
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luciferase. Followed the injection of luciferase substrate (D-luciferase, free acid), bioluminescence 
images showed the tumor enhancement around the ovary region. Tissues collected 20 minutes after 
injection of luciferase substrate showed metastases in spleen, liver, lung, and kidney (Figure 6.16) 
 
Figure 6.16 Bioluminescence images of orthotopic ovarian tumors and metastases. 
Bioluminescence images of SKOV3 ovarian cancer mice show the subcutaneous and orthotopic 
tumors. Organs, including spleen, liver, lung, and kidney, have metastasis lesion. (Data from Dr. 
Jingjuan Qiao) 
 
T1 and T2 weighted MR images of SKOV3 ovarian cancer mice were collected with 
gradient echo acquisition and fast spin echo acquisition respectively at 4.7 T. T1 weighted MR 
images of SKOV3 mice show the liver enhancement followed by the administration of 
ProCA32.CXCR4 up to three hours, and the liver intensity started to wash out after three hours of 
injection. The tumor metastases have SNR enhancement, which exhibited the same pattern 
observed in Mel290 mice (Figure 6.18). The signal-noise ratio of metastases in the liver increased 
after administration of ProCA32.CXCR4 gradually and reach to the highest SNR at 24 hours after 
injection. Moreover, the SNR started to wash out after 24 hours after injection. However, owing 
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to the higher liver enhancement in 4.7 T than in 7.0 T, metastases, in contrast, exhibited darker 
lesions when compared with the rest of liver tissues.  
 
Figure 6.17 T1 weighted MR images (gradient echo) of SKOV3 orthotopic mice model with 
ProCA32.CXCR4 injection. 
T1 weighted MR images of SKOV3 mice collected before and after the injection of 
ProCA32.CXCR4. Metastatic tumor lesions (pointed by red arrows) shows strong contrast with 
liver tissue and can be distinguished after the administration of ProCA32.CXCR4. 
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Figure 6.18  The intensity percentage increase of tumor region in SKOV3 mice model after 
ProCA32.CXCR4 injection. 
 
6.3 Conclusion and discussion 
The liver is a common site for cancer metastasis. UM almost exclusively metastasizes to 
the liver. The mechanism of the liver-specific metastases is not well known yet. Based on the 
findings that liver cells produce some chemoattractants (i.e., CXCL12) (199) and elevated 
expression of CXCR4 in several UM cell line studies (197, 200), one hypothesis is tumor cells that 
are overly express CXCR4 hijack the CXCR4/CXCL12 axis during the metastatic process and 
spread to the liver (140, 151, 152). CXCR4 is proposed to be a prognostic marker in acute 
myelogenous leukemia, breast cancers, colorectal cancers, and melanoma (99, 197, 201, 202). 
Thus, the development of imaging agents for CXCR4 may be highly informative regarding cancer 
diagnosis and prognosis.  
           By demonstrating elevated CXCR4 expression levels in UM patient liver metastases, UM 
cell lines, as well as metastatic UM mouse models, we validated the diagnostic value of CXCR4 
as an imaging biomarker in UM. Multiple attempts have been made towards to develop CXCR4 
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molecular imaging agents over the years using different imaging technologies including SPECT, 
PET, and near-infrared imaging (203-205). MRI has the advantage of being able to provide high 
spatial resolution imaging without ionizing radiation and depth limitation. However, limited by 
the sensitivity of current MRI contrast agents and the low local concentration of receptors on the 
tumor cell surfaces (50), the application of MRI in molecular imaging is very challenging. We 
developed a CXCR4 targeted MRI contrast agent ProCA32.CXCR4 that exhibited 8 to 10 times 
increase in both r1 and r2 relaxivities over clinical GBCAs and enabled sensitive MRI detection of 
CXCR4. We have applied a metastatic UM mouse model M20-09-196, with small metastases in 
the liver, to demonstrate the imaging capacity of ProCA32.CXCR4. MR imaging following 
ProCA32.CXCR4 administration is able to detect UM micro-metastases in mouse livers as small 
as 0.1mm2, which is a significant improvement in the detection limit of MRI for liver lesions (193). 
Several factors contributed to the robust detection of micro-metastases at the early stages. First, 
CXCR4 targeting enabled ProCA32.CXCR4 accumulation at metastases sites. Secondly, high 
relaxivities of ProCA32.CXCR4 significantly improved the sensitivity of MR imaging. Compared 
with small molecule chelator, ProCA32.CXCR4 has secondary coordination shell and optimized 
rotational correlation time, which contributes to the relaxivities improvement (206).  
           Furthermore, both high r1 and r2 of ProCA32.CXCR4 doubled the confidence and avoided 
artifacts of detection by applying both T1 and T2 weighted acquisition. Another challenge in 
imaging UM metastases in the liver is to identify pathological growth patterns of metastases with 
MR imaging (194). MR images of M20-09-196 mice following administration of 
ProCA32.CXCR4 exclusively enhanced nodular growth pattern metastases. This enhancement 
might be caused by the CXCR4 expression difference of metastases with different growth patterns.  
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Administration of ProCA32.CXCR4 achieved detection of liver metastases using MDCI 
by MRI. In UM mouse model Mel290, the intensity changes over time exhibited different patterns 
in liver metastases than in the adjacent liver. Tumor region intensity steadily increased up to 24 
hours after ProCA32.CXCR4 injection due to in vivo dynamic binding to CXCR4, followed by a 
slow wash out after 24 hours to 48 hours. However, tumor region intensity showed a small transient 
increase (at 12 min) right after ProCA32 injection due to in vivo distribution and wash out after 3 
hours.  
On the other hand, the liver region in both mice injected with ProCA32.CXCR4 and 
ProCA32 showed similar enhancement patterns over time. This unique property of 
ProCA32.CXCR4 provides a possibility of acquiring MDCI using MRI. MDCI provides an 
additional avenue to non-invasively differentiating tumors from healthy livers taking advantage of 
biomarker binding capability. Besides, ProCA32.CXCR4 has excellent tumor permeability, which 
is different from some nanoparticles or chelator-based targeting contrast agent that mostly enhance 
the tumor boundary (207). This allows for mapping heterogeneous CXCR4 expression inside the 
tumor. This property may facilitate monitoring of CXCR4 expression changes through the tumor 
tissue during progression and treatment.  
The relatively long half-life of ProCA32.CXCR4 makes the best imaging time for 
optimized tumor enhancement around 24 to 48 hours after injection, which might be one limitation 
for clinical usage. We are in the process of optimizing PEG modification of ProCA32.CXCR4 to 
tune the PK/PD properties. Another concern would be ProCA32.CXCR4 nonspecific interactions 
with CXCR4 expressed on normal cells (i.e., immune-related cells). Further studies should be done 
to evaluate ProCA32.CXCR4 carefully before it can be taken to clinical application. 
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6.4 Summary 
  In this study, we verified that CXCR4 is a diagnostic imaging biomarker by its elevated 
expression level in liver metastases in UM patients, UM cell lines, and mouse models. 
Additionally, we have successfully designed a CXCR4-targeted, protein-based contrast agent, 
ProCA32.CXCR4, which can detect UM hepatic metastases as small as 0.1mm2. The detected 
liver micrometastases were further validated by histological analysis, which is well-correlated with 
MR images. Our results indicate that ProCA32.CXCR4 enables precision MRI capable of defining 
molecular signatures for identifying metastases.  
   In summary, we report results validating our hypothesis that CXCR4 is a diagnostic 
imaging biomarker for liver metastases using UM patient samples, UM cell lines, and animal 
models. Additionally, we successfully designed a CXCR4-targeting, protein-based contrast agent, 
ProCA32.CXCR4, for early detection of UM hepatic metastases. The detected liver 
micrometastases were validated by histological analysis and correlated well with MR images. Our 
results indicate that this contrast agent can enable precision MRI (pMRI) capable of defining 
molecular signatures for identifying metastases, and possibly for treatment stratification. 
7 PRECLINICAL APPLICATIONS OF PROCA32.CXCR4 FOR DETECTION OF 
FIBROSIS AND HCC AND MONITORING TREATMENT EFFECT  
7.1 Introduction 
7.1.1 Hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy with 
increasing new cases (208, 209). Statistics show that: from 2011 to 2015, the liver cancer death 
rate rose 2.7% every year in female patients and 1.6% for male patients (1). Chronic liver diseases, 
including hepatitis B (210, 211), hepatitis C (211), alcoholic and non-alcoholic fatty liver (212) 
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and cirrhosis are the major risk factors for the HCC. Inflammation and fibrosis are two major 
phytological processes in HCC development. Chronic hepatitis caused by HBV and HCB 
combination infection significantly increases the risk of HCC development. HBC can lead to HCC 
even without the involvement of fibrosis (213). However, HCC progressed from HCV infection 
almost exclusively established on the cirrhotic liver (214). 
7.1.2 Current state-of-art for HCC detection and surveillance monitoring 
Since 2001, imaging-based diagnosis of HCC has been established to replace the biopsy-
based diagnosis, and HCC diagnosis can be established based on imaging combined with 
laboratory tests (215). The HCC diagnosis at a late stage has a poor prognosis for the limit options 
of treatments. The early detection of HCC is of significant importance because of surgical resection 
yields similar or even better outcome than orthotopic liver transplantation, which solved the 
problem of the long waiting list, the high expense of transplantation and give patients better 
prognosis (216). 
Different scientific associations and societies have developed slightly inconsistence 
imaging-based diagnostic systems and algorithm (Figure 7.2) for hepatocellular carcinoma. The 
imaging-based diagnostic systems have evolved because of the advance of understanding about 
HCC imaging features. The systems are developed for patients with a high risk of developing HCC 
for screening and surveillance. The first line for screening patients with high risk usually combines 
ultrasound with serum test screening of biomarkers (including alpha-fetoprotein (AFP), protein 
induced by vitamin K absence) according to the Japan Society of Hepatology (217). With people 
shows positive results on the screening test, dynamic CT/ MRI are recommended for imaging 
diagnosis and staging. The imaging features of HCC including arterial phase hyperenhancement, 
wash out appearance, corona enhancement, capsule appearance, etc. (215, 217) The typical 
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vascular pattern of HCC lesions are well agreed on including the hyper-enhancement in the arterial 
phase and hypo-enhancement (washout) appearance in the venous phase. The wash in and wash 
out features are caused by the blood supply difference of HCC lesions and healthy liver, which 
lead to the wash-in of contrast agents differently. The HCC lesions primarily have blood supply 
from the artery, so it has hyper-enhancement on arterial phase.  
A comprehensive review of guidelines including the Asian Pacific Association for the 
Study of the Liver (APASL), Japanese Society of Hepatology (JSH), American Association for 
the Study of Liver Diseases (AASLD), and the European Association for the Study of the Liver 
(EASL) summarized the difference and similarity across the guidelines from those major scientific 
societies (218-221). Tumor size is the primary concern to assess HCC according to the AASLD 
and EASL. The JSH and APASL emphasize more on the vascular imaging pattern of HCC lesion. 
There is a slight difference between the societies regarding the choice of imaging contrast media 
as well, JSN advocates the liver-specific contrast agent, whereas the AASLD and EASL accept 
exclusively extracellular MRI contrast agents. The contrast agents for HCC detection can be 
majorly divided into extracellular agents and post-vascular phase agents (Figure 7.1). Most used 
extracellular vascular contrast agents for CT, MRI and contrast-enhanced US (CEUS) are iodine 
contrast agent, gadolinium-based small chelators and Sonovue respectively. The post vascular 
phase agents can be classified into two groups: Kupffer-specific contrast agents and hepatocyte-
specific contrast agents. Sonazoid has very stable Kupffer-specific enhance around 20 min after 
injection. Gadolinium contrast agents for MRI, Primovist, and Multihance have the benefit of 
showing the regular vascular pattern on imaging right after injection and later hepatocyte-specific 
enhancement after being uptake by hepatocytes starts from 4 to 5 min after injection. A systematic 
review carried out to compare the sensitivity of MRI and multidetector CT shows that MR imaging 
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has higher per-lesion sensitivity (80%) than CT (68%) and recommended for diagnosis of HCC in 
the chronic liver disease patients (222). 
 
 





Figure 7.2 The algorism of establishing HCC diagnoses according to the European 
Association for the Study of the Liver (EASL). Figure adapted from (223).  
 
The differentiation of HCC from other liver nodules including high-grade dysplasia, benign 
hypervascular liver lesions, and malignant hypervascular liver lesions are of significant importance 
because the lesions listed above have hypervascular structure and similar vascular phase 
enhancement with HCC. Especially for the early stage of HCC lesions which has not formed 
enough artery blood supply, which might not show typical vascular enhancement patterns (218). 
7.1.3 Treatment options for HCC  
Orthotopic liver transplantation yield the best outcome for HCC patients who are eligible. 
HCC patients met Milan criteria had a significantly better prognosis, and longer survival time, the 
five-year survival rate for patients treated with local tumor destruction, resection, and orthotopic 
liver transplantation is 37.6%, 55.5% and 77.2% respectively (224).   
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The poor prognosis of HCC and lack of effective treatments make seeking for new 
diagnostic and therapeutic approaches an unmet and urgent medical need. Sorafenib is an oral 
multi-kinase inhibitor that targets the Raf kinases, vascular endothelial growth factor receptor 
(VEGFR), and platelet-derived growth factor receptor (PDGFR) tyrosine kinases for anti-tumor 
and anti-angiogenesis effects. It demonstrated beneficial for overall survival (225). Most HCC 
patients have gone through cirrhosis, followed by inflammation, this process is mediated by 
chemokines (225). As a result, the role of chemokines in HCC development and the potential in 
targeted therapies has raised the interest of research in the related field. CCL20-CCR6 mediate the 
MAPK phosphorylation and affect the HCC progression (226).  
CXCR4-CXCL12 axis is involving in cell migration and immune-cell recruitment. CXCR4 
was found to have elevated expression in cirrhotic liver inflammatory foci (227). CXCR4 has 
multiple functions in the liver inflammation prior to liver cirrhosis and HCC, hepatocytes over-
express CXCL12 following liver injury (228). We hypothesis there will be CXCR4 overexpression 
in HCC and it can be a potential biomarker for treatment stratification, and drug treatment effect 
monitoring.  
7.2 Results 
7.2.1 Pathology analysis of DEN-induced HCC 
Mice with a C57BL/6 genetic background were used to develop DEN induced the HCC 
mouse model. All animal experiments performed in this study complied with an animal protocol 
reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at Georgia 
State University. 
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Detailed material and method see chapter 2.9.4. Three DEN-induced HCC mice with 
different treatment and one normal mouse as control were used for monitoring and comparing the 
CXCR4 expression level change using MRI scanning with one bolus tail vein injection of 
ProCA32.CXCR4 (0.025mmol/kg).  
DEN induced HCC mice were treated with four different combination treatments. One 
group of animals treated with saline buffer, one group of animals treated with Doxorubicin, one 
treated with Doxorubicin and ProAgio (229). Mice from different groups were selected for MRI 
imaging to monitoring and comparing the treatment effects of different combination. All mice for 
MRI imaging were injected with one bolus dosage of ProCA32.CXCR4 through the tail vein. MRI 
scanning of the liver region of mice was collected before, 3 hours, 24 hours and 48 hours after 
contrast agent injection (Doxorubicin treated mouse and HCC mouse treated with a combination 
of Doxorubicin and ProAgio deceased after 24 hours and 48 hours scanning not collected). Right 
after imaging, mice were euthanized. Organs and tissues, including liver, heart, spleen, kidney, 
brain, tail, and muscle, were collected. The mice livers were measured and weighted, one small 
piece of liver from each mouse was reserved for ICP-OES analysis, the rest was fixed with 10% 
neutral buffered formalin for 3-7 days and embedded with paraffin for further histology analysis. 
DEN-induced HCC mice liver is cirrhotic and enlarged, as seen in Figure 7.3, HCC weight 
is heavier and texture harder than the normal liver. Unifocal, multifocal tumor formed in the liver, 
color paler than normal liver tissue. There is no observable difference after Doxorubicin treatment 




Figure 7.3 Comparison of normal mouse liver and HCC mouse liver with different treatment. 
 
7.2.2 MRI images of HCC mice 
7.2.2.1 Normal control mouse 
DEN-induced HCC mice with buffer, Doxorubicin, and Doxorubicin combined with 
ProAgio treatment were selected for MRI imaging. Normal mouse with ProCA32.CXCR4 
injection is imaged with the same protocol as control. Dosage of ProCA32.CXCR4 injection is 
0.025mmol/kg, MRI images collected before the injection of ProCA32.CXCR4 and 3 hours, 24 
hours, 48 hours after injection. T1 weighted images, T2 weighted images, T1 mapping, and T2 
mapping were collected at each time points. 12 to 16 slides of MRI images were collected for each 
mouse with 1mm thickness, no gap. Detailed parameter for imaging collection sees chapter 2.10.  
Normal mouse with ProCA32.CXCR4 injection shows a similar pattern as observed before 
for liver imaging. On both T1 weighted and T2 weighted imaging, the signal-noise ratio 
enhancement after injection showed a consistent pattern (Figure 7.4). T1 weighted MRI imaging 
shows an SNR increase after 3 hours injection of ProCA32.CXCR4 and SNR washed out at 24 
hours and 48 hours after contrast agent administration. T2 weighted MRI imaging shows SNR 
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decreased after 3 hours of ProCA32.CXCR4 administration and SNR recover at 24 hours and 48 
hours after contrast agent administration.  
T1 mapping of the mouse liver shows the liver t1 time change before and after 
ProCA32.CXCR4 injection (Figure 7.5). Before ProCA32.CXCR4 injection, the liver t1 time is 
618.0 ms, at 3 hours after ProCA32.CXCR4 administration, the liver t1 decrease to 484.3 ms. 
Along with the washout of contrast agent, t1 time of liver increased at 24 hours and 48 hours, to 
523.7 ms and 558.3 ms respectively.  
T2 mapping MRI scanning shows the quantitative representation of the t2 time of the liver 
(Figure 7.6), the mean t2 time of liver before ProCA32.CXCR4 administration is 39.0 ms, it 
decreased to 35.0 at 3 hours after contrast agent administration, after 24 hours and 48 hours 
administration of ProCA32.CXCR4, the mean value of t2 time of liver goes back to 33.0 ms and 
37.0 ms respectively along with the concentration of ProCA32.CXCR4 in liver washed out. 
The signal enhancement of the whole liver is homogenous. In normal mouse, 
ProCA32.CXCR4 distributed to the liver through blood flow and caused signal intensity change, 
and the enhancement reached a peak at 3 hours and washed out along with ProCA32.CXCR4 wash 
out. The enhancement pattern of the normal mouse with ProCA32.CXCR4 injection is consistent 
on T1 weighted, T2 weighted, T1 mapping, and T2 mapping acquisition, which shows the 
distribution of ProCA32.CXCR4 in the liver after injection. ProCA32.CXCR4 distributed to the 
liver after tail vein injection, and the concentration reaches to the peak and 3 hours after and wash 
out ever since. As a result, the normal mouse with ProCA32.CXCR4 injection shows T1 signal 
enhancement, T2 signal decrease at 3 hours after injection, t1 and t2 time shortening at 3 hours 
after injection when compared with pre-scan and the change goes back at 24 hours and 48 hours 
after injection along with the washout of ProCA32.CXCR4. 
154 
The H&E staining of the normal liver shows the regular structure of mouse liver, liver 
lobule well- structured and hepatocytes lays in line with each other and form sinusoidal lining cells 
form sinusoidal space. 
 
 
Figure 7.4 T1, T2 weighted MRI images and SNR of the normal mouse at different time 
points following ProCA32.CXCR4 injection. 
Normal mouse with ProCA32.CXCR4 injection shows hyper signal intensity enhancement on T1 
weighted MRI images, and hypo signal intensity enhancement on T2 weighted MRI images after 
administration of ProCA32.CXCR4. The quantitative analysis of SNR shows consistent 
enhancement pattern followed ProCA32.CXCR4 injection. On T1 weighted acquisition, SNR 
increases at 3 hours after injection of contrast agent and wash out at 24 hours and 48 hours after 
injection. On T2 weighted acquisition, SNR decreases at 3 hours after contrast agent injection and 





Figure 7.5 T1 mapping MRI images and t1 time of normal mouse at different time points 
follow ProCA32.CXCR4 injection. 
T1 mapping of normal mouse follows the injection of ProCA32.CXCR4 shows the t1 time of liver 





Figure 7.6 T2 mapping MRI images and t2 time of normal mouse at different time points 
follow ProCA32.CXCR4 injection. 
T2 mapping of normal mouse follows the injection of ProCA32.CXCR4 shows the t2 time of 
liver decrease at 3 hours and 24 hours after injection of ProCA32.CXCR4 and goes back at 48 




Figure 7.7 H&E staining of normal mouse liver.  
 
Buffer treated HCC mouse has enlarged and cirrhotic liver with tumor forming in the liver 
(Figure 7.3), the MRI images of buffer treated HCC mouse shows the tumor nodule forming in the 
left part of liver on both T1 weighted and T2 weighted images (Figure 7.8, Figure 7.9 red circle 
regions). The pre-scanning of T1 and T2 weighted MRI images shows the left part of the liver has 
10 – 20 HCC tumor nodules with a diameter of 0.5 to 3 mm. The HCC tumor nodules show 
hyperintensity in T2 weighted imaging because of the intrinsic higher t2 time of tumors. The 
quantitative analysis of SNR of HCC tumor nodules is based on the data of the tumors in the red 
circle. The SNR analysis of tumors on T1 weighted imaging clearly shows HCC tumor has slightly 
higher SNR than normal liver (Figure 7.4), the HCC tumor SNR on T1 weighted images is 34.7 
whereas the normal mouse SNR is 31.3. The SNR of HCC tumors on T2 weighted images is 
significantly higher than normal liver SNR; the normal liver SNR is 7.1. However, the HCC tumor 
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T2 SNR is 46.8. The dramatic difference in SNR enables the HCC tumor distinguishing on T2 
weighted images.  
Interestingly, after the injection of ProCA32.CXCR4, the HCC tumors intensity 
significantly enhanced when compared with pre-scanning on T1 weighted images. The tumor SNR 
keep increasing up to 24 hours. Quantitative analysis of SNR on pre and after contrast agent 
administration T1 weighted images (Figure 7.8) shows that at 3 hours after administration of 
ProCA32.CXCR4, the SNR of HCC tumors increase from 34.7 to 63.8, and SNR continuing 
increasing at 24 hours to 81.1 and wash out since then. At 48 hours after ProCA32.CXCR4 
administration, the SNR goes back to 48.1. 
The T1 weighted imaging SNR change pattern at different time points after 
ProCA32.CXCR4 administration in buffer treated HCC mouse is different from the normal mouse 
and consistent with the SNR change pattern of uveal melanoma mouse with ProCA32.CXCR4 
injection. For the mice carry CXCR4 high expression tumors (both uveal melanoma and HCC), 
the T1 weighted SNR increase after the administration of CXCR4 targeted contrast agent 
ProCA32.CXCR4 up to 24 hours, and SNR wash out after that. For buffer treated HCC mouse, the 
SNR at 24 hours after injection is one time higher when compared with before injection (Figure 
7.8), however, the uveal melanoma SNR is around 50% more than pre-scan (Figure 6.1). It 
indicates that the interaction of ProCA32.CXCR4 with CXCR4 in vivo are similar in uveal 
melanoma mouse models and HCC mouse model. HCC tumors might have higher CXCR4 
expression levels than uveal melanoma, so it has higher SNR enhance than uveal melanoma. The 
T1 mapping result is consistent with the T1 weighted images and further proved the CXCR4 
molecular imaging is achieved by administration of ProCA32.CXCR4. T1 mapping of buffer 
treated HCC mouse (Figure 7.10) shows that the t1 time of HCC tumor is intrinsically longer than 
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liver, the t1 time for HCC tumor is 1590 ms, after the administration of ProCA32.CXCR4, the t1 
time is shortening to 1401 ms at 3 hours and 1355 ms at 24 hours and goes back to 1588 at 48 
hours. The T2 mapping of the same animal (Figure 7.12) shows the similar change pattern as T1 
mapping, the t2 time of HCC tumors is 93.7 ms, which is higher than the t2 time (39 ms) of the 
normal liver. After administration of ProCA32.CXCR4, the t2 time is shortening up to 24 hours, t2 
time of HCC tumor is 74.3 ms at 3 hours and 66.0 ms at 24 hours and goes back to 84.3 ms at 48 
hours.  
 
Figure 7.8 T1 weighted MRI images and SNR comparison of buffer treated HCC mouse at 
different time points following ProCA32.CXCR4 injection. 
T1 weighted MR images of buffer treated HCC mouse shows increase SNR on T1 weighted images 
on pre-scan. Red circle regions represent tumor nodules with high CXCR4 expression, after the 
injection of ProCA32.CXCR4, HCC tumor nodules with high CXCR4 expression exhibit 
enhancement up to 24 hours, at 24 hours, the SNR of tumor nodules is two times higher than the 
pre-scan SNR. At 48 hours, the SNR decreases. Green circle regions represent tumor nodules with 
low CXCR4 expression. For tumor nodules with low CXCR4 expression, the SNR enhancement 
is lower than tumor nodules with high CXCR4 expression. 
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Figure 7.9 T2 weighted MRI images and SNR comparison of buffer treated HCC mouse at 
different time points follow ProCA32.CXCR4 injection. 
T2 weighted MR images of buffer treated HCC mouse shows the tumor nodules circled by red 
circle exhibit higher SNR. Tumor nodules circled by the red circle shows about double of the value 
of SNR when compare with the rest part of the liver (represented by the green circled regions). 
After the injection of ProCA32.CXCR4, the SNR of tumors decreases at 3 hours after injection 





Figure 7.10 T1 mapping MRI images and t1 time of tumor nodules of buffer treated HCC 
mouse at different time points following ProCA32.CXCR4 injection. 
T1 mapping of buffer treated HCC mouse to analysis the t1 time of tumor nodules (represented by 
red circled regions). The t1 time of tumor nodules on pre-scan is 1590 ms, after the administration 
of ProCA32.CXCR4, the t1 time is shortening to 1401 ms at 3 hours and 1355 ms at 24 hours and 
goes back to 1588 at 48 hours. T1 mapping results of buffer treated HCC mouse is consistent with 
T1 weighted images. 
 
Figure 7.11 T1 mapping MRI images and t1 time of other regions of buffer treated HCC 
mouse at different time points follow ProCA32.CXCR4 injection. 
T1 mapping of buffer treated HCC mouse to analysis the t1 time of regions other than tumor nodules 
(represented by red circled regions). The t1 time of 809.3 ms, after the injection of 
ProCA32.CXCR4, t1 time of the same region decreases to 703.0 at 3 hours after injection and goes 




Figure 7.12 T2 mapping MRI images and t2 time of buffer treated HCC mouse tumor 
nodules at different time points following ProCA32.CXCR4 injection. 
T2 mapping of buffer treated HCC mouse to analysis the t2 time of tumor nodules (represented by 
red circled regions). T2 mapping of the buffer treated HCC mouse shows the similar change pattern 
of CXCR4 high expression nodules as T1 mapping, the t2 time of HCC tumors on before injection 
scan is 93.7 ms, which is higher than the t2 time (39.0 ms) of the normal liver. After administration 
of ProCA32.CXCR4, the t2 time is shortening up to 24 hours, t2 time of HCC tumor is 74.3 ms at 




Figure 7.13 T2 mapping MRI images and t2 time of buffer treated HCC mouse other 
regions than tumor nodules at different time points following ProCA32.CXCR4 
injection. 
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T2 mapping of buffer treated HCC mouse to analyze the t2 time of other regions than CXCR4 high 
expression nodules. The t2 time of the other region than tumor region of buffer treated HCC mouse 
(represented by the red circle region) shows the t2 time of red circle region slightly decreases at 3 




Figure 7.14 Correlation of MR images and histological results of buffer treated HCC 
mouse. 
Histological correlation of buffer treated HCC mouse liver with both T1 and T2 weighted MR 
images. 
 
Doxorubicin treated HCC mouse has distinctly different MRI imaging results than the 
buffer treated HCC mouse, the T1 weighted images (Figure 7.15) of Doxorubicin treated mouse 
shows the signal decrease in both liver and tumor region when compare with pre-scan. The T1 
SNR slightly decrease at 3 hours after administration of ProCA32.CXCR4 and goes back at 24 
hours. The T2 SNR decrease at 3 hours after administration of ProCA32.CXCR4 and further 
decrease at 24 hours. The t1 and t2 time of the HCC tumor treated with Doxorubicin decreased at 
3 hours after administration and went back at 24 hours (Figure 7.17, Figure 7.18). The t1 time of 
HCC mouse treated with Doxorubicin is 1474 ms on the pre-scan and decrease to 1293 ms at 3 
hours after ProCA32.CXCR4 injection. At 24 hours after administration of ProCA32.CXCR4, the 
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t1 time of HCC tumor goes back to 1429 ms. The t2 time of Doxorubicin treated HCC mouse tumor 
is 92.3 ms before the administration of ProCA32.CXCR4 and decrease to 75.7 ms at 3 hours after 
injection, at 24 hours, the t2 goes back to 93.7 ms. The t1 and t2 time of Doxorubicin treated HCC 
tumor is similar with buffer treated HCC tumor, but the dynamic change of the t1 and t2 time is 
different which is caused by the CXCR4 expression change with Doxorubicin treatment.  
The results proved that, for the HCC tumor treated with buffer and Doxorubicin, it is 
difficult to conclude the treatment effect, since the SNR on T1 weighted, T2 weighted images are 
similar with two different treatments. The T1 mapping and T2 mapping gave the results of t1 and 
t2 time of HCC tumor, which is similar as well for the buffer treated mice, and Doxorubicin treated 
mice. The MRI imaging without administration cannot provide enough information for treatment 
effect evaluation. With the administration of CXRC4 targeted contrast agent ProCA32.CXCR4, 
however, we can have further information regarding the molecular signature of HCC tumor change 
followed by different treatments. For the HCC mouse treated with buffer, tumor intensity and t1 
time significantly enhanced after ProCA32.CXCR4 was introduced, which enabled by the CXCR4 
binding of ProCA32.CXCR4 and achieving of CXCR4 molecular imaging using MRI.  
On the contrary, HCC mouse with Doxorubicin treatment did not show this change. For 
the reason that, after chemotherapy, CXCR4 level decreased before visible tumor size shrinking 
and tumor number decreased can be observed. It is enabling early assessment of treatment effect 
before any anatomical structure change can be detected. Treatment effect assessment and 
monitoring is another important application of molecular imaging using MRI. With the advantage 
of non-radiation exposure to MRI scanning, patients can be repeatedly assessed for treatment 
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follow-up. Molecular imaging provides information on a molecular level; such incidences happen 
ahead of macroscopic changes can be observed. 
 
Figure 7.15 T1 weighted images of Doxorubicin treated HCC mouse.  
Six continuous T1 weighted MRI images of Doxorubicin treated HCC mouse at before, 3 hours 
and 24 hours after the injection of ProCA32.CXCR4. Red circle regions represent the HCC region 
from which the SNR was analyzed. The SNR of tumor nodules of Doxorubicin treated HCC mouse 
shows a decrease after 3 hours injection of ProCA32.CXCR4 and goes back at 24 hours after 




Figure 7.16 T2 weighted MRI images of Doxorubicin treated HCC mouse. 
Six continuous T2 weighted MRI imaged of Doxorubicin treated HCC mouse at pre-injection, 3 
hours and 24 hours after injection of ProCA32.CXCR4. The red circle regions represent the tumor 
regions selected for SNR analysis. T2 weighted images of Doxorubicin treated HCC mouse shows 
SNR decrease at 3 hours after the injection of ProCA32.CXCR4 and SNR go back at 24 hours 
after injection of ProCA32.CXCR4. 
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Figure 7.17 T1 mapping MRI images of Doxorubicin treated HCC mouse. 
Six continuous slides of T1 mapping of Doxorubicin treated HCC mouse at different time points 
following ProCA32.CXCR4 injection. T1 time analysis based on the regions circle by red circles. 
T1 time of the tumor nodules of Doxorubicin treated HCC mouse shows the t1 time decrease 
followed the administration of ProCA32.CXCR4. The t1 time of tumor nodules before 
ProCA32.CXCR4 injection is 1474.0 ms, at 3 hours after injection, the t1 time decreases to 1293.0 
ms and at 24 hours goes back to 1429.0 ms. The t1 time results are not consistent with the T1 
weighted images of the same animal. T1 mapping is a more precise way to represent the tissue 





Figure 7.18 T2 mapping MRI images and t2 time of Doxorubicin treated HCC mouse at 
different time points following ProCA32.CXCR4 injection. 
Six continuous slides of T2 mapping of Doxorubicin treated HCC mouse at different time points 
following ProCA32.CXCR4 injection. T2 time analysis based on the regions circle by red circles. 
T2 time of tumor nodules of Doxorubicin treated HCC mouse decrease to 75.7 ms at 3 hours after 
the administration of ProCA32.CXCR4. T2 time of tumor nodules on pre-scan is 92.3 ms at 24 
hours after ProCA32.CXCR4 administration, the t2 time goes back to 93.7 ms. The t2 time change 
pattern of Doxorubicin treated HCC mouse is consistent with the T2 weighted images and T1 
mapping results of the same animal. 
 
The HCC mouse receiving combination treatment of Doxorubicin and ProAgio is different 
from HCC mouse with buffer treatment and HCC mouse with Doxorubicin treatment. The HCC 
mouse with a combination treatment of Doxorubicin and ProAgio shows no tumor nodules when 
compare with other treatment groups. The middle region of the liver (Figure 7.19, red circle region) 
has slightly higher intensity when compare with the rest, which is the fibrotic/ cirrhotic liver tissue.  
            The SNR analysis of this region shows no significant difference after injection of 
ProCA32.CXCR4. On the T1 mapping and T2 mapping (Figure 7.20, Figure 7.21), the cirrhotic 
region remained unchanged after the administration of ProCA32.CXCR4. This is a very interesting 
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finding because the cirrhotic region from buffer treated HCC behaves differently on MRI images 
followed by the same contrast agent administration. The buffered treated HCC mouse has signal 
enhancement after injection of ProCA32.CXCR4 but the combination treatment HCC mouse 
cirrhotic liver seems has ProCA32.CXCR4 delivery difference because no significant 
enhancement observed followed the contrast agent injection. This phenomenon might be related 
to the neovascular forming, followed by the ProAgio treatment. The newly formed vascular is not 
connecting to the existing vascular structure so ProCA32.CXCR4 is not able to deliver to the 
ProAgio treated mouse liver. This is causing hypo enhancement after the ProCA32.CXCR4 
administration. On top of ProAgio, the Doxorubicin treatment reduced the CXCR4 expression 
level, which leads to the reduce of enhancement based on CXCR4 molecular imaging. Overall, 
due to the new vascular forming effect of ProAgio and CXCR4 expression reduction followed by 
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Doxorubicin treatment, the combination treatment mouse shows dim enhancement followed the 
administration of ProCA32.CXCR4. 
 
 
Figure 7.19 T1, T2 weighted MRI images and SNR of Doxorubicin and ProAgio treated 




Figure 7.20 T1 mapping MRI images and t1 time of Doxorubicin and ProAgio treated HCC 
mouse at different time points follow ProCA32.CXCR4 injection. 
 
 
Figure 7.21 T2 mapping MRI images and t2 time of Doxorubicin and ProAgio treated HCC 




Figure 7.22 T1 weighted images before and after injection of ProCA32.CXCR4 of HCC 
mice with different treatment. 
Comparison of T1 weighted images of HCC mouse with different treatment, before and after 
different time points of ProCA32.CXCR4 administration. Buffer treated HCC mouse shows a 
significant enhancement of whole liver regions, CXCR4 high expression nodules enhanced more 
than the rest region of liver, indicating the CXCR4 targeting effect at 24 hours after the injection 
of ProA32.CXCR4, which is consistent with the MR imaging results from other animal models, 
including uveal melanoma mouse model. Normal mouse and HCC mouse with other treatment do 
not show the CXCR4 targeted enhancement. ICP-OES to analysis the gadolinium content of tumor 
tissues confirmed the CXCR4 targeting effect of ProA32.CXCR4 and consistent with the MR 
images enhancement. 
 
7.3  Discussion and conclusion 
HCC is a primary liver malignancy with poor prognosis and a prevalent healthcare concern 
for society. Advance in imaging diagnosis already make HCC diagnosis establish based on 
imaging the reality. Improvement in diagnosis algorithm successfully improved the percentage of 
HCC patient surveillance and early detection. The introduce of Milan criteria for screening liver 
transplantation candidates significantly improve the success rate for HCC patients qualified for 
orthotopic liver transplantation.  With all the advances in HCC surveillance and management, new 
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approaches for early detection and treatment effect evaluation using clinical imaging remains an 
unmet medical need.  
Chemokines are considered to play an important role in HCC development for their roles 
in cell migration, inflammation, and immune cell recruitment. These incidences usually happen 
before cirrhosis forming, and chronic viral infection is a major etiology for HCC. Researchers have 
found that the CXCR4-CXCL12 axis involved in chronic viral hepatitis transition to liver cirrhosis 
and HCC. As a result, imaging targeting CXCR4 can be a new approach for HCC detection and 
related treatment effect monitoring.  
With DEN induced HCC mouse model, we observed the elevated CXCR4 expression level, 
which proved by the hyperintensity T1 weighted imaging followed by CXCR4 targeting MRI 
contrast agent PrOCA32.CXCR4. Owing to the high relaxivities of ProCA32.CXCR4, CXCR4 
molecular imaging has been achieved in HCC tumor mice and showed elevated CXCR4 expression 
level in HCC mouse tumor. T1 mapping and T2 mapping of the same mouse has consistent result 
demonstrating the targeting effect at a longer time after injection of ProCA32.CXCR4 (24 hours). 
Within difference HCC tumor nodules, there is inconsistency regarding tumor tissue t1 and t2 time. 
However, the longitude analysis of tissue relaxation time along time points shows consistent 
tendency change based on CXCR4 expression level difference. For HCC mouse with buffer 
treatment, it has higher CXCR4 expression levels, which lead to a delayed time point after injection 
enhancement owing to the dynamic CXCR4 binding process. For HCC mouse with Doxorubicin 
treatment, it does not exhibit the same pattern of contrast enhancement at different time points, 
which is a result of CXCR4 level difference and molecular dynamic contrast enhancement property 
alteration.  
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Doxorubicin has limited treatment effect on HCC patients, the liver appearance of 
Doxorubicin treated HCC mouse has no significant improvement when compared with buffer 
treated HCC mouse. Interestingly, the CXCR4 molecular imaging shows the molecular dynamic 
enhancement property difference between the treated HCC mice and untreated ones. ICP-OES 
analysis of gadolinium content in HCC tumor gives the consistent result that after doxorubicin 
treatment, HCC tumor has lower gadolinium content when compared with the control. It is the 
evidence that Doxorubicin might affect the CXCR4-CXCL12 axis but no significant improvement 
in tumor size shrinking, etc.  
CXCR4 is potentially a target for HCC treatment drug development, and CXCR4 imaging 
can be used for monitoring the treatment effect. ProCA32.CXCR4 achieved first CXCR4 
molecular imaging to assess biomarker expression in HCC in our knowledge and is a potential tool 
for related treatment effect monitoring and assessment. 
8 MULTICOLOR MRI BY DUAL CONTRAST ENHANCEMENT IMAGING AND 
INTEGRIN V3 TARGETED CONTRAST AGENT  
8.1 Introduction 
8.1.1 Mn2+ based MRI contrast agents 
The report of NSF and gadolinium-associated brain deposition bring about the 
development of safer alternative of gadolinium-based contrast agents. One approach is to replace 
Gd3+ with other paramagnetic metal ions that relax the water proton efficiently. Non-lanthanide 
metals have been investigated for their potential to be MRI contrast agent as alternative of 
gadolinium. Manganese is undoubtedly an attractive candidate for low toxicity. Unlike 
gadolinium, manganese is a physiologically present metal that serves as co-factor of a series of 
enzyme and essential to maintaining human health. Study regarding the toxicity assessment of 
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manganese demonstrated it as a low toxic substance (230). Although Mn2+ possess fewer unpaired 
electrons (five) when compared with gadolinium (seven), it still provides decent positive 
enhancement on MR imaging.  
The only Mn2+ based contrast agent that had been proved for clinical usage was 
mangafodipir trisodium (Mn-DPDP), marketed under the tradename of Teslascan® in 1990. Mn-
DPDP has similar T1 relaxivity (2.8 mM-1· s-1) with gadolinium diethylenetriaminepentaacetic 
acid (4.5 mM-1· s-1) in aqueous solution. However, in liver relaxivity of Mn-DPDP is 21.7 mM-1· 
s-1, which is significantly higher than gadolinium-based contrast agents (231). Mn-DPDP does not 
have inner sphere water molecule and shows slow transmetallation with endogenous metal ions 
such as Ca2+, Zn2+, etc. The released manganese is uptake by hepatocytes and shows high relaxivity 
in liver tissue. However, due to the low sales, and concern about toxicity, Mn-DPDP withdrawn 
from the United States in 2003 and Europe in 2010.  
 Thermostability and inertness to transmetallation have to be taken into consideration when 
design manganese-based MRI contrast agents. Cu2+ and Zn2+ usually have a higher affinity to 
given ligand than Mn2+ in general. Ca2+ and Mg2+ have lower affinity but are present in higher 
concentration physiologically. Thus, although Mn2+ is less toxic than Gd3+, the high amount of 
manganese exposure can still cause adverse neurological effects and Parkinson-like symptoms 
(232).   
8.1.2 Multicolor MR imaging with dual contrast agents 
Flask et al. recently reported that in the presence of two MRI contrast agents A and B, the 
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                                                                                                                           Equation 8.2 
 
where [A] is the concentration of imaging agent A; T1pre and T2pre are the pre-contrast T1 
and T2 relaxation times; T1 and T2 are the post-contrast T1 and T2 relaxation times; r1A and r2A are 
the relaxivities of contrast agent A; [B] is the concentration of contrast agent B, and r1B and r2B are 
the relaxivities of contrast agent B.  
Based on these equations, we hypothesis that if T1pre, T2pre, T1, and T2 are measured 
before and after simultaneous injection of two different contrast agents with known relaxivities, 
[A] and [B] can be calculated by equation 5.1 and 5.2. Assuming these two different contrast agents 
have preferred sensitivity to longitudinal and transverse relaxation parameter, respectively. (e.g., 
a Gd3+-based T1 agent and an Mn
2+-based T2 agent). The recently developed Magnetic Resonance 
Fingerprinting (MRF) methodology simultaneously generate inherently co-registered T1 and T2 
relaxation time maps using a unique acquisition and quantification strategy that combines a prior 
acquisition parameter variation with a dictionary-based pattern matching algorithm.  
Optimized MRF acquisition obtains quantitative T1 and T2 maps in 10–50 seconds per 
imaging slice, providing the possibility to dynamically generate quantitative maps of these two 
important MRI parameters simultaneously. 
176 
 
Figure 8.1 The workflow of multicolor MRI with dual contrast agent. 
 
 Based on our platform of developing protein-based contrast agents with different 
paramagnetic metals, and our achievement in targeted ProCAs, we reasoned that Multi-color 
protein MRI contrast agents targeted to biomarkers could be developed by designing several types 
of paramagnetic metal-binding sites into our developed ProCAs.  We can further develop multi-
color pMRI using multi-contrast Magnetic Resonance Fingerprinting (MRF) methodology (MC-
MRF) to investigating the tumor microenvironment. 
8.1.3 Integrin v3 
Integrins are one of the best-understood cell adhesion receptors. Integrins mediate cell 
adhesion, transmit a signal between the extracellular ligand with cytoplasmic domain and 
triggering intracellular signal pathways (233). The initial understanding of integrins’ function is a 
cellular linkage between cells to extracellular matrix (ECM) proteins. A common integrin 
recognition motif shared by various extracellular matrix protein is the RGD peptide sequence 
(234). Integrins also mediate cell-cell adhesion with a more restricted recognition. The DXSXS 
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motif from the metal ion-dependent adhesion site (MIDAS) is proved to be critically important for 
RGD sequence binding (235), and the mutation in that site can affect ligand binding (236). 
Integrin family consists of more than 24 integrins and each of them formed by a non-
covalent association of two different subunits  and . Integrins always form a heterodimer. 18  
and 8  subunits assort with each other and form 24 distinct integrins (233) (Figure 8.2Error! 
Reference source not found.). Integrins involved in cell attachment, migration, angiogenesis and 
cancer formation, etc. 
 
Figure 8.2 Integrin receptors. 
Figure adapted from reference (233). 
 
Angiogenesis is crucial in tumor progression. Tumor growth will be mostly limited if no 
neovascular formed (237). The angiogenesis can turn on the dormant tumor cell switch, promote 
tumor invasion, and metastasis. ECM structure degradation facilitates tumor cell invasion. As an 
essential cell adhesion molecule and adhesion mediator of the cell to ECM, integrins play an 
extremely important role in cancer development. Among a wide range of integrins, v3 is the 
most important one in angiogenesis (238). Even more notably, v3 presents on activated 
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endothelial cells and newly form vascular but absent on normal vasculature and resting endothelial 
cells. A study of wound healing revealed that v3 is highly expressed on blood vessels in 
granulation tissue but not normal skin (238). Taken together, v3 is a suitable biomarker for 
assessing the angiogenesis in tumors. 
Breast cancer is the second most diagnosed cancer in women in the United States. 
Biomarker HER2 (human epidermal growth factor receptor) is a well-recognized biomarker for 
breast cancer staging and diagnosis and a successful example of the biomarker in cancer diagnosis 
and therapy. Integrin v3 is related to angiogenesis and proposed as a prognostic factor for breast 
cancer. One study demonstrated the functional role of integrin v3 in breast cancer and the 
association with the invasiveness of breast cancer (239); administration of monoclonal antibodies 
LM609 blocks the breast cancer growth and angiogenesis.  As a result, v3 targeted imaging can 
potential evaluate the angiogenesis of breast tumor and predict the invasively of breast tumor. 
Attempts have been made towards v3 targeted molecular imaging. An 
18F labeled RDG 
dimer peptide with PEG4 linker has successfully achieved v3 specific enhancement using PET 
imaging (240). A radiolabeled RGD peptide 99mTc-NC100692, which can target v3 was 
demonstrated to enable enhancement of breast cancer malignant lesions (241). We propose a 
protein-based contrast agent contain the repetition of RGD sequence for v3 can serve as an MRI 
contrast agent and imaging integrin v3 non-invasively with no involvement of radiation. 
8.2 Results 
8.2.1 Relaxivities measurement of Mn2+ based ProCA32.CXCR4 
The relaxivity of manganese ProCA32.CXCR4 was measured in a similar protocol as 
gadolinium ProCA32.CXCR4. Bivalent manganese ions and ProCA32.CXCR4 was loaded in a 
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2:1 ratio and both longitudinal and transverse relaxivity were measured with 1.4 T relaxometer 
and 7.0 T Bruker scanner. Mn-ProCA32.CXCR4 exhibits both high r1 and r2 relaxivities. In 1.4 T, 
the r1 equals to 60.0 mM
-1s-1 and r2 equals to 133.2 mM
-1s-1 (Figure 8.3). In 7.0 T, the r1 equals to 
11.9 mM-1s-1 and r2 equals to 142.8 mM
-1s-1. 
 
Figure 8.3 Relaxivities measurement of Mn-ProCA32.CXCR4 in 1.4 T.  
The longitudinal and transverse relaxivity of Mn-ProCA32.CXCR4 was assessed with 1.4 T 
relaxometer. Mn2+ and ProCA32.CXCR4 loaded in 2:1 ratio. The r1 equals to 60.0 mM
-1s-1 and r2 
equals to 133.0 mM-1s-1. Measurements are done in buffer consists of 50 mM HEPES, 100 mM 





Figure 8.4 Relaxivities measurement of Mn-ProCA32.CXCR4 with 7.0 T Bruker scanner. 
The longitudinal and transverse relaxivity of Mn-ProCA32.CXCR4 was assessed with a 7.0 T 
Bruker scanner. The r1 equals to 11.94 mM
-1s-1 and r2 equals to 142.79 mM
-1s-1Measurements are 
done in buffer consists 50 mM HEPES, 100 mM NaCl at pH 7.2, 37°C. 
 
 
The relaxation time of contrast agents’ solution has a linear relationship with their 
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                                                                                                                           Equation 8.4 
T1, T2 is the relaxation time of contrast agent solution, T1 buffer and T2 buffer are the relaxation 
time of buffer only. [C] is the concentration of contrast agent, r1 and r2 are the relaxivities of 
contrast agent. 
Based on the linear relationship of relaxation time and contrast agent concentration, 
Christian E. Anderson et al. proposed a linear model for systems contains two contrast agents 
(242), the solution contains two contrast agents A and B, the relaxation time of solution is 
contributed by both contrast agents’ relaxivities. (Equation 8.1, 8.2) 
The concentration of two contrast agents can be estimated based on the longitudinal 
relaxation time and transverse relaxation time of solution system that contains two contrast agents 
if the relaxivities of contrast agents are known. (Figure 8.5) C, D shows that the estimated 




Figure 8.5 Determine the concentration contrast agents from relaxivities measurement, 1.4 
T. 
(A), (B). Relaxivities measurement of both Gd-ProCA32.CXCR4 and Mn-ProCA32.CXCR4 
under 1.4 T. (C), (D). Correlation of known concentration and estimated concentration of Gd-
ProCA32.CXCR4 and Mn-ProCA32.CXCR4 respectively. 
 
8.2.2 Mn2+ binding affinity measurement of hProCA32.collagen1 
 
Figure 8.6 Determine the manganese binding affinity of hProCA32.collagen1.  
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The Manganese binding affinity of protein contrast agent is pivotally significant. By an 
Mn2+-Tb3+ competition assay described in chapter 2.4.5, the Kd of Mn
2+ binds to 
hProCA32.collagen1 was calculated to be 1.13 × 10-20 M (Figure 8.6). 
8.2.3 Expression, purification, and characterization of ProCA32.RGD for integrin 
V3 imaging 
ProCA32.RGD was designed base on ProCA32, with the four repetitions of RDG sequence 
at the C terminus for Integrin v3 binding. ProCA32.RGD sequence and structure are showed in 
Figure 8.7. ProCA32.RGD is bacterially expressed, purified follow the similar protocol of 
ProCA32.CXCR4 expression and purification. ProCA32.RGD expressed with competent cell 
BL21 (DE3) pLysS strain. After the 0.5 mM isopropyl β-D-1-thiogalactopyranoside induce 
expression, the ProCA32.RGD was successfully expressed (Figure 8.8. A).  
After the expression by competent cell, the cell pellet was collected and ProCA32.RGD 
purification was carried out, followed the established protocol of purification described in chapter 
2.2.3. Briefly, followed the overnight expression after IPTG induction, cell pellet is collected by 
centrifuge and resuspended in PBS buffer. Cells were broken with sonication; the supernatant was 
collected after centrifuge. Supernatant then boiled, incubated with streptomycin and dialyzed in 
10 mM HEPES buffer for overnight. Ion exchange column was used to separate ProCA32.RGD 
with impurities and finish the purification of ProCA32.RGD (Figure 8.8.C). 
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Figure 8.7 Predicted secondary structure, solvent accessibility, and models of 
ProCA32.RGD. 
Prediction of secondary structure, solvent accessibility, and final models using I-TASSER (158). 
C-score is the confidence of protein model predicted by I-TASSER, which is typically in the 
range of [-5,2], where the higher value of C-score corresponding higher confidence of the 
prediction. 
 
Figure 8.8 Expression and purification of ProCA32.RGD. 
(A), (B) ProCA32.RGD expression and purification SDS-PAGE with Coomassie blue staining. 
(A)  Cell pellet samples after different time of ProCA32.RGD expression is collected and analyzed 
with Coomassie blue staining, after the induction with IPTG, ProCA32.RGD was expressed, 
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orange box highlighted the ProCA32.RGD bands. (C) The FPLC spectrum of ProCA32.RGD, 
samples eluted from different peaks were analyzed by SDS-PAGE (B).  
 
8.2.4 Relaxivities and metal-binding affinity measurement of ProCA32.RGD 
Longitudinal relaxivity and transverse relaxivity of ProCA32.RGD was measured with 1.4 
T relaxometer followed the standard protocol described in chapter 2.3. Different concentration of 
ProCA32.RGD (from 0 µM to 40 µM) were prepared in 50 mM HEPES, 100 mM NaCl, PH 7.2; 
in a loading ratio with gadolinium of 1:2. The longitudinal relaxivity of ProCA32.RGD is 29.2 
mM-1s-1 and the transverse relaxivity of ProCA32.RGD is 40.7 mM-1s-1 under 1.4 T magnetic field 
(Figure 8.9). The relaxivities of ProCA32.RGD is consistent with the values of ProCA32 and 
ProCA32.CXCR4. All protein-based contrast agents mentioned above exhibited both high r1 and 
r2 relaxivity and enable the robust contrast enhancement in MR imaging. 
 
Figure 8.9 Relaxivity measurement of ProCA32.RGD. 
Relaxivity assessment of ProCA32.RGD with 60 MHz relaxometer. At 1.4 T, r1 of 




The metal-binding affinity of ProCA32.RGD was measured following the protocol 
described in chapter 2.4. The metal binding affinity of ProCA32.RGD to Ca2+, Zn2+, Tb3+ and Gd3+ 
were summarized in Table 8.1 Summary of the metal-binding affinity of ProCA32.RGD.. 
ProCA32.RGD presents high affinity to Tb3+, Gd3+ and excellent selectivity of Gd3+ over Ca2+ and 
Zn2+. The high metal binding affinity and good selectivity of Gd3+ over physiologically present 
metals such as Zn2+ and Ca2+ of ProCA32.RGD provided the foundation to be a contrast agent 
with robust imaging capacity. 
 
Table 8.1 Summary of the metal-binding affinity of ProCA32.RGD.  
 
Data from Dr. Yueshuang Leng. 
 
8.2.5 Integrin v3 targeting study of ProCA32.RGD 
ProCA32.RGD was designed as Integrin v3 targeting contrast agent for integrin v3 
targeted molecular MR imaging application. The integrin v3 targeting capability of 
ProCA32.RGD was assessed by immunofluorescence staining and cell attachment assay. 
Immunofluorescence staining of ProCA32.RGD was carried out with human umbilical vein 
endothelial cells (HUVECs). HUVECs have high expression level of v3. With same 
concentration incubation (5 µM) of ProCA32 and ProCA32.RGD, HUVECs with non-targeted 
contrast agent ProCA32 incubation shows no fluorescence on the cell surface and HUVECs with 
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integrin v3 targeted contrast agent ProCA32.RGD incubation show strong red fluorescence on 
the cell surface. Which proved that ProCA32.RGD interacts and targets integrin v3.  
Cell attachment experiment was carried out to test the specific binding of ProCA32.RGD 
to integrin v3. There are over 28 different kinds of integrins in the big integrin family. The 
specific binding of ProCA32.RGD to integrin v3 will facilitate integrin v3 specific imaging. 
Chinese hamster ovary (CHO) cells transfected with different kinds of integrins, including v3, 
IIb3, v5, and v6 were used for cell attachment study. Results of cell attachment study (Figure 
8.10) show that CHO cells with integrin v3 expression has a significantly higher attachment to 
ProCA32.RGD than CHO cells expresses no integrin and other integrins including v3, IIb3, 




Figure 8.10 Integrin v3 targeting study of ProCA32.RGD. 
HUVEC cell with integrin v3 expression was used for immunofluorescence staining to test the 
integrin v3 targeting capability of ProCA32.RGD. HUVEC cells with ProCA32 incubation 
(control) shows rare red color fluorescence on the cell surface. HUVEC cells with ProCA32.RGD 
incubation exhibit strong fluorescence staining on the cell surface that indicates the presence of 
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ProCA32.RGD. CHO cells with different transfection of integrins (v3, IIb3, v5, v6) were 
incubated with ProCA32.RGD to test the specific binding of ProCA32.RGD. CHO cell with v3 
expression shows significantly higher cell attachment than CHO cell with other integrins 
expression and control. 
 
8.2.6 Application of ProCA32.RGD for breast cancer and metastases detection 
Orthotopic breast cancer mouse model derived from the 4T1luc cell was used for testing 
the imaging capability of ProCA32.CXCR4. The 4T1 cell was stably transfected with firefly 
luciferases and an aliquot of 5 × 104 cells injected orthotopically in the mouse breasts. Orthotopic 
breast tumors formed after 10 to 14 days of the injection of 4T1luc cells.  
Before MR imaging, 4T1luc mice were injected with luciferase substrate (D-luciferin, Free 
Acid, ThermoFisher) and imaged by a bioluminescence system to visualize the location of tumor 
and potential metastases formed. After 10 min of D-luciferin injection, 4T1luc mice start to show 
the bioluminescence enhancement around the breast, mouse located in the right side shows 
enhancement gradually around kidneys, indicating there are potentially kidney metastases forming 
in that mouse. Bioluminescence imaging was taken every five minutes after 10 min; the highest 
luminescence enhancement showed around 25 to 30 min after injection of luciferase substrate 
(Figure 8.11).  
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Figure 8.11 Bioluminescence imaging of 4T1luc mouse model. 
Bioluminescence imaging of 4T1luc breast cancer mice after different time of injection of 
luciferase substrate (D-luciferin, Free Acid, ThermoFisher).  
 
T1 weighted, T2 weighted, and T2 mapping images of 4T1luc mice were collected by 7.0 T 
Bruker scanner (Figure 8.12, Figure 8.13). The signal-noise ratio analysis of tumor on T1 weighted 
images shows that: before injection of ProCA32.RGD, the SNR of the tumor is 14.3, similar to the 
liver SNR; after the injection of ProCA32.RGD, the SNR of the tumor keep increasing up to 50 
min after injection. At 24 hours after injection of ProCA32.RGD, the SNR decreases to a similar 
level to the pre-scanning. 
ProCA32.RGD has both high r1 and high r2 values; the T2 weighted images shows a similar 
enhancement pattern as T1 weighted images. After the injection of ProCA32.RGD, the SNR on T2 
weighted image decrease when compared with pre-scan. SNR of the tumor on T2 weighted images 
keep decreasing up to 40 min after injection and after 24 hours, the contrast effect washed out, and 
the tumor SNR recovered back to the pre-scan level. 
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Figure 8.12 T1 weighted MR images of 4T1luc breast cancer mouse. 
T1 weighted MR images of 4T1luc breast cancer mice were collected before and 20, 30, 40, 50 
min and 24 hours after injection of ProCA32.RGD. SNR of breast tumors (represented by red 
circled regions) increase after the administration of ProCA32.RGD, the enhancement keeps 
accumulating up to 50 min. The SNR decreased after 24 hours of administration. 
 
Figure 8.13 T2 weighted MR images of 4T1luc breast cancer mouse. 
T2 weighted MR images of 4T1luc breast cancer mouse were collected before and after 20, 30, 40, 
50 min and 24 hours after the administration of ProCA32.RGD. SNR of T2 weighted MR images 
(represented by red circled regions) was keep decrease up to 50 min after ProCA32.RGD 
administration and washed out after 24 hours after administration. 
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8.3 Conclusion and discussion 
In this chapter, we discussed the potential application of protein-based contrast agents 
platform technique using other magnetic metals than gadolinium. We investigated the manganese-
based contrast agent specifically using CXCR4 targeted protein contrast agent ProCA32.CXCR4. 
 The relaxivities (both r1 and r2) of ProCA32.CXCR4 under 1.4 T and 7.0 T magnetic field 
are investigated, respectively. The r1 of Mn-ProCA32.CXCR4 equals to 60.0 mM
-1s-1 and r2 equals 
to 133.2 mM-1s-1 at 1.4 T. The r1 and r2 of Mn-ProCA32.CXCR4 are 11.9 mM
-1s-1 and 142.8 mM-
1s-1, respectively. Manganese based protein contrast agent shows both high r1 and r2 relaxivities 
under 1.4 T. At 7.0 T, the r1 decreased when compared with 1.4 T, but r2 is highly reserved. As 
oppose to Gd-ProCA32.CXCR4, Mn-ProCA32.CXCR4 has a dominant effect on transverse 
relaxivity than longitudinal relaxivity. The r1 / r2 of Gd-ProCA32.CXCR4 and Mn-
ProCA32.CXCR4 are different and suitable for application of multicolor MR imaging in vivo. 
Besides the relaxivity advantage of Mn2+ based protein contrast agents, we proved that the binding 
affinity of Mn2+ to hProCA32.collagen1 is strong enough to prevent potential Mn2+ associated 
toxicity. 
The correlation of estimated contrast agents’ concentration calculated using equation 5.1 
and 5.2 and relaxation time measurement of Gd-ProCA32.CXCR4 and Mn-ProCA32.CXCR4 
mixture with the known concentration of Gd-ProCA32.CXCR4 and Mn-ProCA32.CXCR4 has a 
linear relationship. It is the in vitro validation of MRF and dual contrast agent application. Further, 
in vivo experiment, including initial liver perfusion and live animal study are needed to be 
performed to establish the MRF approach with protein contrast agent platform technique. 
Integrin v3 targeted contrast agent ProCA32.RGD was developed and characterized. 
ProCA32.RGD has high relaxivities (r1 = 29.2 mM-1 s-1, r2 = 40.7 mM-1 s-1, 1.4 T), high metal 
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binding affinity and good metal selectivity over physiologically present metal ions such as Zn2+ 
and Ca2+.  
The imaging capacity of ProCA32.RGD was tested in 4T1luc breast cancer mice. Non-
PEGylated ProCA32.RGD was used for animal experiment. Since the molecular weight of the 
non-PEGylated contrast agent is smaller than the PEGylated one. The corresponding 
pharmacokinetics and pharmacodynamics properties are expected to be different from the 
PEGylated agents. MR images acquired before and 20 min, 30 min, 40 min, 50 min, and 24 hours 
after injection. SNR of breast tumor significantly increased after administration of ProCA32.RGD, 
at 50 min after injection, the enhancement of intensity reaches the peak and washout effect 
observed at 24 hours after injection. Similar patterns observed on T2 weighted MR images, SNR 
decrease after administration of ProCA32.RGD up to 50 min after injection and the wash out effect 
and SNR increase observed after. 
Application of ProCA32.RGD in breast cancer detection is an initiative of studying in vivo 
application of integrin v3 targeted contrast agent. Non-PEGylated ProCA32.RGD was used in 
the animal experiment and successfully enhance tumor for the first time. Non-PEGylated 
ProCA32.RGD enhance the tumor at earlier points. However, the enhancement pattern of 
PEGylated and non-PEGylated ProCA32.RGD need to be compared, and pharmacokinetics 
difference of these two agents need to be studied before a solid conclusion can be reached. 
 
9 SIGNIFICANCE AND FUTURE DIRECTION 
Molecular imaging is aiming at revealing the molecular and cellular level information 
regarding diseases in a non-invasive way. The development of technology enables achieving 
molecular imaging through a variety of imaging platforms. PET and SPECT are the imaging 
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modalities that researchers focused on most to achieve molecular imaging for their high sensitivity. 
Most of the achievement of molecular imaging has been done with nuclear medicine approaches 
involving radiation.  
The standard care of cancers has been evolved and improved over the past decades and 
primarily improved the life quality of cancer patients as well as extended the survival life span of 
cancer patients. A considerable effort has been made toward the development of novel therapeutic 
approaches for cancers. This brings the medical needs of advanced imaging techniques for 
characterization of diseased region repeatedly and safely for cancer early diagnosis and during the 
follow up of disease progression. Therefore, MRI becomes an attractive alternative approach for 
the non-radiation involvement and no-depth limitation. 
The biggest challenge to achieve molecular MRI is the relatively low sensitivity of current 
contrast agents for clinical usage. The average r1 value of gadolinium-based contrast agents is 
between 3-5 mM-1s-1. As a result, in order to achieve molecular imaging of biomarkers using 
contrast agents with such relaxivity requires the local concentration of contrast agents to be mM 
range. However, the concern of the toxicity of gadolinium-based contrast agents restrained the 
high dosage applications. How to balance the dosage of gadolinium contrast agents to maximize 
imaging capacity and minimize toxicity remains a difficulty in gadolinium contrast agents’ 
development. Another challenge of achieving molecular imaging is lacking contrast agents with 
biomarker targeting capability. The development of biomarker targeting contrast agent with 
improved relaxivities is expected to resolve the problem. 
Taken safety, enhance capacity together, the good strategy of designing MRI contrast 
agents for molecular imaging of specific biomarkers should consider improving the relaxivity, 
gadolinium binding affinity, and metal selectivity over physiologically existing metals. Besides, 
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constructing a structure that targeting keys biomarkers plays an essential role in disease 
development is a necessity of achieving biomarker molecular MRI. 
The criteria for screening a good biomarker for molecular imaging should include location, 
disease relevance, therapeutic value. More specifically, biomarkers located at extracellular 
compartment are easier to access; the biomarkers can predict the cancer progression with their 
expression level and help the staging of cancer are of better disease relevance; the biomarkers are 
therapeutic targets and responsive to treatment have better therapeutic value. In this dissertation, 
we first verified CXCR4 as a good biomarker for uveal melanoma detection. Our rationale of study 
CXCR4 based on following facts: CXCR4 is by far the most common chemokine receptor 
expressed by cancers and over 23 different kinds of cancers express CXCR4; CXCR4-CXCL12 
axis directs the cancer metastasis; CXCR4 considered as an adverse prognostic factor and 
therapeutic targets for cancer-related therapies. Based on the fact that uveal melanoma almost 
exclusively metastases to the liver, we studied the CXCR4 expression with cell line, tissue, and 
mice models. The role of CXCR4 in uveal melanoma development and the value of CXCR4 in 
uveal melanoma is controversial according to the previous researches from different groups. We 
evaluated the CXCR4 expression levels of different metastatic uveal melanoma cells and 
metastases UM in patients’ livers. CXCR4 is generally over-expressed throughout the cell lines 
and UM metastases in livers. Metastatic mouse model study shows the CXCR4 expression levels 
of UM metastases in liver elevated even the primary UM in the eye are of low to medium CXCR4 
expression. These results validated the high expression level of CXCR4 in UM metastases in the 
liver, and CXCR4 is a potential biomarker for UM metastases imaging. The overexpression of 
CXCR4 is observed in UM metastases. We are the first to systematically studied and established 
a biomarker to trace and image the UM metastases in the liver. In the future, the pathological role 
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of CXCR4 in UM metastases will be further studied and investigated. Multiple cancer 
immunotherapies target CXCR4 are under investigation and proved to be beneficial for UM 
metastases management. The CXCR4 molecular imaging will be beneficial for treatment planning 
and effect monitoring of UM patients with liver metastases involvement. 
CXCR4 imaging agents that able to detect cancers are previously reported by researchers. 
Most of them are PET or SPECT agents. We are devoting in develop CXCR4 targeted MRI 
contrast agent to achieve CXCR4 molecular imaging without radiation and better safety profile. 
We successfully developed the CXCR4 targeted contrast agent ProCA32.CXCR4 for molecular 
imaging with MRI. ProCA32.CXCR4 is expressed and purified with high yield. The metal binding 
affinities, relaxivities, thermokinetic stability, transmetallation, and toxicity of ProCA32.CXCR4 
are extensively studied and evaluated. ProCA32.CXCR4 has high gadolinium binding affinity, 
good metal selectivity over physiologically present metal ions such as calcium and zinc. The good 
gadolinium binding affinity and metal selectivity make ProCA32.CXCR4 a safe contrast agent for 
translational usage. ProCA32.CXCR4 possess bulkier structure than the small chelator contrast 
agents and inner-sphere water and outer sphere water that boost the relaxivities. Taken together, 
ProCA32.CXCR4 is a safe MRI contrast agent with significantly improved relaxivity. CXCR4 
targeting capability of ProCA32.CXCR4 is proved by immunofluorescence cell lines study and 
indirect ELISA. ProCA32.CXCR4 possess significantly improved relaxivities and CXCR4 
targeting capability, which enables imaging the small uveal melanoma metastases in mice livers 
and showing heterogeneity enhancement of UM tumor lesions owing to the good permeability. 
CXCR4 molecular imaging with ProCA32.CXCR4 significantly improved the current detection 
limit for liver lesions (1-2 cm). With ProCA32.CXCR4 administration, metastatic UM lesions 
range from 0.01 mm2 to 0.08 mm2 were enhanced and detected. 
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Administration of ProCA32.CXCR4 achieved detection of liver metastases using 
molecular dynamic contrast imaging by MRI. In the Mel290 murine model, intensity changes over 
time exhibited different patterns in liver metastases than in adjacent liver tissue. Tumor region 
intensity steadily increased up to 24 h after ProCA32.CXCR4 injection due to in vivo dynamic 
binding to CXCR4, followed by a slow wash out after 24 h to 48 h. We measured a transient 
increase (at 12 min) immediately after ProCA32 injection due to in vivo distribution, with 
subsequent wash out after 3 h. Similar enhancement patterns were observed in the liver regions of 
mice injected with both ProCA32.CXCR4 and ProCA32. This unique property of 
ProCA32.CXCR4 provides a possibility of acquiring molecular dynamic contrast imaging using 
MRI. MDCI provides an additional avenue to non-invasively differentiate tumors from healthy 
livers by taking advantage of biomarker binding capabilities. In this study, we also demonstrated 
ProCA32.CXCR4 exhibits excellent tumor permeability, which is very different from most 
nanoparticles or chelator-based targeting contrast agents that mostly enhance the tumor boundary. 
This property allows for mapping heterogeneous CXCR4 expression inside the tumor and may 
facilitate monitoring of changes in CXCR4 expression through the tumor tissue during progression 
and treatment. 
The CXCR4 molecular imaging with MRI is successfully achieved with UM mice models. 
In the future, ProCA32.CXCR4 is planned to be tested in the larger animals such as canine and 
primate to verify the imaging capability and study the dosage upscale for human translational 
usage. Pharmacokinetics study of ProCA32.CXCR4 is initiated and ProCA32.CXCR4 has a 
relatively longer half-life and correspondingly longer imaging window. We are going to try 
different modification/ PEGylation of ProCA32.CXCR4 to tune the PK/PD properties and tease 
out the best way for post-expression modification protein-based MRI contrast agents. Currently, 
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we are using lysine PEGylation (multiple sites) and cysteine PEGylation (single site) for 
ProCA32.CXCR4 modification. Both lysine-PEGylated and cysteine-PEGylated 
ProCA32.CXCR4 showed good imaging capability. Cysteine-PEGylated ProCA32.CXCR4 is 
preferred for now because the site-specific property and homogenous PEGylated product meet the 
industrial standard better. Other PEGylation approach for protein contrast agent modification is 
ongoing. N-terminus PEGylation can be another approach for ProCA32.CXCR4 modification.  
Besides the successful application of ProA32.CXCR4 in UM liver metastases detection. 
We expanded our study on ProCA32.CXCR4 to the detection of primary liver cancer and treatment 
effect monitoring. HCC is the most common primary liver cancer, and the development of HCC 
is through a serious of biomedical incidences. Chronic liver diseases are major risk factors of HCC, 
and the surveillance of chronic liver diseases including viral infection, alcoholic and non-alcoholic 
fatty liver is highly suggested to monitoring the disease progresses. We tested the imaging 
capability of ProCA32.CXCR4 in detecting HCC with a chemical-induced murine model 
monitored the CXCR4 expression level changes followed by different treatment groups. The HCC 
in the murine model is detected by the administration of ProCA32.CXCR4 and the CXCR4 
molecular imaging by ProCA32.CXCR4 can assess the CXCR4 expression level changes. Thus, 
the CXCR4 molecular imaging by ProCA32.CXCR4 can not only achieve cancer and metastases 
detection in uveal melanoma but also HCC. The value of CXCR4 molecular imaging has been 
proved in cancer detection and cancer treatment monitoring. 
The tumor microenvironment is a complex environment supporting and facilitating tumor 
growth. Angiogenesis and fibrosis are played critical roles in the development of cancers. We 
developed contrast agents targeting other biomarkers such as collagen and integrin v3 for cancer 
microenvironment imaging. We assessed the Non-PEGylated ProCA32.RGD in a breast cancer 
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murine model and the imaging property proved to be dynamic. We observed that the SNR of tumor 
regions increase to almost double within a one-hour time frame followed the ProCA32.RGD 
administration. This result suggesting the earlier time points followed contrast agent 
administration might of great imaging value. Instead of tracing longer time points after injection 
as we did with PEGylated protein contrast agents, it could be another option to use non-PEGylated 
protein-based contrast agents if the stability, solubility, and toxicity been thoroughly studied and 
verified. Thus, one future direction of the protein contrast agent development will be assessing the 
influence of different PEGylation on PK/PD property. 
Protein-based MRI contrast agents are platform technique that highly transferable to design 
and engineer versatile contrast agents. By engineering different targeting peptide into ProCAs, we 
can design contrast agents targeting different biomarkers. CXCR4, HER2, EGFR, PSMA, and 
collagen targeted contrast agent has been developed and well-studied. Other contrast agents that 
targeting biomolecules that play an important role can be designed and develop in future research. 
For example, checkpoints biomarkers such as PDL-1 can be good biomarker or imaging in the 
future study. 
Owing to the safety concern of gadolinium-based contrast agents, MRI contrast agents use 
other paramagnetic metals such as manganese have been studied as an alternative of gadolinium. 
Manganese is physiologically existing and possesses relatively high relaxivity. Mn-DPDP is a 
manganese-based contrast agent approved in clinical usage for liver imaging. We explored the 
possibility of developing a manganese-based protein MRI contrast agent in this dissertation. Mn2+-
ProCA32.CXCR4 was proved to be possess high relaxivity (r1 = 11.94 mM
-1s-1, r2 = 142.79 mM
-
1s-1, 7.0 T), even higher than Gd3+-ProCA32.CXCR4. The binding affinity of Mn2+ with 
hProCA32.collagen1 was measured with competition assay and calculated as 1.13 × 10-20 M. To 
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compare the gadolinium-based ProCA32.CXCR4 and manganese-based ProCA32.CXCR4, Gd-
ProCA32.CXCR4 has better r1 property and Mn-ProCA32.CXCR4 has better r2 property. These 
preliminary data of manganese-based protein contrast agent is promising. In the future, we plan to 
further characterize the manganese-based protein contrast agents and modify the metal binding 
pockets of scaffold protein to accommodate better for manganese contrast agents.  
One of the most challenging tasks of molecular imaging is to differentiate different cell 
content. Take uveal melanoma imaging with ProCA32.CXCR4 as an example, CXCR4 has 
expressed on the uveal melanoma cells as well as the T lymphocytes. If we can differentiate 
CXCR4 from different cells, we can understand better the local tumor microenvironment. Protein-
based MRI contrast agents with different paramagnetic metals provide the possibility of 
differentiating different biomarkers by quantitative assessment of concentrations of different 
contrast agents. As described in chapter 8, the local concentration of two contrast agents target 
different biomarkers can be calculated by the T1 and T2 relaxation time of the tissue. The technical 
obstacle is how to acquire the T1 and T2 mapping that provides the T1 and T2 relaxation times at 
the same time. The information must be collected in a time-sensitive assay that allows analyzing 
the T1 and T2 relaxation times of same region simultaneously to calculate the local concentration 
of different contrast agents corresponding to the biomarker distribution. Conventionally, collecting 
T1 mapping and T2 mapping is time-consuming procedure. This technical barrier can be overcome 
by magnetic resonance fingerprinting (MRF) approach. MRF acquisition is expected to collect 
both T1 mapping and T2 mapping with a time-resolved, dictionary-matching fashion. Taking 
advantage of MRF acquisition and protein contrast agents targeting different biomarkers that based 
on different paramagnetic metals, we are expected to subtype different cell population, quantify, 
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